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Ovarian cancer is the most lethal gynaecological malignancy in the developed world. High 
grade serous (HGS) ovarian carcinoma (OC) represents the majority of cases and most 
frequently presents at advanced stage, where the five year survival rate is around 30%. Over 
the last two decades, our understanding of the molecular events underpinning HGS OC has 
advanced substantially, identifying cases rendered deficient in homologous recombination 
DNA repair (HR) by virtue of BRCA1 or BRCA2 (BRCA) mutation (BRCAm). BRCAm patients 
experience a distinct clinical phenotype which has been translated into stratification of 
routine OC care, with poly-(ADP-ribose) polymerase (PARP) inhibitors showing marked 
efficacy in this patient group. However, phenotypic characterisation of HGS OCs in non-BRCA 
molecular subtypes is less well defined and ultimately molecular characterisation of OC 
beyond BRCAm is not used to guide disease management or prognostication.  
This body of work performs characterisation of clinical specimens from patients diagnosed 
with OC, identified retrospectively using the Edinburgh Ovarian Cancer Database, through 
which detailed patient outcome data is available. These analyses aim to determine the 
clinical consequences of molecular events that underpin OC, correlating specific events with 
survival and chemotherapy response. 
Firstly, a cohort of OC treated with pegylated liposomal doxorubicin (PLD) is identified and 
characterised using next generation sequencing (NGS) analysis for the BRCA genes to 
determine whether BRCAm patients are more sensitive to this non-platinum DNA damaging 
agent. HGS OCs with BRCA sequence aberrations demonstrated significantly higher response 






Pre-existing gene expression data for a cohort of 265 HGS OC patients is then used to 
identifying a subgroup of patients who have high expression of C11orf30/EMSY, whose gene 
product encodes a BRCA2-binding protein reported to disrupt BRCA2 function. These 
patients are demonstrated to behave similarly to BRCAm patients, showing prolonged 
survival and hypersensitivity to platinum-based chemotherapy. The survival benefit of high-
EMSY HGS OC patients is recapitulated in multiple independent datasets, including the MRC 
ICON7 clinical trial cohort.  
Finally, integrated molecular characterisation of a large HGS OC cohort is performed to 
investigate the overlap and interplay between genomically and transcriptomically-defined 
subgroups described in HGS OC. Tumour-infiltrating lymphocytes are quantified and overlaid 
with molecular data to deconvolute the clinical impact of molecular subtypes with high 
granularity. These analyses reveal differential distribution of genomic subgroups between 
transcriptionally-defined subtypes, and identify the Angio subtype as a subtype 
demonstrating poor tumour engagement by the immune system. Patients with HGS OC 
harbouring CCNE1 copy number gain are demonstrated to display poorer outcome. 
Integrated molecular subtyping separates HGS OCs into three classes each with distinct OS 
profiles, and reveals potential novel context-specific associations of molecular events with 
clinical outcome.   
Together, these data extend our knowledge of the clinical impact of molecular subtypes of 






Lay Summary  
Ovarian cancer is the most deadly cancer of the female genital tract. We now know that 
patients with the most common type of familial ovarian cancer, who have gene mutations in 
one of the BRCA genes, respond better to normal chemotherapy and ultimately survive for 
longer than those without these mutations. They also show marked sensitivity to “magic 
bullet” therapies that target the underlying biology of their cancer. This body of work further 
investigates how the biology behind ovarian cancers determines how well patients respond 
to treatment and how long they survive from their disease.  
Tumour samples from patients who have been treated for ovarian cancer have been 
collected and analyzed to look for gene mutations and to see how different genes are being 
used within ovarian cancer cells. This work identifies multiple biological groups of ovarian 
cancer, demonstrating that patients whose cancer is driven by different biology show 
differences in survival and treatment response.  
Specifically, patients with BRCA gene mutations are shown to respond better to a drug called 
PLD. A group of patients who have high levels of a gene called EMSY is then identified and 
shown to behave very much like those with BRCA gene mutations: they respond better to 
normal chemotherapy and survive for longer. Lastly, a large collection of ovarian cancers is 
analyzed by multiple techniques to build a more granular picture of ovarian cancer subtypes 
and to characterise how these impact upon patient outcome.  
Together, this work extends our knowledge of how ovarian cancer biology impacts upon a 
patient’s disease journey, paving the way to better tailor treatment toward the underlying 
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1 CHAPTER 1: INTRODUCTION  
1.1 The definition of cancer 
In its broadest definition, cancer is a disease of uncontrolled cellular replication. The healthy 
human cell employs a host of regulatory mechanisms that tightly control the rate of normal 
cell division, ensuring genomic integrity before propagation of genetic material to its 
daughter cells [1]. Cancer circumvents these guardian mechanisms to allow cellular 
proliferation in a deregulated manner [2, 3]. In solid tumours, this results in the formation of 
a primary mass comprising millions of cancer cells per cm3 of tumour. However, the primary 
cause of cancer-related death is tumour spread – the dissemination and growth of cancer 
cells locally and throughout the body [4]. 
 
1.2 The worldwide cancer burden  
1.2.1 Cancer incidence  
Cancer represents a leading cause of morbidity and mortality worldwide: within the United 
Kingdom (UK), around 300,000 cases are diagnosed per year, projected to increase to over 
400,000 by the year 2030 [5]. By comparison, over 1.5 million new cancer cases are diagnosed 
each year in the United States (US), accounting for around 600,000 deaths per annum [6]. 
Cancer represents an extremely heterogeneous collection of distinct disease entities, both 
clinically and molecularly [7, 8]. Different cancer types occur at markedly different 
frequencies and display striking differences in clinical outcome, even between different 













1.2.2 The financial burden of cancer care  
Cancer also represents a substantial economic burden. While modern therapeutics and 
treatment strategies are improving the lives of cancer patients, both the use of new drugs 
and the prolonged disease journey of patients have significant implications for the financial 
burden of cancer [9]. Indeed, the total cost per annum in the UK of the four most 
predominant cancer types alone – breast, colorectal, lung and prostate – amounts to over 
£1.5 billion per annum [10]. Estimations of yearly cost per patient vary greatly between 
cancer types, but are reported in excess of £12,000 in breast and colorectal cancers in the UK 
[11]. These costs will undoubtedly increase substantially over the next decade, particularly 
with the increasing integration of targeted molecular therapies into everyday cancer care 
[12].  
 
1.3 Fundamentals of Cancer Biology 
1.3.1 Cancer initiation  
1.3.1.1 Tumour suppressor genes 
Tumour suppressor genes (TSGs) encode proteins whose function guards the cell against 
malignant transformation [13]. As such, inherited defects in these genes underlie many 
familial cancers [14]. Largely, TSGs function to regulate cell growth – for example through 
cell cycle checkpoint maintenance or by induction of cell cycle arrest in the context of 
inappropriate growth signalling – or to maintain the integrity of the genome via 
deoxyribonucleic acid (DNA) repair or sensing of DNA damage [3, 15]. 
TSG inactivation is classically thought to require inactivating events (‘hits’) to both maternal 





preserved in the event of a single hit owing to the remaining intact gene copy producing 
functional protein [16]. Familial cancers frequently arise in the context of a single pre-existing 
TSG hit within the germline [14]. In this setting the second hit is acquired throughout life to 
allow cancer initiation, typically through a second mutational event, loss of heterozygosity 
(LOH) at the locus, or other mechanism of gene inactivation [17] (Figure 1.2). In contrast, 
sporadic cancers usually involve the acquisition of two separate TSG hits throughout life [16]. 
While subtle genomic events such missense mutations or small insertions or deletions 
(indels) are common mechanisms of TSG inactivation, it has become clear that other events 
– including large scale gene deletions and translocations, as well as gene silencing by 
promoter hypermethylation – are also mechanisms of TSG ‘hits’ [18].  
The classic example of these two cancer initiation scenarios is sporadic versus hereditary 
retinoblastoma, the disease upon which Knudson’s findings were based [16]. The biology of 
retinoblastoma is underpinned by loss of the TSG RB1 [19, 20]. In the hereditary form, 
retinoblastoma occurs at younger age and is frequently bilateral, consistent with the need to 
acquire only a single additional hit in RB1 throughout life [16]. By comparison, the non-
hereditary form occurs later and is usually unilateral, owing to the need for two independent 
RB1 hits to arise.  
However, examples of TSG loss-of-function in the context of a single hit are now widely 
known, referred to as so-called dominant-negative events, whereby the gene product of the 
single mutated gene copy abrogates the function of wild-type protein produced within the 







Figure 1.2 The two-hit model for TSG inactivation. 
 
 
1.3.1.2 Oncogenes  
While TSGs act to safeguard healthy cells against malignant transformation, oncogenes act 
to promote deregulated cell growth [3]. In their basal state, these cancer-promoting genes 
are known as proto-oncogenes, which in turn can become abnormally activated or 
overexpressed, promoting malignant cellular transformation [22]. Typically, proto-
oncogenes encode proteins which function as growth factors, growth factor receptors, signal 





Copy number (CN) gain and mutations leading to loss of regulatory function in proto-
oncogenes are common mechanisms of oncogene activation [7, 23, 24].  
Activating mutations in EGFR, encoding the epidermal growth factor receptor (EGFR), and 
gene amplification of MYC, a pro-proliferative transcription factor which promotes cell cycle 
progression, are classic examples of oncogene activation [24-26].  
 
1.3.2 Hallmark cancer traits 
In order to override the mechanisms the healthy human cell employs to prevent deregulated 
growth and division, cancer cells must acquire successive molecular events that enable 
tumour development [3]. These molecular events bestow the cancer cell with malignant 
characteristics that give it the ability to override the normal safeguard mechanisms that 
regulate cell division, facilitating cancer development and metastatic spread of the cancer 
cells. The central “hallmarks” of cancer were conceptualised into six core characteristics in a 
landmark review by Hanahan and Weinberg in 2000 [3], and were later updated to include 
four further emerging hallmarks and enabling characteristics (Figure 1.3) [2].  
 
1.3.2.1 Sustained proliferative signalling  
One of the most fundamental characteristics of cancer cells is sustained proliferation. While 
normal cell division is tightly orchestrated by pro- and anti-proliferative signals, cancer cells 
hijack mitogenic signaling pathways to promote chronic growth and division [3, 7, 24]. Cancer 
cells may express growth factors, upregulate growth factors receptor expression, or 
permanently activate pathway components downstream of growth factor reception to 





The mitogen-activated protein kinase (MAPK) pathway is one such pathway that is a frequent 
target of mutational activation in a multitude of cancers. Accordingly, such pathways have 
become attractive therapeutic targets, and MAPK pathway inhibition has become one 
example where successful oncogenic signaling inhibition has translated into clinical practice 
[31, 32]. Pathways that are targets of activation across multiple cancer types (pan-cancer) 
are particularly attractive targets, as developed drugs have the potential to demonstrate 
efficacy in multiple disease settings.  
 
1.3.2.2 Evading growth suppression 
In order to sustain chronic proliferation, cancer cells must bypass the mechanisms that block 
deregulated growth in normal cells. Indeed, in the context of chronic proliferative signaling 
in an otherwise healthy cell – for example by mutational activation of an oncogene – cellular 
growth is quickly arrested in a phenomenon known as oncogene-induced senescence [33-
35]. Such defensive mechanisms are frequently mediated by the gene products of TSGs, and 
mutational inactivation of these defenses is a common event in cancer [7, 35, 36]. TP53 is 
perhaps the most famous such TSG, and is the most commonly mutated gene across cancer 
types, interfering with its protein product’s ability to regulate cell cycle progression [7]. This 
hallmark characteristic includes evading cell-cell contact inhibition, allowing cancer cells to 








Figure 1.3 Hallmark capabilities of cancer cells [2, 3]. 
 
1.3.2.3 Resisting cell death  
Under the physiological stress of repetitive cell division and chronic pro-proliferative 
signaling, normal cells may be triggered to undergo cellular senescence or apoptosis, a 
programmed cell death fate [35, 39]. In order to benefit from sustained mitogenic signaling, 
and to withstand cell stresses induced by chronic proliferation, cancer cells must acquire the 





Such defects may arise in the upstream sensors of cellular stresses such as DNA damage, or 
in the downstream mediators of apoptosis [7, 40-42]. Additional mechanisms of resisting cell 
death, including induction of autophagic cellular component recycling in response to cell 
stress, have only relatively recently been uncovered, and their exact role in tumour 
progression and therapy resistance still being elucidated [43].  
 
1.3.2.4 Enabling replicative immortality  
One key cellular safeguard against cancer development is the limited proliferative potential 
of normal cells [44]. During normal cellular replication, hexameric nucleotide repeats at 
chromosome ends – known as telomeres – are incompletely replicated [45]. This leads to 
progressive telomere erosion with each cell division, commonly referred to as the end 
replication problem (ERP) [46-48]. Once telomeres become heavily eroded, cells are 
triggered to senesce, permanently exiting the cell cycle [49]. Thus, ERP represents an 
important safeguard against the acquisition of an immortal cell phenotype with limitless 
replicative potential.  
Cancer cells must overcome this replication-limiting phenomenon to obtain the replicative 
potential required for tumour formation [3, 44]. Frequently, this characteristic is acquired 
through expression of the telomere-repairing enzyme telomerase by genomic or epigenomic 
modifications of telomerase reverse transcriptase-encoding gene, TERT, which replenishes 
telomeres in order to evade ERP [50, 51]. However, telomerase-independent mechanisms of 
telomere maintenance have also been identified, most notable alternative lengthening of 
telomeres (ALT), which is thought to be a homologous recombination (HR)-mediated 





1.3.2.5 Inducing angiogenesis 
Like normal cells, cancer cells require oxygen and nutrients and must clear metabolic waste 
products to sustain chronic replication and resist cell death. This means that once the tumour 
mass reaches a threshold size – estimated at around 1-2mm3 – they must induce the 
formation of new blood vessels to overcome the oxygen and nutrient diffusion limits 
restricting growth [55-57]. This process is termed angiogenesis, mediated by pro-angiogenic 
factors such as vascular endothelial growth factor (VEGF), extending the existing circulatory 
network toward the growing tumour. Creation of a pro-angiogenic environment, both 
through VEGF signaling and downregulation of anti-angiogenic signals, is promoted by 
oncogenic signaling, hypoxic stress and interactions between the tumour with the 
surrounding stroma [58].  
Accordingly, induction of angiogenesis is now being exploited therapeutically: both 
monoclonal antibodies against VEGF-A and small molecule inhibitors of pro-angiogenic 
signaling have demonstrated anti-tumour efficacy in some disease settings [59-63]. These 
include the monoclonal antibody bevacizumab which has displayed efficacy in a number of 
malignancies, including metastatic renal and colorectal cancer, as well as ovarian cancer [59-
62].  
 
1.3.2.6 Activating invasion and metastasis 
Local and distant dissemination of cancer cells underlies the majority of cancer-related death. 
In most cancer types, this process requires changes in cell surface protein expression that 
modulates cell-cell and cell-extracellular matrix (ECM) interactions, mediating the invasion 





downregulation of surface molecules that promote contact inhibition and cell quiescence, 
most notably E-cadherin, that usually regulate the formation of discrete layers of functional 
epithelium [65, 66].  
Activating invasive and metastatic phenotypes may involve the transition from an epithelial 
to a more mesenchymal phenotype, frequently termed epithelial to mesenchymal transition 
(EMT), a process which has become the focus of intense research effort [67]. This so-called 
EMT program is orchestrated by a number of key transcription factors, most notably the 
Snail, ZEB and TWIST transcription factor families [68]. Indeed, activation of EMT has been 
associated with the acquisition of a more stem cell-like phenotype with greater 
chemotherapy resistance, and these cell populations may therefore represent those most 
likely to seed subsequent chemoresistant relapse [69].  
 
1.3.2.7 Avoiding immune destruction  
The importance of the interaction between host immune system and the tumour has become 
increasingly apparent over the last two decades [70-74]. A number of mechanisms have been 
identified by which tumours avoid detection and active engagement by the immune system: 
reduced immunogenicity by modulation of major histocompatibility complex (MHC) 
molecule expression, promotion of an immunosuppressive tumour microenvironment by 
cytokines such as interleukin (IL)-10 and transforming growth factor (TGF)-B, and expression 
of immunoregulatory molecules including programmed death ligand (PDL)-1 and cytotoxic T 
lymphocyte antigen (CTLA)-4 are just some examples of mechanisms by which tumours avoid 





Active engagement of the tumour by the immune system has been identified as a marker of 
good prognosis in in a number of malignancies [79-81]. In particular, infiltration of CD8+ 
cytotoxic T cells appears is associated with prolonged survival in a number of tumour types, 
including ovarian cancer [82, 83]. Conversely, expression of molecules able to down-regulate 
the anti-tumour immune response has been associated with poorer outcome in some cancer 
types [83-88]. Accordingly, stimulation of anti-tumour immune response has been the focus 
of intense research [78, 89, 90], and immunomodulatory cancer therapy is now 
demonstrating marked clinical efficacy in some disease settings [91-93].  
 
1.3.2.8 Deregulating cellular energetics  
Following glycolysis of glucose to pyruvate in the cytosol, normal cells pass this product to 
the mitochondria for energy in aerobic conditions [94]. However, cancer cells demonstrate 
an abnormal aerobic glycolysis metabolic phenotype whereby the majority of energy is 
produced by glycolysis rather than by subsequent reactions within the mitochondria [2, 94]. 
This so-called “metabolic switch”, associated with oncogene activation, produces adenosine 
triphosphate (ATP) less efficiently than oxygen-requiring mitochondrial oxidation, and it 
remains unclear exactly what advantage this confers [95]. One proposed explanation is that 
such energetics may be more supportive of large-scale biosynthesis of macromolecules due 
to the consequential availability of glycolytic intermediates [96].   
 
1.3.2.9 Genome instability 
While the normal human cell maintains their genomic integrity through a range of repair 





[97], cancer cells typically need to withstand much higher mutation rates in order to acquire 
the genomic defects that confer both survival advantage and other hallmarks of cancer [2, 7, 
98, 99]. Numerous defects in mechanisms of DNA damage response and repair have been 
identified across the numerous cancer types, and many hereditary cancer predisposition 
syndromes are underpinned by inheritance of germline inactivation of DNA repair-associated 
genes [1].  
Cancer cells must not only withstand increased mutational rate and burden, but also gross 
changes in DNA, including both local and gross CN changes as well structural genomic events 
[7, 100, 101]. It is now clear that such gross genomic events are common mechanisms of both 
tumour suppressor gene inactivation and oncogene activation [18, 24, 101]. Because both 
discrete mutations and more gross genomic changes contribute to acquisition of the other 
hallmarks of cancer, genomic instability is regarded as an enabling hallmark characteristic [2].  
It has become that clear that the inherent plasticity of unstable cancer genomes contributes 
to tumour evolution, giving rise to substantial spatial and temporal heterogeneity within a 
single tumour [98, 102]. The causes and implications of this heterogeneity have recently 
become the focus of intensive research, hoping to distinguish late-acquired ‘branch’ events 
from early events in the hope of identifying targetable driver biology at the trunk of the 
cancer genome’s evolutionary tree [98, 102].  
 
1.3.2.10 Tumour-promoting inflammation 
While the immune system can play an anti-cancer role, it has also become clear that 
inflammation can promote tumour initiation and progression [103, 104]. Chronic 
inflammatory conditions, such as cirrhosis of the liver and inflammatory bowel disease, are 





Inflammation appears to contribute to the tumour microenvironment by providing factors 
such as growth hormones, pro-angiogenic factors and molecules that facilitate remodeling 
of the ECM, as well as mutagenic reactive oxygen species (ROS) [106]. Collectively, these 
promote sustained tumour growth and progression, angiogenesis, tumour invasion and 
metastasis, and increased mutation rate – key hallmarks of cancer – making tumour-
promoting inflammation the second enabling hallmark [2].  
 
1.4 Cancer Therapy  
1.4.1 Surgery 
Surgery remains a cornerstone of cancer treatment and standard care for many solid tumours 
begins with primary surgical resection. Alternatively, for some cancers, chemotherapy 
therapy may be initiated prior to surgery (neoadjuvant chemotherapy), aimed at shrinking 
the tumour, maximizing probability of later surgical success and reducing post-surgical 
morbidity [107-109]. The core goal of surgery is optimal cytoreduction: removal of as much 
of the tumour as is reasonably achievable, leaving as few cancer cells behind as possible. 
Frequently, adjuvant chemotherapy is prescribed to follow surgery in an effort to destroy 
remaining cancerous cells in order to prevent or delay recurrence. In cancers diagnosed at 
early stage, surgery alone may be curative.   
 
1.4.2 Chemotherapy 
Together, surgery, chemotherapy and radiotherapy represent the pillars of conventional 
anti-cancer therapy. Chemotherapies induce cell death in highly proliferative cells such as 





However, these agents also act on healthy non-cancerous dividing cells such as the bone 
marrow and gastrointestinal epithelium, and off-target effects at these sites manifest as 
chemotherapy side effects. Bone marrow suppression, neurotoxicity and damage to organs 
such as the heart, kidney or lungs remain serious side-effects of many chemotherapy 
regimens [112]. Common side effects of systemic chemotherapy also include 
nausea/vomiting, diarrhoea, loss of appetite and hair loss.      
 
1.4.3 Radiotherapy  
 
Radiotherapy represents a key therapeutic option in modern cancer care, with around half 
of oncology patients being treated with radiation at some stage in their disease journey 
[113]. Radiotherapy utilizes ionizing radiation to kill cancer cells by direct and indirect DNA 
damage leading to cell cycle arrest and cell death [114]. Typically, radiotherapy is delivered 
as protons, electrons, gamma-rays or X-rays. Like chemotherapy, radiotherapy also damages 
normal cells, however radiation dose to normal tissues are minimized by delivery techniques 
while maximizing dose to tumour cells [115, 116].  Furthermore, external radiotherapy is 
non-invasive and relatively low in cost, making it an attractive therapeutic option for a 
multitude of malignancies [117].  
 
1.4.4 Targeted therapies 
In recent years, the design and development of novel molecular targeted therapies has been 
the focus of a huge research effort [118]. Indeed, a number have now been licensed for use 
in routine cancer care, and a multitude are advancing through ongoing clinical trials [31, 62, 
119-121]. These agents are tailored toward the biology of a patient’s underlying disease, and 





these therapies are targeted at the fundamental biology of cancer cells outlined in section 
1.3.2. 
These agents were originally thought to represent therapeutic strategies that would have 
few off-target effects and therefore a favourable toxicity profile, but it has become clear that 
targeted agents are not without toxicities that can lead to both dose limitation and impact 
on patient quality of life [122, 123]. However, their toxicity profiles are indeed distinct from 
those of conventional chemotherapies [123].  
Undoubtedly, targeted agents have led to profound advances in the treatment of malignancy 
and have improved the lives of countless patients both in the context of clinical trials and 
increasingly in routine clinical practice [118]. Clearly, such treatment would never have been 
conceived without the substantial advancements in our understanding of the diverse biology 
underpinning cancer development and progression [2, 3]. However, these therapies have 
substantial financial implications: by way of example in the UK, addition of the anti-
angiogenic agent bevacizumab to standard treatment for colorectal cancer was estimated to 
increase cost by over £60,000 per quality-adjusted life year [124]. Indeed, the substantial 
economic burden of such treatments has been an obstacle to routine use of these agents in 
some settings.  
Furthermore, resistance to targeted agents is common and frequently develops rapidly 
following initiation in many disease settings [125-127], underscoring the need to further 
develop both the repertoire of available agents and the optimal chronology for the use of 






1.5 Common tumours of the female genital tract 
Cancers of the genital tract account for around 13% of female cancers diagnosed per annum 
(Figure 1.1), with over 100,000 new cases diagnosed in the US in 2018 [6]. Of these, 
endometrial, ovarian and cervical cancers account for 57%, 20% and 12% of cases and 35%, 
44% and 13% of deaths, respectively, with other sites representing only a minority of cancer 
cases (Table 1.1) [6]. Thus, while ovarian cancers represent around one fifth of malignancies 
at the female genital tract, they account for almost half of cancer deaths per year at these 
disease sites.   
 
1.6 Ovarian carcinoma 
1.6.1 Incidence and clinical outcome   
Ovarian cancer represents a leading cause of cancer death worldwide, with over 22,000 new 
cases, accounting for around 14,000 deaths, per annum in the US alone [6]. The majority 
(around 90%) of diagnosed ovarian cancers are ovarian carcinomas (OCs), the majority of 
which are diagnosed at advanced stage [128]. Advanced stage OC is associated with 
particularly poor prognosis: patients diagnosed with stage III disease display 5- and 10-year 
survival rates of around 36% and 23%, with corresponding rates of 17% and 8% in those 
diagnosed at stage IV [129]. These data underscore the poor survival rate in OC that present 






Table 1.1: Cancer incidence in the US population, 2018 [6].  
 









Female - all sites 878,980 286,010     
All FGT 110,070 32,120 12.5 21.8   
Uterine cervix 13,240 4,170 1.5 1.5 12.0 13.0 
Uterine corpus 63,230 11,350 7.2 4.0 57.4 35.3 
Ovary 22,240 14,070 2.5 4.9 20.2 43.8 
Vulva 6,190 1,200 0.7 0.4 5.6 3.7 
Vagina and other 
female 
5,170 1,330 0.6 0.5 4.7 4.1 




1.6.2 Diagnosis and staging 
A major challenge for early detection of OC is its presentation: early stage OC is frequently 
asymptomatic, and where patients do present with symptoms they are often generic in 
nature [130]. Abdominal pain, constipation, fatigue, vaginal bleeding, diarrhoea and 
abdominal distension are recognized symptoms of all OC stages, many of which may be 
overlooked or attributed to alternative diagnoses by physicians [130]. In advanced stage 
disease, patients present with nausea, abdominal bloating and distension, anorexia and early 
satiety as disease bulk increases in the abdomen. Patients may present with ascites and/or 
palpable abdominal or nodal masses.  
OC disease stage is determined by its dissemination: stage I cases are confined to the ovaries 
and stage II disease displays only pelvic extension (collectively termed ‘early’ stage), while 
stage III and IV cases presents with extension beyond the pelvis and metastasis to distant 
sites, respectively (collectively termed ‘advanced’ stage) [131]. International federation of 






Table 1.2: FIGO staging in ovarian carcinoma. Adapted from J. Prat 2015 [131].  
Stage I.  TUMOUR CONFINED TO OVARIES OR FALLOPIAN TUBE(S) 
IA tumour limited to one ovary (capsule intact) or fallopian tube; no tumour on 
ovarian or fallopian tube surface; no malignant cells in the ascites or 
peritoneal washings 
IB tumour limited to both ovaries (capsules intact) or fallopian tubes; no tumour 
on ovarian or fallopian tube surface; no malignant cells in the ascites or 
peritoneal washings 
IC tumour limited to one or both ovaries or fallopian tubes, with any of the 
following:  
IC1: surgical spill; IC2: capsule ruptured before surgery or tumour on ovarian 
or fallopian tube surface; IC3: malignant cells in the ascites or peritoneal 
washings 
Stage II. TUMOUR INVOLVES ONE OR BOTH OVARIES OR FALLOPIAN TUBES WITH 
PELVIC EXTENSION (BELOW PELVIC BRIM) OR PRIMARY PERITONEAL 
CANCER 
IIA extension and/or implants on uterus and/or fallopian tubes and/or ovaries 
IIB extension to other pelvic intraperitoneal tissues 
Stage 
III. 
TUMOUR INVOLVES ONE OR BOTH OVARIES OR FALLOPIAN TUBES, OR 
PRIMARY PERITONEAL CANCER, WITH CYTOLOGICALLY OR HISTOLOGICALLY 
CONFIRMED SPREAD TO THE PERITONEUM OUTSIDE THE PELVIS AND/OR 
METASTASIS TO THE RETROPERITONEAL LYMPH NODES 
IIIA1 positive retroperitoneal lymph nodes only (cytologically or histologically 
proven) 
IIIA1(i) IIIA1(I): Metastasis up to 10 mm in greatest dimension; IIIA1(II): Metastasis 
more than 10 mm in greatest dimension 
IIIA2 microscopic extrapelvic (above the pelvic brim) peritoneal involvement with 
or without positive retroperitoneal lymph nodes 
IIIB macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in greatest 
dimension, with or without metastasis to the retroperitoneal lymph nodes 
IIIC macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in 
greatest dimension, with or without metastasis to the retroperitoneal lymph 
nodes (includes extension of tumour to capsule of liver and spleen without 
parenchymal involvement of either organ) 
Stage 
IV. 
DISTANT METASTASIS EXCLUDING PERITONEAL METASTASES 
IVA pleural effusion with positive cytology 
IVB parenchymal metastases and metastases to extra-abdominal organs 








1.6.3 Recurrent ovarian carcinoma 
Recurrence is the primary cause of death in OC patients: while primary OC is generally highly 
sensitive to therapy, recurrent disease accrues platinum resistance, eventually resulting in 
therapy failure [132]. Even in the context of aggressive primary debulking surgery and 
adjuvant chemotherapy, the majority of OC patients will experience disease relapse, at which 
point treatment is considered non-curative. The reported relapse rates for OC diagnosed at 
advanced and early stages are ≥70% and 20-25%, respectively [133].  
Around a quarter to one half of OC recurs in the pelvis [134-137]. Other common relapse 
sites are the upper abdomen and retroperitoneal lymph nodes (LNs), with less common sites 
including superficial LNs and the liver [137]. Other sites, such as the brain, bone or skin, are 
rare [137]. Additionally, recurrence confined to the LNs represents a rare pattern of disease 
relapse [138, 139]. Interestingly, the use of bevacizumab or intraperitoneal (IP) 
chemotherapy appears to impact upon patterns of relapse: IP chemotherapy is associated 
with a larger proportion of extra-visceral site (LNs, lung, brain, skin or bone) recurrence 
relative to those in the lower abdomen or pelvis [140]. Patients treated with extensive 
bevacizumab treatment have been reported to experience more extra-visceral recurrence, 
including LN involvement [141]. However, it is unclear whether these patterns are 
manifestations of differences in underlying disease biology of those patients who are most 






1.6.4 Ovarian cancer therapy  
1.6.4.1 First-line therapy  
The current standard of care for OC treatment comprises maximal surgical debulking of the 
tumour mass and adjuvant platinum-taxane combination chemotherapy [130]. There 
remains debate as to the optimal chronology of chemotherapy administration: two large 
studies comparing primary surgery and adjuvant chemotherapy versus neoadjuvant 
chemotherapy (NAC) followed by debulking showed no progression-free survival (PFS) or 
overall survival (OS) detriment in the NAC-treated arm, with fewer surgery-related 
morbidities reported in this group [142, 143].  
NAC seems a particularly attractive therapeutic option in advanced stage cases where 
complete resection has been deemed likely unachievable [144]. However, there are concerns 
that while NAC-treated patients do not appear to experience inferior OS, NAC may promote 
platinum resistance [145]. While uptake of NAC followed by interval debulking is on the rise, 
primary surgery remains the current standard of care in many centres [146].  
It has become increasingly clear that the success of primary debulking surgery has a profound 
impact upon OC survival [147-150]. Historically, optimal cytoreduction was defined as 
residual disease (RD) of less than 2cm in diameter, and these patients were demonstrated to 
experience significantly superior survival when compared to those with larger macroscopic 
residual disease [148, 151, 152]. However, more modern definitions have refined the criteria 
for optimal resection to those with RD of less than 1cm [142, 149], or indeed to those with 






1.6.4.2 Management of relapsed ovarian cancer  
Relapsed disease is the major cause of ovarian cancer deaths: most patients will develop 
recurrence which decreases in chemosensitivity with sequential therapy exposures [132]. 
The management of recurrent disease is typically dependent on time from previous therapy: 
platinum-sensitive relapse (relapse >6 months after preceding platinum) is commonly re-
challenged with platinum-based chemotherapy, frequently achieving meaningful responses 
and reserving other agents for later in the disease journey [130, 154, 155]. Conversely, those 
deemed platinum resistant, with disease relapse within 6 months of previous platinum-based 
combination chemotherapy, will often be challenged with non-platinum regimens [130, 133]. 
These agents include pegylated liposomal doxorubicin (PLD) and weekly paclitaxel. 
The role of surgery for relapsed disease has been unclear for many years, with robust studies 
of the relative outcome of secondary-resected patients reporting only recently. 
Retrospective data from the DESKTOP I study suggested that secondary surgery confers a 
survival benefit only where it achieves complete resection in the context of patients who 
have good performance status, no/minimal ascites, and achieved complete resection during 
first-line debulking [156, 157]. The subsequent DESKTOP II study prospectively confirmed 
these clinical factors as predictors of optimal resection in platinum sensitive relapsed OC at 
second debulking [158].   
An interim analysis of the much-anticipated DESKTOP III trial randomizing patients with these 
characteristics to chemotherapy alone or chemotherapy plus secondary surgery recently 
reported prolonged PFS and treatment-free survival time in the surgery-receiving arm [159]. 
Together, these data demonstrate a role for secondary resection in patients that have good 
performance status, present with little or no ascites, and achieved zero macroscopic RD at 





1.6.4.3 Targeted therapies  
Increasingly, targeted molecular therapeutic options are becoming part of routine ovarian 
cancer care. The two principle classes of licensed targeted therapies in OC are poly-(ADP-
ribose)-polymerase (PARP) inhibitors and anti-angiogenic agents, following demonstration of 
their efficacy in phase III trials [60, 61, 120, 160].  
 
1.6.4.3.1 PARP inhibitors  
The rationale for PARP inhibition has its basis within the HR-deficient OC umbrella subgroup, 
the archetypal examples being germline BRCA1 or BRCA2 (BRCA)-mutant (BRCAm) OC (see 
section 1.9.1). PARP proteins play a crucial role in the repair of single-stranded DNA (ssDNA) 
damage: in response to DNA breaks, PARP-1 cleaves nicotinamide adenine dinucleotide 
(NAD) to release adenosine diphosphate (ADP)-ribose, which is successively attached 
adjacent to the break site to form a long, negatively charged poly-(ADP-ribose) chain [161, 
162]. These chains act as a scaffold for the recruitment of the base excision repair (BER) 
components, facilitating repair of the ssDNA break [162]. PARP-inhibited cells accumulate 
double stranded DNA (dsDNA) breaks (DSBs) via conversion of ssDNA damage into DSBs 
during replication through defective ssDNA repair or trapping of PARP at sites of damage 
[163-167].  
Within BRCAm cells, and cells that are HR-deficient through other mechanisms of pathway 
disruption, the resulting dsDNA damage accumulates in the absence of efficient DSB repair 
by HR, leading to cell death [163-166]. Hence, inhibition of PARP in the context of HR activity 
loss is incompatible with cell viability, and exhibits synthetic lethality [164, 168]. Accordingly, 
a number of PARP inhibitors have been developed and utilised clinically, demonstrated 





appear most effective in BRCAm patients, it has become clear that a population of BRCA wild-
type (BRCAwt) OC also benefit from PARP inhibition [172], and there has been an intense 
body of research looking to identify other markers of PARP inhibitor sensitivity [170].  
Until recently, PARP inhibitor licenses have been limited to those patients with demonstrated 
HR deficiency, primarily through germline BRCA loss [173]. However, licensing beyond the 
germline BRCA-mutant population is now emerging [120, 174]. 
  
1.6.4.3.2 Anti-angiogenic agents  
In order to sustain the growing mass, tumours must induce the formation of new blood 
vessels (see section 1.3.2.5) [2, 3]. Therapeutically targeting this process of angiogenesis has 
been an area of great interest in a number of solid tumours, aimed at both the molecules 
that signal the need for new blood vessel formation and at the downstream signaling that 
ultimately leads to angiogenesis. Two broad classes of anti-angiogenic agents have emerged: 
monoclonal antibodies that target VEGF and receptor tyrosine kinase inhibitors (TKIs) aimed 
at the VEGF receptor (VEGFR) or other angiogenesis-associated receptors [175].  
Within OC specifically, the use of such therapeutic approaches has been examined in a 
number of phase III trials demonstrating the efficacy of anti-angiogenic agents in the 
advanced stage disease setting [60, 176-178]. These agents include the anti-VEGFA 
humanized monoclonal antibody bevacizumab [60, 176] and the small molecule inhibitors 
cediranib [177], pazopanib [179], and nintedanib [178], each of which have been 
demonstrated to confer PFS benefit. However, to date OS benefit has only been reported in 
a subset of high-risk OC [176]. In the context of routine practice, additional of bevacizumab 
to standard chemotherapy is now licensed for use in advanced stage first-line OC and 





1.6.4.4 Ongoing development of targeted therapeutic strategies in ovarian 
cancer  
While there has clearly been some success in identifying OC biology that can be 
therapeutically targeted which is now finding its way into routine clinical practice [173], these 
agents typically only delay the development of disease recurrence [60, 120, 160, 169-171, 
176-178]. Accordingly, further characterization of the biology that underpins OC and the 
mechanisms by which these tumours recur and develop chemoresistance is required to 
identify further therapeutic targets. A number of novel targeted approaches are in pre-
clinical testing or early trials. These include inhibitors targeting cell cycle regulators like WEE1 
Kinase [181, 182] and cycle cell checkpoint kinases 1 and 2 [183, 184], agents targeting 
mutant P53 protein [184], as well as novel combinations of PARP inhibitors with anti-
angiogenic agents [185].  
 
1.7 Hereditary ovarian carcinoma 
Around 20% of OCs are associated with pathogenic variants in the germline, most commonly 
BRCA1m or BRCA2m [186, 187]. Inherited defects in other HR-associated genes have also 
been identified in OC, including BARD1, PALB2, RAD51, NBN and BRIP1 [187-190]. Non-HR 
DNA repair associated genes are also targets of OC-predisposing germline mutations, 
including mismatch repair (MMR)-defective (Lynch Syndrome-associated) OC: inherited 
defects, most commonly in MLH1, MSH2, MSH6 and PMS2, predisposes individuals to bowel 
and endometrial malignancy, as well as an increased risk of OC [191, 192]. BRCA-associated 
OC accounts for around 75-80% of inherited OC, while Lynch Syndrome patients account for 
around 10-15% [193]. Li-Fraumeni Syndrome, caused by an inherited TP53 mutation, 





1.8 Histologically-defined subtypes of ovarian carcinoma and their 
classification 
1.8.1 Ovarian carcinoma histotypes and their developmental origins  
Historically, epithelial OC was grouped into four core histologically-defined subtypes 
(histotypes): serous OC, endometrioid OC, clear cell (CC) OC and mucinous OC [194] (Table 
1.3 and Figure 1.4). Further to these histotypes were a substantial number of ‘mixed’ OC, 
comprising elements of multiple histotypes. However, more modern classifications reflect 
the recent recognition that the serous OC group in fact comprises two molecularly distinct 
cancers: high grade serous (HGS) OC, which accounts for the vast majority of cases, and low 
grade serous (LGS) OC which accounts for ≤5% of cases [195-197]. Furthermore, it is now 
recognised that most OCs that were previously regarded to comprising mixed histological 
subtypes actually represent variants of HGS OC demonstrating variable morphological 
patterns [194].  
We now know that the five main histologically-defined OC subtypes (HGS, endometrioid, CC, 
mucinous and LGS OC) arise from discrete developmental origins: HGS OC is thought to 
predominantly arises from the distal fallopian tube (FT) epithelium [198, 199], while LGS OCs 
are believed to progress in a step-wise fashion from adenofibromas or serous cystadenoma 
to LGS OC via serous borderline tumour (SBLT) [195]. It is now thought that many of these 
LGS OC precursors are derived from cells originating in the FT [200]. In contrast, endometrioid 
and CC OC are associated with endometrioisis [198, 199, 201-207], while the origins of 
mucinous OC are poorly defined, with many representing metastases from malignancies of 
the GI tract [208]. In addition to these five histotypes is carcinosarcoma of the ovary, which 
represents a disease entity comprised of both malignant epithelial and malignant 





A wealth of evidence now demonstrates that these histotypes represent discrete disease 
entities at both the genomic and transcriptomic level, and that these histologically-defined 
groups each have distinct clinical behaviour [202, 210-217]. Accordingly, there is a clear need 
for histotype stratification within both the research and clinical setting [194, 218].  
 
Table 1.3: Characteristics of the five main histological subtypes of OC. Adapted from [219]. 
 HGS Endometrioid CC Mucinous LGS 
Proportion of 
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Early stage: FIGO stage I or II; advanced stage: FIGO stage III-IV; amp, amplification; SBLT, 







Figure 1.4. Low (left) and high (right) power views of H&E-stained slides depicting examples 
of OC histotypes: HGS (A and B), endometrioid (C and D), CC (E and F), LGS (G and H) and 





1.8.2 High grade serous ovarian carcinoma 
HGS OCs account for the majority (around 70%) of OC cases, the vast majority of which are 
diagnosed at advanced stage [194]. HGS OC are typically highly sensitive to platinum-
containing chemotherapy in the first-line setting, with response rates of around 80%, 
however the majority of patients will develop disease recurrence which accrues resistance 
to platinum [132]. The five-year survival rate in advanced stage HGS OC is estimated at 
around 30% [220].  
The origins of HGS OC have been the subject of great debate over the last two decades [221]. 
Originally thought to arise from the ovarian surface epithelium (OSE), identification of 
precursor lesions in the FTs of germline BRCAm patients following risk-reducing salpingo-
oophrectomy challenged the understanding of HGS OC’s origins, instead pointing toward the 
FT epithelium [205, 221-223]. This notion was supported by the transcriptomic and 
proteomic similarities between HGS OC and the FT epithelium [202, 224], and was supported 
by the identification of shared TP53 mutations between HGS OC and identified serous tubal 
intraepithelial carcinoma (STIC) in the FT [199, 203]. The morphology and immunophenotype 
of FT epithelium and the identified precursor lesion also resemble that of HGS OC [205]. 
Furthermore, FT epithelial cells transformed in vitro bare resemblance to HGS OC, and mice 
harbouring BRCA-TP53-PTEN-mutant FT epithelial cells develop tumours with histology 
resembling that of HGS OC [198]. Collectively, these observations shaped our current 






1.8.3 Endometrioid and clear cell ovarian carcinoma 
 
Endometrioid OC represents the histotype with most favourable outcome: both 
endometrioid and CC OC are more commonly diagnosed at earlier stage in comparison to 
HGS OC [225-228]. However, endometrioid OC are typically chemosensitive while their CC 
counterparts are reported to display greater intrinsic chemoresistance [214, 225-229]. 
Indeed, advanced stage CC OC are reported to experience poorer PFS and OS compared to 
advanced stage HGS OC [227, 228].  
Together, endometrioid OC and CC OC represent the majority of Lynch Syndrome-associated 
OC cases [230-232], and both of these histotypes are associated with endometriosis [233]. 
Accordingly, both CC OC and endometrioid OC gene expression profiles bear resemblance to 
that of endometrial tissue [202, 207, 234].  
Historically, endometrioid OCs have been sub-classified as grade I, grade II or grade III. 
However, it is now recognised that high grade endometrioid OC more closely resembles HGS 
OC both molecularly and clinically, while low grade endometrioid OC represents a more 
distinct ‘true endometrioid’ OC subtype [235]. Indeed, many of cases of previously described 
high grade endometrioid OC may now be classified as HGS OC at contemporary review, with 
only a modest number of true high grade endometrioid OCs [236]. 
 
1.8.4 Mucinous ovarian carcinoma 
Mucinous OC represent a histotype associated with poorly defined developmental origins 
[208] and intermediate prognosis, despite the majority of cases being diagnosed at early 
stage [237, 238]. Mucinous OC are frequently intrinsically chemoresistant, with advanced 





While mucinous OC were once thought to represent a significant portion of OC cases, the 
majority of what was previously described as mucinous OC are now known to represent 
metastases from other malignancies, typically gastrointestinal cancers, leaving few true 
primary mucinous OC [202, 241].  
 
1.8.5 Low grade serous ovarian carcinoma  
Prior to the identification of LGS OC as a distinct clinical and molecular tumour type, LGS OC 
was classified in the traditional three-tiered grading system alongside their HGS OC 
counterparts under the umbrella term of serous OC [242]. LGS OCs account for the majority 
of what was previously described as serous grade I tumours, with a minority of grade II serous 
tumours also representing true LGS OC [242, 243].  
Following the proposal of a two-tier grading system for serous tumours [242], the biology of 
the LGS versus HGS tumour came under greater scrutiny, eventually leading to the 
understanding that these tumours have distinct molecular abnormalities (discussed below in 
section 1.10.3), developmental origins and clinical outcome [195, 215, 244]. Unlike HGS OCs, 
LGS OC are believed to develop in a step-wise fashion from serous cystadenoma via SBLT to 
invasive carcinoma [245-247]. With regard to patient outcome, patients with LGS OC usually 
experience a far more indolent disease course versus their HGS counterparts: a recent study 
comparing the clinical outcome of LGS and HGS OC identified five year OS rate of around 65% 
and 45% in stage IIIC and stage IV LGS OC patients, compared to 35% and 20% in HGS OCs 
[244]. However, LGS OCs are frequently diagnosed earlier in life versus HGS OC, with a 
median age of diagnosis around 50-55 versus 60-65 in HGS OC [244, 248]. Therein, recurrent 





1.8.6 Diagnosis of different OC histotypes  
Accurate classification of OC into its histologically-defined subtypes is of great importance in 
both the clinical and research settings: these classifications may have marked implications 
with regard to patient prognostication and eligibility for entry into certain clinical trials [194]. 
In the research setting, correct histotype assignment has clear implications for making 
accurate conclusions regarding identification of underlying disease biology, and the accurate 
association of specific molecular events with clinical phenotypes. 
Histotype assignment is primarily made by morphological assessment alongside 
immunohistochemistry (IHC) of tumour material. IHC is particularly useful in cases where 
histotype is unclear from morphology alone [247]. Examples of this include the distinctions 
between LGS and HGS OC demonstrating moderate differentiation, assessment of HGS OC 
displaying clear cell change versus true CC OC, the distinction of true high grade endometrioid 
OC from HGS OC, and the distinction of LGS versus endometrioid OC.  
Both LGS and HGS OC demonstrate nuclear WT1 positivity [236, 249], but differ in P53 
expression pattern: LGS OC demonstrate wild-type P53 expression, with variable nuclear 
positivity between tumour cell nuclei [250], and lower proliferation reflected in a lower Ki-
67 labelling index [251]. Conversely, HGS OCs demonstrate high Ki-67 labelling indices and 
aberrant P53 expression patterns, displaying either null expression or strong diffuse nuclear 
P53 positivity [250-252].  
In contrast to LGS and HGS OC, non-serous tumours are generally WT1 negative [236, 249]. 
Mucinous OC display a distinct morphological profile, alongside CK7 and CK20 positivity and 
ER negativity [128]. Morphologically, endometrioid OC bear resemblance to their uterine 





index between that of HGS and LGS OC [251]. CC OC are generally ER negative but display 
HNF1-β and NAPSIN A positivity, with a similar Ki-67 labelling index to endometrioid OC [236, 
251].  
 
1.9 Genetic and molecular changes in high grade serous ovarian 
carcinoma  
1.9.1 DNA sequence 
The most ubiquitous DNA sequence events in HGS OC is TP53 mutation, which occurs in ≥95% 
of cases (Figure 1.5) [210, 253, 254]. Indeed, many believe that P53 pathway disruption is 
definitional of this tumour type and that those few tumours without direct mutational 
inactivation of TP53 instead have P53 pathway inactivation via non-TP53 events, such as CN 
gain of the P53 regulator-encoding genes MDM2 or MDM4 [254]. Around a quarter of TP53 
mutations are frameshifting indels, nonsense mutations or splice junction variants which 
each result in complete loss of P53 protein (so-called ‘P53-null’ tumours) [252]. The vast 
majority of the remaining TP53 events are detrimental missense mutations, with a minority 
of in-frame indels and larger deletions [252]. Typically, in-frame indels and missense events 
lead to product of protein which is improperly regulated, leading to accumulation of P53 
within the nucleus of the cell, and hence these tumours are sometimes referred to as ‘P53 
positive’, displaying strong diffuse nuclear positivity [252]. 
Despite almost ubiquitous TP53 mutation, a canonical cancer-associated defect, HGS OCs do 
not display the classical activating oncogenic mutations typical of many other solid tumour 
types [210, 255]. These tumours are instead characterized by genomic instability, manifesting 
as extensive CN changes and large-scale genomic rearrangements [210, 256]. Despite the 





demonstrate some recurrent discrete events, frequently targeting DNA repair genes [210, 
256].  
Around half of HGS OCs display identifiable defects in components of the HR pathway, the 
archetypal defects being germline or somatic BRCA mutations which together account for 
around a fifth of HGS OC [210, 257-261] (Figure 1.5). BRCAm tumours are rendered HR-
deficient, the consequence of which is extensive genomic instability and hypersensitivity to 
DNA damage [262-264]. HR-deficiency also provides a rationale for use of PARP inhibitors 
(see section 1.6.4.3). 
 
While around half of HGS OCs harbour some form of identifiable HR defect, germline 
BRCA1m, germline BRCA2m, somatic BRCA1m and somatic BRCA2m only account for around 
8%, 6%, 4% and 3% of cases, respectively [210, 258-261]. A further group representing ≤5% 
of patients are characterized by germline or somatic mutations in non-BRCA HR components 
(non-BRCA-HRm) – such as BARD1, BRIP1, CHEK2, PALB2 or RAD51 mutation – and the 
current data suggest that these non-BRCA-HRm tumours demonstrate a similar HR-deficiency 
phenotype to their BRCAm counterparts (see section 1.11.2) [170, 187, 260, 265, 266]. The 
remaining HGS OC with identifiable HR defects are accounted for by CN gain of the gene 
encoding the BRCA2-binding protein EMSY [267-269] (see section 1.9.2), or by BRCA1 gene 
silencing by promoter hypermethylation [210]. However, it is unclear at present whether 







Figure 1.5 Identified genomic abnormalities in HGS OC, identifying likely HR-deficient (right) 
and HR-proficient (left) tumours. Reproduced with permission from Hollis et al. 2016 [219]. 
 
1.9.2 Structural and copy number variants 
Displaying few recurrent oncogenic driver mutations, HGS OC is primarily a disease of 
structural genomic variation and these tumours typically display extensive genomic 
instability [256]. It has become clear that structural variants (SVs) represent a common 
mechanism of TSG inactivation: while previous studies identified loss of RB1, NF1 and PTEN 
by mutation in minority of HGS OCs [210], whole genome sequencing (WGS) analysis of HGS 
OCs has revealed inactivation of these genes by SV is common (increasing the rate of 
functional loss to approximately 20% of cases for RB1 and NF1) [256]. Thus far, 
characterization of the clinical impact of these events is virtually unstudied, although 
concurrent loss of HR and RB1’s gene product, pRB, has been identified in a high proportion 
of HGS OCs who go on to experience exceptional survival [275].  
Among HR-proficient HGS OCs, amplification of the Cyclin E1-encoding gene CCNE1 is a 
common event with around 14% of cases harbouring CCNE1 CN gain (CCNE1g) [210, 256, 
276]. Given the large number of HR-proficient tumours accounted for by CCNE1g, and that 





targeting of CCNE1 is an appealing avenue of investigation [277]. Some studies have 
suggested that this event is associated with primary platinum resistance [256, 276, 278]. 
However, it remains unclear whether these tumours display greater intrinsic 
chemoresistance when compared to their non-CCNE1g HR-proficient counterparts and there 
have been conflicting reports regarding CCNE1 expression and association with primary 
chemosensitivity [279].  
Intriguingly, CCNE1g and loss of BRCA1 function appear to exhibit synthetic lethality [280]. 
This not only supports the notion that loss of HR function and CCNE1g are mutually exclusive 
events in HGS OC, but also presents a unique opportunity to therapeutically target the HR 
pathway in CCNE1g tumours [256, 277, 280]. Indeed, it has been suggested that the 
proteasome inhibitor bortezomib may be effective in this patient group: bortezomib has 
been identified as an inhibitor of the HR pathway, and may therefore induce synthetic 
lethality in CCNE1g cancer cells [280, 281].  
CN gain of EMSY/C11orf30, encoding the BRCA2-binding protein EMSY, has also been 
reported as a recurrent event in a subgroup of HGS OCs [210, 269, 282]. However, it remains 
unclear whether tumours harbouring this abnormality display and HR-deficient-like 
phenotype.  
Most recently, signatures of CN variation across the HGS OC genome have been used to 
identify CN-based subgroups of disease with differential outcome and propensity for 






1.9.3 Gene expression  
The identification of HGS OC subgroups defined by their gene expression profiles has been 
the focus of extensive research over the last decade [210, 211, 284-288], however 
meaningful consensus on how best to utilize transcriptomic data to sub-classify HGS OCs has 
not yet been achieved. Numerous studies have produced gene expression-based subgroups 
or prognostic signatures by supervised and unsupervised methods, based on small to large 
numbers of measured transcripts [210, 211, 284-295]. 
The first transcriptomic subgrouping study, conducted by Tothill et al. [211], characterized 
over 250 OCs, of which the majority were serous tumours of high grade, with a minority of 
endometrioid OC and serous OC of low grade. Their unsupervised subgrouping approach 
produced six subgroups within their cohort, referred to as C1-C6. The vast majority of serous 
grade II-III tumours were accounted for by the C1, C2, C4, and C5 subgroups; these groups 
demonstrated high expression of stromal response genes, high expression of immune 
response-related genes, low expression of stromal response genes, and enrichment of genes 
involved in mesenchymal development, respectively. The C1 ‘stromal’ subgroup, the largest 
of the subgroups, was identified as a subgroup of poor prognosis with C2, C4 and C5 patients 
collectively demonstrating superior PFS and OS compared to C1 patients [211]. Consistent 
with their gene expression profile, C1 tumours displayed the greatest levels of desmoplasia, 
while the two C3 and C6 subgroups had the least desmoplasia and the best survival consistent 
with the notion that these groups largely comprised endometrioid OC and what we now 
know as LGS OCs.  
Following the Tothill subgrouping study, The Cancer Genome Atlas (TCGA) performed 
genomic and transcriptomic characterization of HGS OCs, identifying four gene expression-





differentiated and proliferative based on their relative expression profiles, with the 
immunoreactive and mesenchymal subgroups bearing resemblance to the C2 and C5 Tothill 
subgroups, respectively [210, 211]. While these groups did not demonstrate significant 
differences in clinical outcome within the TCGA, more recent reproduction of these groups 
identified the immunoreactive subgroup as a group of better prognosis relative to the 
mesenchymal and proliferative groups within an independent cohort from the Mayo clinic 
[284]. The same study identified de novo subgroups reminiscent of those defined by TCGA, 
demonstrating greater survival differences.  
Unsupervised transcriptomic subgrouping of HGS OCs from Edinburgh revealed three 
subgroups termed Immune, Angio and AngioImmune, harbouring upregulation of immune 
response-related genes, angiogenesis-related genes, and both gene sets, respectively [285]. 
Together, the Tothill and TCGA studies suggest the existence of a subgroup of HGS OC 
characterized by activation of immune-related genes [210, 211], and consistent with these 
data the Edinburgh-derived Immune subgroup demonstrated superior survival [285]. 
Interestingly, this group may also represent those patients who do not benefit from the anti-
angiogenic agent bevacizumab, and indeed this agent may even reduce the survival within 
this subgroup [285]. Recently, similar analyses revealed differential benefit from 
bevacizumab addition to standard chemotherapy between the TCGA-derived subgroups 
demonstrating confinement of significant PFS improvement to the proliferative subtype 
[296].  
Most recently, a study identifying transcriptomic subgroups using pooled gene expression 
data from the public domain identified five subgroups: these subgroups largely recapitulated 
those identified by TCGA with the addition of an anti-mesenchymal group essentially defined 





mesenchymal subtype was associated with improved survival versus the mesenchymal 
subtype. Interestingly, this study also identified the mesenchymal subtype as those least 
likely to undergo optimal cytoreductive surgery [286]. 
Further to transcriptomic subgrouping approaches, numerous studies have endeavoured to 
produce transcriptomic risk scores for predicting outcome in HGS OC. These have included 
risk signatures from the TCGA investigators [210], Yoshihara et al [289, 290] and Bonome et 
al [291], among many others [292-295]. A recent meta-analysis of these signatures revealed 
variable correlation of these signatures, with a number of signatures showing little or no 
agreement [287]. Indeed, some risk signatures actually demonstrated inversely correlation. 
Concurrently, the same group produced a consensus risk signature which appeared to 
perform well across many of the current publicly available dataset [288].   
It is clear that a substantial body of work has been undertaken to characterize HGS OCs at 
the gene expression level [210, 211, 284-295]. However, the findings of these studies – 
whether they be transcriptomically-derived molecular subgroups or gene signatures 
quantifying relative risk – are ultimately yet to be used clinically. To date, gene expression-
based characterization is not used to stratify care or to evaluate risk in routine management 
of HGS OC. This is partly due to lack of consensus in exactly how to sub-classify these tumours 
based on transcriptomic characterization, and the lack of evidence supporting the 
prospective use of such tools in directing patients towards alternative therapeutic regimens.  
 
1.9.4 Identified molecular changes in acquired chemoresistance  
Relapse of HGS OC with acquired therapy resistance represents the primary cause of death 





[260]. Thus, identification of molecular events associated with acquisition of resistance is of 
great clinical interest, with the hope to identify biology that can be targeted therapeutically 
to delay or reverse chemoresistance.  
A common mechanism of acquired resistance in the context of HR deficiency is reversion of 
HR-inactivating mutations, such as BRCAm reversion, via secondary genomic events (Figure 
1.6) [256, 297-299]. These events typically restore the open reading frames (ORFs) of genes 
disrupted by frameshifting indels, or revert mutant alleles back to wild-type [256, 297-299]. 
Such events have been associated with resistance to both conventional DNA damaging 
chemotherapy and to PARP inhibition, consistent with the notion that they restore HR activity 
[297, 299, 300]. However, the allele fraction of such detected reversion events eludes to the 
presence of multiple distinct chemoresistance-associated mechanisms arising in parallel, 
reflecting the substantial heterogeneity of these tumours and underscoring the challenge of 
managing chemoresistant recurrence [301]. Indeed, multiple independent reversion events 
have been identified in different samples from the same patients [256]. Demethylation of 
the BRCA1 promoter has also been proposed as a mechanism of restoration of HR by re-
expression of BRCA1 [256].  
Paclitaxel, commonly used in combination with platinum as first-line therapy for HGS OC, is 
a known substrate of the drug efflux protein MDR1 encoded by ABCB1, and elevation of its 
expression has been proposed as a mechanism of acquired therapy resistance [302, 303]. 
Indeed, it has been shown that MDR1 is highly expressed in OC cells with derived resistance 
to paclitaxel and olaparib [302]. WGS analysis recently demonstrated that MDR1 is over-
expressed in some recurrent HGS OCs via SVs involving ABCB1 that lead to promoter hijacking 
[256]. Furthermore, alterations in the 5’ end of ABCB1 which may impact upon its regulation 











While a number of mechanisms of acquired therapy resistance have been elucidated to date, 
comprehensive characterization of the chemoresistant relapse specimens alongside their 
chemosensitive counterparts has only been conducted in relatively small patient series [256, 
298, 304]. Larger sequential sampling studies are required to better elucidate unidentified 
mechanisms of therapy resistance to conventional and targeted therapies, and to 
characterize the timing of such events.  
Moreover, the identified biology underpinning chemoresistance is yet to be harnessed 
clinically to prevent or reverse the development of resistance. Given the implied role of 
MDR1 activity in therapy resistance, efflux pump inhibition represents a therapeutic 
opportunity to re-sensitize cells to cytotoxic agents that are MDR1 substrates [256]. 
However, thus far the efficacy of MDR1 antagonists has been disappointing in other disease 
settings [305] and despite some promising in vitro data [306, 307], clinical investigations of 
these agents in OC remain in their early stages [308, 309]. Emerging data from studies 
characterizing matched diagnosis-relapse samples will undoubtedly shed light on further 
opportunities for targeted reversal of therapy resistance, and these investigations are an 
urgent unmet need in OC. 
 
1.10  Genetic and molecular changes in non-HGS ovarian carcinoma  
1.10.1 Endometrioid and CC ovarian carcinoma 
Consistent with shared developmental origins and molecular pathogenesis, mutations 
deregulating the PI3K pathway are common in endometrioid and CC OCs: around 20% and 
10% of cases harbour PTEN mutations, with around 30% and 50% display activating PIK3CA 
mutations, respectively [310-316]. Furthermore, both subtypes also harbour high 





endometrioid and around 50% in CC), and a minority display mutation of PPP2R1A, encoding 
a protein phosphatase 2A subunit [317-319]. 
However, unlike CC OC, endometrioid tumours commonly display Wnt-activating CTNNB1 
mutations (in around half of cases), while such mutations do not commonly occur in the CC 
histological subtype [217, 310, 311, 320]. Endometrioid OC cells also typically express the 
hormone receptors ER and PR [194]. Furthermore, chr20q13.2 amplification is common in CC 
OC, but not in endometrioid OC.  
A study deriving genomic subtypes of CC OC using unsupervised clustering of array 
comparative genomic hybridization (aCGH) data identified two CN-based subgroups of CC OC 
displaying significantly differential PFS and borderline significant differential disease-specific 
survival [321]. However, these groups have not yet been validated in an independent CC OC 
cohort, in part due to the relative rarity of true CC OC.  
 
1.10.2 Mucinous ovarian carcinoma 
Molecular characterization of mucinous OC has been hindered both by its relatively low 
prevalence, and the confusion of true primary mucinous OC with metastases from tumours 
of gastrointestinal origin [194]. HER2 amplification and KRAS mutation are known to be 
common events in these neoplasms (displayed in around 20% and 50% of cases, 
respectively), however this tumour type is largely understudied due to the rarity of true 
primary mucinous OC [237, 322]. 
Unlike HGS OCs, mucinous OCs appear relatively genomically stable, displaying low levels of 
LOH across the genome [323]. A relatively recent study conducting exomic sequencing of 





appears exclusive to carcinomas and borderline mucinous tumours, whereas this event 
appears not to occur in benign tumours of this type [216]. KRAS mutation was common 
across all benign and borderline tumours as well as carcinomas, whereas TP53 mutations and 
BRAF mutations were more common in carcinomas. Other recurrent events identified 
include mutations in GNAS, NRAS and RNF43, as well as CDKN2A loss [216].  
 
1.10.3 Low grade serous ovarian carcinoma 
LGS OC is a relatively recently identified disease entity and its low prevalence has hindered 
both identification and characterization of this subgroup of OC [195-197], however these 
tumours are now recognized as a separate entity to their HGS counterparts [215, 242, 244, 
250, 324]. Unlike HGS OC, a large proportion of LGS OCs display classic oncogenic driver 
mutations, including MAPK pathway-activating KRAS and BRAF mutations in 50% of cases 
with apparent mutual exclusivity [215, 324, 325]. Additional to KRAS and BRAF, mutations in 
NRAS are found in approximately 20% of cases, and a number of KRAS-BRAF-NRAS wild-type 
tumours may display mutations in other RAS/MAPK or ERBB2 pathway players. KRAS 
mutation may be associated with more aggressive, recurrent disease versus BRAF-mutated 
LGS OC, however reproduction of these data in large cohort of LGS OC has been hindered by 
its relative rarity and consequential lack of extensive investigation [326, 327].  
Other commonly mutated genes in LGS OC include USP9X and EIF1AX, which appear to occur 
most frequently in KRAS/NRAS/BRAF-mutant tumours, and have an implicated role in mTOR 
signaling [215]. This may suggest importance of cooperation of mTOR and MAPK signaling in 
some LGS OCs. Although some somatic CN alterations – including loss of CDKN2A/B – are 
common events in LGS OC, these tumours display relative genomic stability when compared 





1.11  A focus on homologous recombination deficiency in high grade 
serous ovarian carcinoma  
1.11.1 Key HR players and their function  
The HR pathway is one of the two major DNA repair pathways for repair of DSBs [329]. Unlike 
the error-prone non-homologous end joining (NHEJ) DSB repair pathway, HR makes use of 
an intact homologous DNA strand as a repair template for the damaged strand, enabling 
high-fidelity repair [330-332]. It also plays a key role in resolution of stalled replication forks 
[333]. HR is a complex, multistep-mechanism of DNA repair, requiring a multitude of 
proteins, many of whom are encoded by genes that are targets of germline or somatic 
mutational inactivation in cancer, including BRCAm [334]. 
 
1.11.1.1 Structure and function of BRCA1 
The BRCA1 gene encodes 1863 amino acids across its 24 exons, and is one of the most 
intensively studies genes to date [335, 336]. Its product, a 208kDa protein, is highly 
multifunctional with identified roles in DNA repair as well as cell cycle regulation and the 
wider DNA damage response [337-341]. These include its canonical role in the HR pathway: 
BRCA1 facilitates dsDNA break resection following its association with histones that are 
ubiquitylated in response to DNA damage, and aids recruitment of RAD51 to the dsDNA 
damage sites through associations with BRCA2 and PALB2 [342, 343]. Functional loss of 
BRCA1, and consequential loss of efficient HR, induces hypersensitivity to genotoxic insults, 
including DNA cross-linkers and ionizing radiation [337, 338]. Other functions of BRCA1 
include maintenance of  G1/S, S-phase and G2/M cell cycle checkpoints [341].  
Known domains within BRCA1 include two nuclear localisation sequences (NLS) encoded 





region, including sites for binding of proteins involved in DNA repair, as well as oncogene and 
TSG products. Among these are portions of a PALB2-interacting coiled coil domain and a 
serine cluster domain targeted by ATR and ATM kinases orchestrated by the DNA damage 
response [335, 346]. A BRCA1 C-terminus (BRCT) domain that binds phosphoproteins is 
located toward the C-terminal end of the protein, and a Really-Interesting-New-Gene (RING) 
domain with E3 ligase activity toward the N-terminal region [347-351] (Figure 1.7). These 
BRCT and RING domains are encoded within exons 16-24 and 2-7, respectively. Mutations 
predisposing individuals to cancer, most notably breast cancer (BC) and OC, have been 
identified across the length of BRCA1, suggesting important tumour suppressive function 
across BRCA1’s functional domains [335]. 
 
 







1.11.1.2 Structure and function of BRCA2 
The BRCA2 gene encodes 3418 amino acids across its 27 exons. Like BRCA1, BRCA2 is also 
involved in DNA repair: the 384kDa protein functions almost exclusively in HR, in contrast to 
the multifunctional role of BRCA1 [353, 354]. The primary role of BRCA2 is to recruit RAD51 
to sites of dsDNA damage, a critical step in the repair of DSBs by HR [354]. Loss of BRCA2 
function by BRCA2m hinders recruitment of RAD51 to DSB sites, leading to DNA damage 
hypersensitivity and accrual of gross genomic damage with subsequent replication cycles 
[355-358].  
As with BRCA1, BRCA2’s gene product has multiple functional domains, including eight 
conserved BRC repeats within its eleventh exon, which are known to interact with RAD51 
[359-363]. The C-terminal region contains two known NLS, and also interacts with RAD51 
[364]. Further regions of functional interest include a DNA binding domain, consisting of 
three oligonucleotide binding motifs, a tower domain and an α-helical domain [343, 365]. 
Cancer-predisposing mutations have been identified across BRCA2, including mutations 
within these identified functional regions [366].   
 
1.11.1.3 Function of PALB2, RAD51 and the RAD51 paralogues  
RAD51 plays a critical role in HR, and indeed more widely in DNA repair through numerous 
protein interactors [367]. It forms a nucleoprotein filament at replication protein A (RPA)-
bound DNA damage sites after its recruitment by the BRCA1-PALB2-BRCA2 complex [329]. 
Here, RAD51 catalyzes the core homology search and strand invasion steps that are central 
to HR. Several RAD51 paralog genes, including RAD51C and RAD51D, have been identified as 
having roles in the early stages of HR and have been reported as OC susceptibility genes [359-





Within HR, PALB2 undergoes a coiled-coil-mediated interaction with BRCA1 that facilitates 
the recruitment of the critical HR components BRCA2 and RAD51 [368]. It has also been 
shown to interact directly with RAD51, promoting its recombinase activity [369]. In the 
absence of PALB2, recruitment of BRCA2 and RAD51 is impaired, and efficient HR is 
disrupted. Similarly to BRCA1 and BRCA2, PALB2 mutations are associated with cancer 
predisposition, most notably in BC and OC [187, 370].  
 
1.11.2 The HR-deficient “BRCAness” phenotype in HGS OC 
The so-called “BRCAness” phenotypes describes a distinct set of characteristics originally 
described in germline BRCAm OC population [262]. The core features of this phenotype 
include prolonged survival [262, 371-374], hypersensitivity to multiple lines of platinum-
based chemotherapy [262-264] and greater sensitivity to PARP inhibitors [169, 171, 375-
377]. More recently, it has become apparent that somatic BRCAm and non-BRCA-HRm also 
confer a BRCAness-like phenotype [170, 260, 378, 379], consistent with these features being 
a manifestation of HR-deficiency, rather than of BRCAm per se.  
Interestingly, recent data suggest that not all BRCAness is equal [352]. BRCA2m OC appear to 
demonstrate a more exaggerated HR-deficient phenotype, demonstrating superior OS and 
PFS compared to their BRCA1m counterparts, most notably in long-term survival [264, 371, 
380-383]. It has been suggested that BRCA2m OC may also be more sensitive to platinum-
based chemotherapy [264, 371] and PARP inhibitors [168, 376, 384]. However, this is yet to 
been meaningfully demonstrated in the clinical setting. Furthermore, it has been suggested 
that mutations within BRCA1’s exon 11 may not confer the platinum and PARP inhibitor 





regarded as a single clinical entity, and no stratification by specific gene or mutation site is 
currently implicated in clinical practice.  
 
1.12  Function of non-HR genomic event targets in HGS OC 
1.12.1 Structure and function of TP53 
TP53 is perhaps the most famous of all TSGs, and is the most commonly mutated gene in 
cancer [7]. Its product, P53, forms a homo-tetrameric transcription factor which serves as a 
sentinel of genomic integrity and cell cycle regulation [389]. Unlike classical TSGs, TP53 
mutations exert a dominant negative effect, with mutations in a single allele producing 
mutant protein which abrogates the normal function of wild-type protein produced from the 
remaining intact allele [21].  
Cellular P53 levels increase in response to DNA damage, which go on to activate transcription 
of proteins which function to induce cell cycle arrest, including p21 [389-391]. While control 
of p21 encourages cell cycle arrest at the G1 phase, P53 also acts to engage the G2/M cell 
cycle checkpoint via disruption of the cyclinB1/CDC2 complex [392].  
At its N-terminus, P53 harbours a transactivation domain (TD) critical for its transcriptional 
activity: this region binds basal transcriptional machinery components and p300/CBP 
transcriptional co-activators [393], as well as the N-terminal of the P53-regulator MDM2 
[394]. The TD is subject to phosphorylations by a range of kinases – including ATM, ATR and 
DNA-PK – which alter the affinity of interactions with these binding partners, modulating its 
regulation and activity [390, 391, 395]. A key example of the importance of these events is 
the stabilization of P53 by phosphorylation: under normal conditions, MDM2 ubiquitylates 





binding lead to P53 stabilization and rise in cellular P53 levels in response to DNA damage 
[390, 391].  
Adjacent to the N-terminal transactivation domain is a proline rich region followed by a DNA 
binding domain at amino acids 94-292 [397], wherein the majority of identified pathogenic 
TP53 mutations occur [398-400]. At P53’s C-terminus is a C-terminal regulatory domain 
(CTRD) which sits adjacent to the tetramerization domain [401]. The CTRD is a target of 
diverse post-translational modifications which regulate both P53 function and levels of P53 
within the cell, including phosphorylation, methylation, acetylation, sumoylation, 
ubiquitylation and neddylation events [389].  
 
1.12.2 NF1 function 
Encoded at chromosome 17q11.2, the NF1 gene is most famous for the association of 
germline inactivation with neurofibromatosis [402]. Sporadic NF1 loss has been identified in 
a number of tumour types, including OC, as well as brain, breast and lung cancers [403, 404]. 
Neurofibromin, the gene product of NF1, is a key regulator of Ras activity (Figure 1.8) [405]. 
By acting as a GTPase activating protein (GAP), neurofibromin carries out tumour suppressive 
function by catalyzing the conversion of active Ras to inactive Ras, attenuating the 
downstream activity of the pro-proliferative and pro-survival MAPK, PI3K/AKT and mTOR 
pathways, which are commonly targets of activation in cancer [405-407].  
Other mechanisms of tumour suppression by neurofibromin include regulation of adhesion 
and motility via interactions with focal adhesion kinase (FAK) [408], alternative routes of 
MAPK and PI3K pathway regulation via interactions with Cav-1 [409, 410], and regulation of 






Figure 1.8 The function of neurofibromin, the gene product of NF1. Nf, neurofibromin. 
 
1.12.3 RB1 function 
RB1 is a prototypic TSG [16]. Originally identified as a susceptibility gene for retinoblastoma, 
RB1 mutations have been identified in a range of malignancies, including osteosarcoma and 
small cell lung cancer [19, 20, 412, 413]. The archetypal role of RB1’s gene product, pRB, is 
transcriptional control of cell cycle progression genes via regulation of E2F transcription 
factors in the commonly perturbed INK4A-Cyclin D1-pRB-E2F pathway (Figure 1.9) [414]. 
Active pRB binds and inactivates E2F, leading to transcriptional repression of E2F-target 





hyperphosphorylation of pRB by CDKs leads to loss of E2F sequestration and subsequent 
expression of E2F-target genes that facilitate progression through the cell cycle [416].  
Loss of pRB function and proper regulation disrupts this cell cycle regulatory mechanisms and 
renders cells more susceptible to oncogenic proliferation [417]. Further pertinent roles of 
pRB in the context of carcinogenesis include transcription-independent regulation of cell 
cycle progression via interactions with SKP2 that regulate p27 stability [418], and regulation 










1.12.4 CCNE1 function 
The gene product of CCNE1, Cyclin E1, has a multifunctional role in cell cycle regulation. 
Primarily, it activates CDK2 allowing phosphorylation of Cyclin E1-CDK2 targets which 
subsequently promotes passage from G1 into S phase (Figure 1.9) [420]. Cyclin E1-CDK2 
targets include pRB [421], centrosome replication proteins [422] and proteins involved in 
histone gene transcription [423].  However, Cyclin E1 also has CDK2-independent functions: 
Cyclin E1 plays a role in G1 entry from quiescence and overexpression of Cyclin E1 promotes 






2 CHAPTER 2: DIFFERENTIAL RESPONSE RATE TO PEGYLATED 
LIPOSOMAL DOXORUBICIN BETWEEN BRCA WILD-TYPE AND 




Pegylated liposomal doxorubicin (PLD) is a cytotoxic agent used in the treatment of recurrent 
OC, typically in the context of decreasing efficacy of platinum-based chemotherapy (platinum 
resistance) [130]. Commonly known as Caelyx or Doxil, PLD is a doxorubicin formulation 
modified by encapsulation with a polyethylene glycol (PEG)-ylated lipid bilayer (liposome) 
(Figure 2.1) [425]. This hydrophilic ‘stealth’ liposome capsule confers a number of benefits: 
it increases the drug half-life and decreases gastrointestinal and cardiotoxicity compared to 
free doxorubicin, owing to altered propensity for interaction with circulating proteins and 
limited extravasation potential of PLD across intact normal (non-tumour) vasculature [425-
427]. In contrast, PLD is readily able to extravagate across walls of tumour vasculature. These 
vessels are characterised by looser capillary junctions when compared to normal vasculature, 
leading to more selective uptake within the tumour versus normal tissues, where PLD is 
poorly cleared due to chaotic lymphatic organisation within the tumour mass [428-430].  
 
Figure 2.1 Doxorubicin, pegylated and liposome encapsulated to reduce toxicity and increase 





Like platinum-based chemotherapy, the first-line therapy of choice for OC, DNA damage is a 
principle mechanism of PLD action [432]. There are two primary pathways by which 
doxorubicin exhibits its cytotoxic effects: firstly, it acts as a topoisomerase II poison by 
intercalating into DNA and resulting in formation of covalently-bound DNA-protein 
complexes, ultimately leading to increased levels of DNA breaks [433, 434]. Secondly, 
production of free radicals leads to oxidative stress and damage to cell membranes and DNA, 
resulting in cytotoxicity [432].  
Single-agent PLD response rate is around 12% in the platinum-resistant recurrent OC setting 
[435, 436], and PLD is reportedly preferable to topotecan with regard to both survival and 
toxicity in relapsed OC [437]. Similarly, in the context of platinum sensitive disease relapse, 
platinum-PLD combination therapy may be more effective than platinum-paclitaxel therapy 
[154, 438], and PLD monotherapy appears to confer prolonged OS and PFS in this setting 
when compared to treatment with topotecan [437]. 
Interestingly, a randomised phase II trial comparing two dosage strategies of the PARP 
inhibitor olaparib against single-agent PLD in a population of BRCAm OC demonstrated 
meaningful efficacy of PLD, with an objective response rate (ORR) of 18% and median PFS of 
7.1 months [375]. While this ORR is not wholly beyond the expected rate for PLD in the setting 
of relapse within 12 months of previous chemotherapy, the non-inferiority of PLD versus the 
olaparib-treated arms is of great interest particularly in light of the now widely known 
efficacy of PARP inhibitors in the BRCAm population [120, 169, 375, 439]. These data 
indirectly suggest that PLD may have high efficacy in BRCAm OC.  
Because (i) PLD demonstrated notable efficacy in the above described trial, (ii) DNA damage 





BRCAm is associated with superior response to multiple lines of platinum-based 
chemotherapy, it was hypothesised that OC harbouring BRCAm may experience differential 
response rate to PLD versus the BRCAwt population.  
Three previous studies have attempted to investigate the interaction between BRCAm status 
and PLD response [440-442]. However, these investigations have suffered from a number of 
limitations in design. It is now recognised that the different histologically-defined subtypes 
of OC have markedly different intrinsic chemosensitivity profiles [219], and all previous 
studies relating BRCA status to PLD efficacy have been performed in cohorts comprising 
heterogeneous histological composition. Secondly, all previous studies have limited BRCAm 
status to germline sequencing, despite a significant number of OC known to harbour somatic 
BRCA inactivation [210, 260]. Furthermore, all of these studies comprised a proportion 
“presumed BRCAwt” OC within their comparator cohorts who in fact had no BRCA 
sequencing and were at best screened to ensure a lack of strong family history of malignancy. 
Further to these pan-study limitations, one study limited sequencing to BRCA hotspot regions 
[441], and two analysed PLD response in the context of co-administration with platinum in a 
significant number (approximately 50%) of patients [440, 441].  
The culmination of these limitations is that these analyses may have been confounded by: (i) 
differential intrinsic chemosensitivity of histological subtypes of OC [219]; (ii) increased 
response rate of BRCAm patients to the platinum component of PLD-platinum combinations 
[262]; (iii) the failure to identify patients with somatic BRCAm, who are known to display 
phenotypic similarity to germline BRCAm OC [260, 379]; (iv) the inclusion of “presumed wild-
type” patients in comparator cohorts with or without screening for family history of 
malignancy, particularly in light of the known limited power of family history to predict 





rate in a histologically uniform cohort of OC with comprehensive BRCA sequencing is needed 
to better interrogate the possible relationship between BRCAm status and PLD efficacy.  
Here we seek to identify a cohort of OC treated with single-agent PLD within the Edinburgh 
Cancer Centre, collect tumour material from these patients and use NGS technology to 
sequence the BRCA genes in order to compare the relative response rates of BRCAm and 






2.2 Study Aims  
This body of work seeks to compare the response rates of recurrent OC to single-agent PLD 
between BRCAm and BRCAwt OC. Specifically, this study aims to: 
1. Retrospectively identify OC patients treated with single-agent PLD at the Edinburgh 
Cancer Centre using the Edinburgh Ovarian Cancer Database 
2. Retrieve archival tumour material for PLD-treated cases  
3. Perform contemporary pathology review of retrieved specimens  
4. Extract DNA from macrodissected archival tumour material  
5. Perform NGS sequencing of BRCA1 and BRCA2 using DNA derived from archival 
material  
6. Identify pertinent sequence variants likely to impact upon BRCA1 and BRCA2 protein 
function 
7. Collect PLD response data for each patient using the Edinburgh Ovarian Cancer 
Database alongside archived patient notes 





2.3 Materials and methods  
 
2.3.1.1 Identification of PLD-treated OC  
148 OC patients treated with single-agent PLD between 2001 and 2014 were identified 
retrospectively from the Edinburgh Ovarian Cancer Database (Figure 2.2). Clinical research 
access and ethical approval for correlation of molecular data to clinicopathological features 
and clinical outcome in OC was obtained via NHS Lothian Research and Development 
(reference ID 2007/W/ON/29). Use of human material for translational research was 
approved by the Lothian NRS Human Annotated Bioresource (ethics reference ES/15/0094-
SR158). Tumour material was available for 119 cases (80.4%), from which a 5µm section was 
cut to be stained with haematoxylin and eosin (H&E) and used for contemporary pathology 
review. 10µm sections were taken for nucleic acid extract. Sections and H&E-stained slides 
were prepared by the Lothian NRS Human Annotated Bioresource in accordance with the 
agreement for the use of human tissue specimens in research. 
  
 





2.3.2 Contemporary pathology review  
Contemporary review of histological OC subtype was performed by Professor Simon 
Herrington, an expert gynaecological pathologist. Immunohistochemistry (IHC) documented 
on patient pathology reports, retrieved from available paper and electronic health records, 
and additional IHC staining for WT1 and P53 (see section 2.3.3) were used to aid histotyping 
in cases where subtype was unclear from H&E-stained slides alone [236].  
 
2.3.3 Immunohistochemical staining for WT1 and P53 
WT1 and P53 staining was performed on 5µm sections mounted on charged glass slides using 
antibodies M3561 clone 6F-H2 (Dako, Agilent Technologies, CA, US) and M7001 clone DO-7 
(Dako, Aglient Technologies, CA, US), respectively. Both stains were performed on the Leica 
Bond III Autostainer (Leica Biosystems, Illinois, US) using bond protocol IHC-F by the Division 
of Pathology Laboratories, Western General Hospital, University of Edinburgh, UK. P53 
staining was performed using antigen retrieval method ER1 for 20 minutes and a primary 
antibody dilution of 1:50. WT1 staining was performed using antigen retrieval method ER2 
for 20 minutes and a primary antibody dilution of 1:1000.  
IHC staining for P53 and WT1 was interpreted in consultation with Professor Simon 
Herrington as outlined in Table 2.1 [236, 252]. Staining examples are provided in Figure 2.3 








Figure 2.3 Low (left) and high (right) power views of immunohistochemically P53-stained OC 
tissue. A and B depict a CC OC with variable nuclear intensity (wild-type pattern) P53. C and 
D depict a case of HGS OC demonstrating aberrant positive nuclear P53 expression. E and F 
depict aberrant null nuclear P53 expression in a case of HGS OC with neighbouring stromal 
positivity. 
 
2.3.4 Macrodissection and DNA extraction  
Macrodissection of 10µm formalin-fixed paraffin-embedded (FFPE) tissue sections was 
performed using H&E-stained slides as a guide, marked to identify tumour area by an expert 
pathologist (Professor Mark Arends, Edinburgh CRUK Centre, MRC IGMM, University of 
Edinburgh, UK). Nucleic acids were extracted using the QIAamp DNA FFPE Tissue Kit and 







Figure 2.4 Low (left) and high (right) power views of immunohistochemically WT1-stained OC 
tissue. A and B depict an endometrioid OC showing negative nuclear WT1 expression with 
stromal positivity. C and D depict a case of HGS OC demonstrating positive nuclear WT1 
expression.  
 
Table 2.1 Summary of WT1 and P53 IHC staining interpretation. 
Protein  Classification  Example  Description  Histotype implications 
P53 Wild-type Figure 
2.3A 
Variable nuclear positivity 
consistent with wild-type 
P53 protein being 
correctly regulated with 
the cell cycle  
Indicative of non-HGS 





Invariable strong nuclear 
overexpression of P53 
consistent with missense 
mutation of P53 altering 
normal regulation  
Indicative of TP53-
mutant OC. Consistent 
with HGS or TP53-
mutant endometrioid, 
CC or mucinous OC. 





Complete absence of P53 
protein consistent with 
complete ablation of P53 
expression via 
frameshifting indel, 
nonsense of splice site 
mutation in TP53 
Indicative of P53-
mutant OC. Consistent 
with HGS or TP53-
mutant endometrioid, 
CC or mucinous OC. 
Inconsistent with LGS. 
WT1 Positive  Figure 
2.4A 
Nuclear positivity  Indicative of serous 
tumour (LGS or HGS) 
 Negative  Figure 
2.4B 
Nuclear negativity  Indicative of non-





2.3.5 NGS of BRCA1 and BRCA2 
The exons of BRCA1 and BRCA2 were sequenced on the Ion Torrent platform using the Ion 
Ampliseq BRCA1 and BRCA2 community panel. Of the 119 cases with available tumour 
material, 111 (93.3%) underwent successful DNA extraction and sequencing (Figure 2.2). DNA 
sequence variants were called using Torrent Variant Caller v4.6.0.7 following generation of 
BAM files by Torrent Suite v4.6. The median per-sample mean depth of coverage was 4728X; 
the lowest mean depth of coverage was 916X. A uniformity score was calculated for each 
sample as the proportion of targets covered at 20% of the respective mean sample depth; 
the median per-sample uniformity by this calculation was 90.5%. Functional annotation of 
called variants was performed using Ensembl Variant Effect Predictor (VEP) version 75. 
 
2.3.6 Correction for sequencing artefacts associated with formalin 
fixation  
FFPE-derived DNA is known to demonstrate high levels of fragmentation, hindering the use 
of NGS technologies requiring amplification of mid-length and large DNA segments; use of 
small amplicon captures represents a method to overcome this pitfall [444, 445]. However, 
formalin fixation is also known to damage individual DNA bases, principally through 
spontaneous deamination, leading to extensive sequencing artefacts in FFPE-derived DNA 
[444, 445]. Such  artefacts were evident in these data as a bias bi-allelic single nucleotide 
variants (SNV) spectrum when compared to SNVs present in the TCGA cohort of fresh-frozen 
OCs [210]. Concurrent with the findings of previous studies of the effects of formalin fixation, 
there was a marked excess of C>T SNVs suggesting global cytosine deamination (Figure 2.5): 
cytosine is deaminated to uracil which is subsequently converted to thymine during PCR 






Figure 2.5 SNV spectra of DNA from fresh frozen HGS OCs in the TCGA versus FFPE-derived 
DNA in the PLD-treated cohort. Adapated with permission from Hollis et al 2018 [447]. 
 
In collaboration with Dr Alison Meynert (MRC Institute of Genetics and Molecular Medicine, 
University of Edinburgh, UK), we sought to compensate for these formalin fixation artefacts 
using an allele frequency (AF) threshold filter: if global deamination from formalin fixation 
results in damage (including deamination) across DNA then the bulk of these artefacts should 
be represented by variants with low AF. Accordingly, we applied a minimum AF threshold to 
the variants called within our dataset and compared the resulting set against that of the fresh 
frozen TCGA cohort using two methodologies [210]. Firstly, we analysed the proportion of 
previously documented variants (PDVs), as variants more likely to represent true positives, 
versus the proportion of novel variants (NVs), which are more likely to represent false 
positives (Figure 2.6). Secondly, we compared the SNV spectra (Figure 2.7, Table 2.2).  
At increasing AF thresholds, greater numbers of both PDVs and NVs are removed; analysis of 
the proportion of retained PDVs (likely true positives) versus removed NVs (more likely false 
positives) identified that up to an AF of 10% more NVs are removed than PDVs being retained 





removed versus NVs retained. These data indicate that up to an AF threshold of 10% 
increasing proportions of likely false positives are being removed, while the vast majority of 
true variants are being retained, and that thresholds above 10% begin to eliminate greater 
proportions of likely true variants.  
Similarly, the sum of squares differences between the bi-allelic SNV spectrum in our dataset 
versus TCGA was minimised at an AF threshold of 10% (Figure 2.7, Table 2.2). Together, these 
analyses support the adoption of a 10% AF cut-off, which appears to remove the bulk of 
sequencing artefacts resulting from formalin fixation while retaining the vast majority of 
likely true positive variants. Accordingly, the subsequently presented data include analyses 
of the variants detected at an allele frequency of 10%, with the remaining variants discarded 
as likely formalin fixation artefacts.  
 
Figure 2.6 Proportion of PDVs and NVs removed and retained at various minimum AF filtering 






Figure 2.7 Sum of squares differences of SNV class proportions between FFPE- and fresh 
frozen-derived DNA at various AF filtering thresholds. Adapated with permission from Hollis 
et al 2018 [447]. 
 
Table 2.2 SNV class proportions and sum of squares differences between FFPE-derived DNA 
SNV spectra versus that of the fresh frozen TCGA cohort. Adapated with permission from 
Hollis et al 2018 [447]. 
 Threshold allele frequency Fresh frozen TCGA cohort 
proportions  
SNV class 0.00 0.05 0.1 0.15 
 
C>T/G>A 0.839 0.737 0.554 0.449 0.366 
C>A/G>T 0.017 0.026 0.063 0.064 0.186 
C>G/G>C 0.012 0.023 0.036 0.051 0.175 
A>G/T>C 0.100 0.165 0.286 0.372 0.126 
A>T/T>A 0.015 0.023 0.009 0.013 0.087 
A>C/T>G 0.017 0.026 0.054 0.051 0.061 





2.3.7 Classification of BRCA variants by functional relevance  
Variants were classified by likely functional impact upon their respective proteins. Nonsense 
variants and indel variants leading to frameshifts in the ORF were classified as likely damaging 
to protein function. Splice site variants with reported pathogenicity and missense variants 
with reported pathogenicity were classified as likely damaging. Synonymous variants were 
classified as likely benign, as were missense variants predicted benign by both PolyPhen and 
SIFT prediction tools [448, 449]. Missense variants with conflicting PolyPhen and SIFT 
predictions were classified as variants of unknown significance, while those predicted 
deleterious by both were classified as likely damaging.  
Three recurrently called indel variants were identified in the sequencing data (Table 2.3). 
False positive indel calling is a known pitfall of Ion Torrent sequencing technology around 
problematic genomic regions (principally homopolymer tracts), which are known to be 
present in both BRCA1 and BRCA2 [450]. To investigate these potential false positive variant 
calls, corresponding genomic regions were amplified using PCR and subject to conventional 
(Sanger) sequencing (see section 2.3.8). These data confirmed the suspect variants as false 
positive calls (Figure 2.8).  
 
 













11 13 32907215 BRCA2 GAA GAAA 
6 13 32913676 BRCA2 CAAAAAT CAAAAAAT 








Figure 2.8 Examples of Sanger sequencing confirming false positive recurrently called indels 
in tumour DNA (lower halves) compared to known wild-type sequence (upper halves) at 





2.3.8 Conventional sequencing  
Conventional sequencing of FFPE DNA comprised 5 steps: PCR amplification of template DNA, 
PCR product clean-up, sequencing of purified product, clean-up of the sequencing product, 
and sequence reading. Details of PCR master mix, PCR primers, and PCR amplification 
conditions are summarised in Table 2.4, Table 2.5, Table 2.6, Figure 2.9 and Figure 2.10. 
PCR products were visualized by gel electrophoresis using a 2% agarose gel stained with 
GelRed (Biotium Inc., CA, US) to ensure reaction success and correct product length. PCR 
clean-up was performed by incubation of 5l PCR product with 2l ExoSAP-IT PCR Product 
Cleanup Reagent (Applied Biosystems, ThermoFisher Scientific, Massachusetts, US) for 30 
minutes at 37C, followed by 15 minutes incubation at 80C to denature the ExoSAP-IT 
enzymes. Cleaned products were diluted 1:1.5 with deionised water prior to use in the 
sequencing reaction.  
Sequencing reactions were performed as outlined in Table 2.7 and Figure 2.10, and purified 
using DyeEx 2.0 Spin Columns (Qiagen, Venlo, Netherlands) according to the manufacturer’s 
instructions. Sequencing products were subsequently read using a 3730 DNA Analyser 
(Applied Biosystems, ThermoFisher Scientific, Massachusetts, US) by the MRC Human 
Genetics Unit Technical Services, MRC Institute of Genetics and Molecular Medicine, 

















Table 2.4 PCR primers used for PCR amplification of pertinent genomic regions corresponding 
















AmpliTaq Gold 360 Master 
Mix (Applied Biosystems, 
ThermoFisher Scientific, 































AmpliTaq Gold 360 Master 
Mix (Applied Biosystems, 
ThermoFisher Scientific, 








Table 2.5 Reagents for PCR reaction using AmpliTaq Gold 360 Master Mix. 
Reagent  Concentration µL per 20uL reaction 
AmpliTaq Gold 360 Master Mix (Applied 
Biosystems, ThermoFisher Scientific, 
MA, US) 
2X 10 
Forward primer 20mM 0.2 
Reverse primer 20mM 0.2 
Template DNA  10ng/µL 2 
Deionised water  7.6 
 
 
Table 2.6 Reagents for PCR reaction using Multiplex PCR Master Mix. 
Reagent  Concentration µL per 20uL reaction 
Multiplex PCR Master Mix 
(Qiagen, Venlo, Netherlands) 
2X 10 
Q-Solution (Qiagen, Venlo, 
Netherlands) 
5X 4 
Forward primer 20mM 0.2 
Reverse primer 20mM 0.2 
Template DNA  10ng/µL 2 







Table 2.7 Reagents for sequencing reaction. 
Reagent  Concentration  µL per 20uL reaction  
BigDye Terminator (Applied Biosystems, 
ThermoFisher Scientific, MA , US) 
2.5X 8 
Sequencing primer 20uM 0.5 
Diluted PCR product  1:1.5 dilution of PCR 
product treated with 
ExoSAP-IT 
4 




2.3.9 PLD response data 
Response data were collected retrospectively using the Edinburgh Ovarian Cancer Database 
alongside archived patient notes and electronic healthcare records. PLD responders were 
defined as patients who demonstrated radiological (WHO or RECIST criteria as most patients 
predated RECIST reporting) or CA125 tumour marker response as per GCIG criteria [451]. 
Patients who received less than two cycles of PLD were considered non-evaluable for 
response due to insufficient exposure to drug (Figure 2.2). Those without sufficient 
investigations to evaluate both tumour marker and radiological response were classified as 
non-evaluable. Patients with progressive disease, stable disease and those that succumbed 








2.4 Results  
2.4.1 Frequency of damaging BRCA sequence aberrations and 
characteristics of BRCA-aberrant OC  
111 OC treated with single-agent PLD were successfully sequenced for BRCA1 and BRCA2 
(Figure 2.2). 46 variants were determined as likely to affect protein function as defined above 
in section 2.3.7; 26 were BRCA1 variants and 20 were BRCA2 variants. Of these 46 variants, 
22 were frameshifting indels, 1 was a nonsense mutation, 2 were splice site mutations and 
21 were missense mutations, including 11 cases of the BRCA1 single nucleotide 
polymorphism (SNP) rs1799950 which confers a Gln356Arg amino acid change predicted 
detrimental by both PolyPhen and SIFT damage prediction tools.  
Of the 111 successfully sequenced PLD-treated OCs, 24 (21.6%) harboured a detrimental 
BRCA1 variant and 12 (10.8%) harboured a detrimental BRCA2 variant. One (0.9%) of these 
patients harboured damaging sequence changed in both BRCA1 and BRCA2. These data are 
consistent with previous reports of higher BRCA1m rate versus BRCA2m rate in OC [352].  
Demographics of BRCA-aberrant and BRCAwt OC are described in Table 2.8. All but one of 
the BRCA-aberrant cases were of HGS histology, consistent with previously reported data 
[266, 374, 452], with the remaining case being an endometrioid OC of high-grade histology. 
Between the BRCA-aberrant and BRCA wild-type groups, there was no difference in primary 
surgical debulking status, platinum sensitivity status at time of PLD exposure, FIGO disease 
stage at diagnosis, or in total lines of chemotherapy received before PLD (Table 2.8). 
Consistent with previous reports of younger age at diagnosis of BRCAm OC [266, 374, 452], 
BRCA-aberrant patients within our cohort were diagnosed at significantly younger age versus 














 No. % No. %  
Age at diagnosis, years  
               Median 55  64  
<0.001 ^ 
               Range 39 - 77  41 - 82  
FIGO stage at diagnosis  
               I 1 2.9 1 1.4 
0.470 # 
               II 3 8.6 4 5.6 
               III 23 65.7 48 66.7 
               IV 8 22.9 19 26.4 
               NA 0 0 4  
Histology  
               HGS 34 97.1 70 92.1 
0.429 + 
               Endometrioid 1 2.9 2 2.6 
               Clear Cell 0 0 2 2.6 
               Mucinous 0 0 0  
               LGS 0 0 0  
               Carcinosarcoma 0 0 2 2.6 
Platinum sensitivity at 
PLD initiation 
 
               Sensitive 5 15.2 9 12.5 
0.761 ×                Resistant 28 84.8 63 87.5 
               NA 2  4  
No. of chemotherapy 
lines prior to PLD  
 
               ≤2 25 71.4 61 80.3 
0.429 $ 
               >2 10 28.6 15 19.7 
Debulking status  
               <2cm 14 42.4 23 31.5 
0.282 $                ≥2cm 19 57.6 50 68.5 
               NA 2  3  
Evaluable for PLD  
response 
 
               Evaluable 26 74.3 61 80.3 
0.644 $ 
               Not evaluable 9 15.7 15 19.7 
^ Welch Two Sample t-test; + Fisher’s Exact test, HGS versus non-HGS histology; # Fisher’s 
exact test, early (I-II) versus advanced (III-IV) stage at diagnosis; × Fisher’s exact test; $ Chi-






2.4.2 Frequency of PLD response  
Of the 111 successfully sequenced PLD-treated OC, 24 (21.6%) were non-evaluable for 
response as per the criteria outlined in section 2.3.9 (Figure 2.2). Of the remaining 87 
patients, 17 (19.5%) achieved partial or complete CA125 tumour marker (CA125-PR or 
CA125-CR) or radiological response (radioPR or radioCR), akin to previously reported 
response rates to PLD monotherapy in this setting [435, 436, 453]. Of these, 16 (94.1%) were 
HGS OC, with the remaining case being a carcinosarcoma. Accordingly, the response rate to 
single-agent PLD specifically within HGS OC was 19.3% (16 of 83 evaluable cases). The 
response rate in non-HGS OC was 25.0% (1 of 4 non-HGS OCs). Limited numbers of non-HGS 
OC precluded comparison of response rates to PLD between OC histotypes.  
 
2.4.3 Impact of BRCA sequence aberrations on PLD response in HGS OC  
25 HGS OCs were evaluable for PLD response and harboured BRCA sequence variants 
predicted damaging. Of these, 9 (36.0%) cases achieved a response to PLD; 6 were CA125 
responses, two were radiological responses, and one was radiological and CA125 responses. 
This was significantly higher than the response rate in their BRCAwt counterparts (36.0%, 9 
of 25 BRCA-aberrant HGS OC vs 12.1%, 7 of 58 BRCAwt HGS OCs; Fisher’s exact test, P=0.016) 
(Figure 2.11). Of the 7 BRCAwt responses, three were CA125, two were radiological and two 
were radiological and CA125 responses. 
Within the BRCA-aberrant cohort, 6 patients harboured only the BRCA1 SNP rs1799950 
predicted detrimental to protein function. Within this rs1799950 group, PLD response rate 
was 50.0% (3 of 6 HGS OCs), which was significantly higher than the corresponding rate in 
the BRCAwt cohort (50%, 3 of 6 rs1799950 HGS OCs vs 12.1%, 7 of 58 BRCAwt HGS OCs; 





(bona fide BRCAm) cohort was 31.6% (6 of 19 HGS OCs), which was not significantly different 
to the rs1799950 cohort (31.6%, 6 of 19 versus 50%, 3 of 6; Fisher’s exact P=0.630). There 
was a strong trend for superior response rate to PLD in the non-rs1799950 BRCAm HGS OCs 





Figure 2.11. Response rate to single-agent PLD by BRCA status. Dashed line indicate 95% 






2.5 Discussion  
Retrospective cohorts represent an invaluable resource for translational projects seeking to 
correlate findings from molecular analyses with clinical outcome. Molecular characterisation 
of such cohorts facilitates rapid association of identified biology with long-term clinical 
outcome, bypassing time needed for clinical data to mature when specimens are being 
collected prospectively. Such resources include both local patient databases – such as the 
Edinburgh Ovarian Cancer Database utilized in this study – as well as clinical trial datasets, 
wherein the clinical annotation is often high in quality, depth and uniformity. Indeed, clinical 
trials represent a highly valued resource for validation of findings from other datasets, and 
replication of associations within clinical trial cohort is often essential for defining impactful 
associations. However, retrospective molecular studies must make use of archival tissue, 
typically collected via routine pathological examination of material from surgical procedures, 
most commonly in the form of FFPE specimens. Such samples may be limited in both quantity 
and quality.  
With regard to genomic analyses, FFPE material presents challenges of both highly 
fragmented genomic material and modification of DNA sequence during fixation or storage, 
which can be further compounded by low DNA yield [454]. While fragmentation prevents 
amplification of large genomic regions in a single PCR reaction, this issue can be overcome 
by the use of small amplicon captures which are more amenable to FFPE-derived genomic 
material, as is now the norm in FFPE-compatible NGS panels [455]. Less easily overcome is 
fixation-associated artefacts that affect the DNA sequence itself: sequencing of FFPE-derived 
DNA risks misidentification of these post-collection modifications as pertinent mutational 
events present in the tumour at the time of sampling. While the exact cause of FFPE DNA 





substitutions, thought to be a result of spontaneous deamination [445, 446, 456]. Oxidative 
damage and spontaneous hydrolysis have also been proposed as further mechanisms of 
damage [457, 458].  
We have demonstrated the ability to sequence FFPE-derived DNA at high depth in a cohort 
of PLD-treated OC using an NGS panel targeting BRCA1 and BRCA2. Consistent with previous 
reports of fixation-associated damage in FFPE-derived DNA, we observed a strong bias in the 
spectrum of sequence variation detected within our cohort versus that in NGS of fresh frozen 
OC by the TCGA [210]. Concordant with previous reports, the strongest bias was in C:G>T:A 
SNVs, with other biases also present at lower levels [445, 446, 456]. We have demonstrated 
that use of a minimum AF filter for detected variants minimises these biases, removing the 
bulk of FFPE artefacts whilst retaining the vast majority of likely true variants. While this 
approach inevitably removes a proportion of likely true positive variants, including those 
present within minor subclones of the tumour cell population, it achieves a practical balance 
of true signal retention versus noise reduction, allowing interpretation of DNA sequence 
variants in the context of translational research questions.  
Using this approach, we detected 46 BRCA1 and BRCA2 sequence changes likely to affect 
protein function, including the BRCA1 SNP rs1799950, an SNV conferring Gln356Arg, 
predicted detrimental by PolyPhen and SIFT missense variant prediction tools [448, 449]. The 
BRCA-aberrant population demonstrated a significantly increased PLD response rate of 
around 2.5-fold (31.6% versus 12.1%) when compared to that of the BRCAwt population. 
These data are consistent with the notion that HR deficiency by virtue of detrimental BRCA 
sequence changes confer hypersensitivity to non-platinum DNA damaging agents, as well as 





Compared to the reported poor PLD response rates in unselected OC recurrence [435-437], 
and to the response rate in the relapsed BRCAwt cohort within this study (around 12%), 
BRCA-aberrant patients appear to display markedly greater sensitivity to PLD. These data 
suggest that single-agent PLD should readily be considered as a viable treatment option in 
patients who have had BRCA1 and BRCA2 sequencing that has identified detrimental 
sequence changes, and these data present an additional argument for prospective BRCA 
sequencing in OC. Comparison of the relative efficacy of PLD versus alternative treatment 
options such as taxanes in BRCAm patients who have developed resistance to platinum may 
be warranted to help determine best practice for management of this patient group. These 
studies may prove particularly fruitful in light of in vitro evidence of inferior taxane efficacy 
in BRCA-deficient cells [459-464]. Although these differences have yet to be meaningfully 
established in cohorts of OC patients [465, 466], a corresponding trend has been observed in 
metastatic BC [467]. Notably, despite a greater response rate when compared to the BRCAwt 
population, over half of the BRCAm patients in this study did not demonstrate a response to 
PLD, highlighting the substantial unmet need in the treatment of relapsed HGS OC – even in 
the BRCAm setting.  
While the seemingly poor response rates to PLD in BRCAwt recurrent OC may lead some to 
consider PLD as largely ineffective in this population, there are few alternative active 
treatment options in these patients in the context of platinum resistance, save for taxanes. 
Moreover, platinum resistance develops more quickly in BRCAwt OC compared to their 
BRCAm counterparts [262-264], meaning physicians are quickly faced with the need to 
consider non-platinum treatment options. Given the considerable side effects of PLD and 
their potential impact on patient quality of life, further studies should aim to confirm the low 





population to facilitate more informed decision making regarding further active care versus 
clinical trials of novel agents or palliative options in platinum-resistant BRCAwt recurrent OC 
setting.  
Within patients harbouring only rs1799950, there was around a 4-fold increase in PLD 
response rate compared to the BRCAwt group (50% vs 12.1%), despite low numbers in this 
patient group (n=6). Interestingly, rs1799950 was reported by the 1000 Genomes Project 
reported to possess a minor allele frequency of 0.0596 in European populations, crossing the 
threshold of “common variation” by population genetics conventions. However, this variant 
has been associated with increased risk of BC within Saudi Arabian women (OR 22.8, 95% CI 
1.4-380.1) [468] and increased risk of prostate cancer development in families from the 
University of Michigan Prostate Cancer Genetics Project (OR 2.25, 95% CI 1.21–4.20) [469]. 
Further characterisation of rs1799950 is warranted in light of our data suggesting that this 
SNP may impact upon chemotherapy response. Specifically, the impact of this “common” 
variant on the propensity of individuals to develop OC, BC and other malignancies should be 
investigated. Future work should also aim to determine whether rs1799950 is biologically 
significant with regard to response to platinum-based chemotherapy, whose mechanisms of 
action overlap substantially with PLD, in both in vitro and in vivo settings.  
Gene editing of established cell lines to introduce rs1799950 represents a convenient 
approach for further characterization of this variant in vitro [470]. Comparison of the 
sensitivity of these edited lines to DNA damaging agents, including PLD, with the sensitivity 
of their respective parental lines may well prove fruitful in the defining chemosensitivity-
modulating effects of rs1799950. Indeed, such investigations may well be pertinent in the 
context of other cancer types where defects in HR have been identified in a significant 





Recent data from in vivo models has suggested that PLD may promote recruitment of tumour 
infiltrating T cells in mice harbouring BRCA1-deficient tumours [471]. Given the superior 
prognosis associated with OCs who harbour more tumour-infiltrating lymphocytes (TILs) [71, 
82], this may represent one mechanism by which PLD may confer superior benefit in BRCAm 
patients. Comparison of immunomodulatory effects of PLD treatment between BRCA1m, 
BRCA2m and BRCAwt tumours should be conducted in animal models of disease to further 
characterise the implications of this phenomenon, which may be of particular interest given 
the thus far disappointing efficacy of novel immunomodulatory agents in OC [472, 473].  
It is now known that the distinct histological subtypes of OC represent discrete disease 
entities, which display markedly different chemosensitivity profiles and survival (see section 
1.8). Accordingly, we compared PLD response rates within OCs specifically of HGS histology. 
While BRCAm is most commonly associated with HGS tumours, these events are also 
reported to occur in a minority of OC with non-HGS histology [374, 474]. Owing to the low 
numbers of PLD-treated cases of non-HGS subtypes identified within this study, we were not 
able to evaluate the response rate of these rarer subtypes to single-agent PLD, nor were we 
able to analyse differential efficacy of PLD between BRCAm and BRCAwt tumours within 
these rarer subtypes. Future studies should seek to identify whether the enhanced response 
rate to PLD in BRCA-aberrant HGS OC extends to tumours of different histology with similar 
defects. Clearly, the low frequency of these events in rarer OC histotypes will limit the power 
of these analyses, and collaborative multi-centre studies will likely be required if meaningful 
comparisons are to be made. 
We performed sequencing of tumour DNA without a matched normal specimen, precluding 
the distinction of germline from somatic events. While it is generally assumed, and indeed 





germline inactivation, the data presented here are unable to address the differential impact, 
if any, of somatic versus germline BRCA inactivation with regard to PLD sensitivity.  
In the clinical setting, centres that perform routine BRCA sequencing in OC patients typically 
limit analysis to germline DNA, with few centres routinely performing tumour DNA 
sequencing to identify somatic events. Assuming that germline and somatic BRCAm confer a 
similar benefit with regard to PLD sensitivity, limitation of routine genetic testing to germline 
material risks misclassifying patients as unlikely to respond to PLD (and indeed to PARP 
inhibition) and therefore represents one obstacle to optimal stratification of care.  
Here, we limited analysis to the most common mechanisms of HR inactivation, namely 
BRCAm. In recent years, other mechanisms by which OC can be rendered HR-deficient have 
received increasing interest, principally for their potential as markers of PARP inhibitor 
sensitivity in BRCAwt OC. These events include non-BRCA HRm in genes such as BARD1 and 
PALB2, as well as gene silencing of BRCA1 by promoter hypermethylation and amplification 
of the gene encoding the BRCA2-binding protein EMSY [187, 210, 260]. While limited data 
suggest that patients displaying non-BRCA HRm may behave similarly to BRCAm patients 
[187, 260, 299], other mechanisms such as BRCA1 promoter hypermethylation remain 
controversial with regard to their ability to confer a BRCAness phenotype [271, 273]. Future 
work should aim to identify whether non-BRCA HRm also confer superior sensitivity to PLD, 
however it is likely that these analyses will prove non-trivial owing to the rarity of these 
events. Furthermore, the relative response rate to PLD of BRCAwt HGS OC who demonstrate 
signatures of HR deficiency – such as genomic scarring [475], copy number [283] or SNV 






Given the data presented here suggesting limited activity in the BRCAwt population, and the 
wealth of data now demonstrating HR inactivation by mechanisms other than BRCAm, it is 
conceivable that the remaining BRCAwt PLD-responders may well be rendered deficient in 
HR by other mechanisms. More extensive molecular characterization of PLD-treated HGS OC 
therefore has the potential to more precisely define those patient populations who are likely 






3 CHAPTER 3: IDENTIFICATION OF NOVEL SUBGROUP OF BRCA-
LIKE HIGH GRADE SEROUS OVARIAN CARCINOMAS DEFINED 
BY HIGH EXPRESSION OF EMSY 
 
3.1 Introduction  
3.1.1 Disease journey in BRCAm versus BRCAwt HGS OC 
The majority of HGS OCs display favourable intrinsic sensitivity to platinum-based 
chemotherapy. However, the most patients will experience disease relapse with repeated 
shortening of DFIs following subsequent chemotherapy, until they ultimately succumb to 
disease [132]. 
Over the last decade, it has become clear that BRCAm OC experience a distinct clinical disease 
course compared to BRCAwt OC (see section 1.11) [160, 262, 263, 377, 379, 476]. Principally, 
the hallmarks of this BRCAm OC phenotype are prolonged survival [257, 262, 373], greater 
sensitivity to multiple lines of platinum-based chemotherapy [262, 263, 371] and marked 
sensitivity to PARP inhibition by virtue of HR-deficiency [120, 160, 164, 168, 377].  
 
3.1.2 The EMSY gene and its role in ovarian and breast cancer  
EMSY, located on 11q13.5, is reported to be amplified in 7-13% of non-familial BC and 6-18% 
of HGS OC [210, 269, 282]. Also known as C11orf30, EMSY encodes a nuclear protein, EMSY, 
which binds to BRCA2 within residues 18-46 encoded by its third exon [269]. EMSY acts as a 
negative regulator of BRCA2’s transcriptional activation function and also interacts with 
chromatin remodelling proteins. Specifically, EMSY binds the Royal Family domain-containing 
chromatin regulators HP1β and BS69 at sites adjacent to its N-terminal domain [269].  
However, multiple lines of evidence also point to a function related to DNA repair: EMSY co-





genomic instability and sensitivity to the DNA damaging agent mitomycin C [269, 477]. 
Furthermore, EMSY binds BRCA2 at the same region as RPA and PALB2, and its 
overexpression may override the function of these HR players, disrupting the BRCA2/RAD51-
mediated HR pathway [268].  
Thus, tumours with EMSY overexpression, whether by amplification or CN-independent 
mechanisms of expression regulation, may mimic their BRCA2m counterparts. Consistent 
with this notion, CN gain of EMSY has been predominantly associated with the HGS histotype 
of OC, and has been reported as a marker of poor prognosis in BC [269, 282, 478-482]. 
However, despite the potential for EMSY-amplified HGS OCs to represent a further HR-
deficient subgroup, there has been almost no phenotypic characterisation of HGS OCs 







3.2 Study Aims 
Here, EMSY expression is investigated in cohort of transcriptomically characterised HGS OCs 
to explore the potential impact of this phenomenon on the clinical characteristics of HGS OC, 
with particular reference to the hallmark characteristics of BRCAm OC.   
Specifically, this study aims to:  
1. Identify HGS OCs expressing high levels of EMSY using available transcriptomic data 
from a cohort of patients treated within the Edinburgh Cancer Centre generated 
during a previous translational research study [285] 
2. Collect detailed clinical annotation for the Edinburgh cohort, including survival data 
and detailed response data for multiple lines of cytotoxic chemotherapy  
3. Investigate whether EMSY-overexpressing HGS OCs have differential OS, PFS or 
chemosensitivity 
4. Use publicly available gene expression datasets and associated clinical annotation to 
further explore associations between EMSY expression and clinical behaviour in HGS 







3.3 Methods  
3.3.1 Cohort Descriptions 
265 patients diagnosed with HGS OC, treated at the Edinburgh Cancer Centre between 1984 
and 2006, were identified following contemporary pathology review as part of a previous 
study [285]. All patients received first-line platinum-based chemotherapy either as a single 
agent (carboplatin or cisplatin) or in combination with paclitaxel. Patient demographics are 
summarised in Table 3.1. 
The MRC ICON7 cohort comprised patients consenting to the translational arm of the ICON7 
clinical trial study across multiple sites (UK, France, Canada, Australia, New Zealand, 
Denmark, Finland, Norway, Sweden and Spain). This phase III trial randomised patients to 
carboplatin-paclitaxel combination therapy with or without the anti-angiogenic agent 
bevacizumab in the first-line setting [61]. All patients underwent contemporary pathology 
review. 367 HGS OCs were identified, of which 185 received carboplatin-paclitaxel 
combination therapy with bevacizumab, and 182 received carboplatin-paclitaxel 
combination therapy alone (control arm). 
 
3.3.2 Edinburgh and MRC ICON7 cohort gene expression data  
Transcriptomic characterisation of HGS OCs from the Edinburgh and MRC ICON7 cohorts was 
performed as part of a previous study identifying molecular subtypes of HGS OC in 
collaboration with Almac Diagnostics [285]. Briefly, this study utilised archival FFPE tumour 
specimens, macrodissected to enrich for tumour cells using marked H&E-stained slides as a 
guide. RNA was extracted from macrodissected material, amplified and hybridised to the 





Probe-sets mapping to EMSY expression were isolated from the expression set and per-
sample expression was calculated as mean expression across informative probe-sets (Figure 
3.1).  
 
3.3.3 Publicly available gene expression datasets  
Transcriptomic data for publicly available OC datasets from Pils et al. [485], Tothill et al. [211], 
Mateescu et al. [486] and TCGA [210] datasets were accessed via the curatedOvarianData R 
package [487]. Non-serous histological subtypes of OC were removed from publicly available 
datasets where applicable, and grade I serous samples were excluded as likely LGS OC.  
 
3.3.4 Survival data  
Survival data were extracted from the phenotypic annotation within the curatedOvarianData 
R package [487] for the  Pils et al. [485], Tothill et al. [211], Mateescu et al. [486] and TCGA 
[210] datasets. Survival data for patients within the Edinburgh cohort were collected 
retrospectively using the Edinburgh Ovarian Cancer Database and available paper and 
electronic health records.  
 
3.3.5 Platinum response data  
Radiological and CA125 tumour marker response data for platinum-containing 
chemotherapy regimens were collected retrospectively using the Edinburgh Ovarian Cancer 
Database alongside archived patient notes and electronic health records where applicable. 
Clinical research access and ethical approval for correlation of molecular data to 
clinicopathological features and clinical outcome in OC was obtained via NHS Lothian 





reported as per WHO or RECIST criteria, with many patients predating RECIST reporting [451]. 
CA125 tumour marker responses were reported according to GCIG guidelines [451].  
 
3.3.6 Statistical analyses  
Statistical analyses were performed using R version 3.3.3. Univariable and multivariable 
survival analyses were performed using the Kaplan-Meier method [488] and Cox proportional 
hazards models [489] for PFS and OS using the survival R package [490]. Comparisons of 
survival are presented as univariable and multivariable hazard ratios (uniHRs and multiHRs) 
alongside their corresponding 95% CIs and P-values. For the Edinburgh, Tothill et al, Pils et al 
and TCGA datasets, multivariable analyses accounted for RD following surgical debulking, 
FIGO stage at diagnosis and patient age. Within the MRC ICON7 clinical trial, multivariable 
analyses also accounted for chemotherapy regime (bevacizumab-treated versus control arm) 
where applicable. Patient age and debulking status were not available for the Mateescu et al 
dataset, and multivariable analyses therefore only accounted for stage at diagnosis in this 
cohort.  
Differences in time to progression (TTP) from platinum were evaluated using the Mann-
Whitney U test, after demonstration of non-normality using the Shapiro-Wilk test for 
normality [491]. Frequency comparisons between categorical variables were performed 







3.4 Results  
3.4.1 Identification of threshold for high EMSY within the Edinburgh 
cohort  
Owing to (i) the poor consensus on how many HGS OCs are expected to display EMSY 
overexpression or amplification [210, 269, 282], (ii) the variable reported strength of 
association between EMSY CN and expression [269, 270, 492], and (iii) the lack of a 
distribution-suggested cut-off for high EMSY expression within our dataset (Figure 3.1), an 
exploratory cut-point analysis of univariable survival was proposed to identify the threshold 
for dichotomising the Edinburgh cohort into high- and low-EMSY. This approach comprised 
recurrent computation of univariable Cox proportional hazards models of high- versus low-
EMSY at different thresholds for defining EMSY overexpression (Figure 3.2). EMSY expression 
within the highest 14 percentiles (top 14%) was identified as the optimal threshold, with the 
smallest uniHR for high-EMSY HGS OCs and smallest corresponding CI. This percentile 
threshold approach which was subsequently validated by application to independent 
transcriptomic datasets (sections 3.4.3-3.4.4). 
 
3.4.2 High EMSY expression is associated with prolonged survival in the 
Edinburgh HGS OC cohort 
EMSY expression levels in the cohort of 265 HGS OCs from Edinburgh were interrogated. As 
indicated by the exploratory analysis (Figure 3.2), a threshold of expression within the 14% 
was used to define the high-EMSY population. The high-EMSY population demonstrated 
superior OS and PFS in multivariable survival analyses accounting for extent of RD following 
debulking, stage at diagnosis and patient age [multiHR=0.59 (0.39-0.90), P=0.013 and 
multiHR=0.60 (0.39-0.93), P=0.022, respectively] (Figure 3.3A, Figure 3.3B and Table 3.3 and 













Figure 3.2 Exploratory univariable survival analysis identifying the optimal threshold for EMSY 
overexpression within the Edinburgh cohort. Points indicate HR at the respective percentile 
expression threshold, with tails indicating corresponding 95% CIs. 
 
 
Table 3.1 Demographics of high- and low-EMSY HGS OCs in the Edinburgh cohort.  
  
Low-EMSY High-EMSY   
 
  
n % n % P 
 
HGS OC  Patients 228  37    
 
Stage at Dx I 13 5.9% 1 2.8% NS #  
II 15 6.8% 5 13.9%   
 
 
III 153 68.9% 22 61.1%   
 
 
IV 41 18.5% 8 22.2%   
 
 






<2cm RD  81 40.5% 17 48.6% NS + 
2-5cm RD 51 25.5% 8 22.9%   
 
>5cm RD 68 34.0% 10 28.6%   
 




Age at Dx median 
years 
61 (range 32-86) 61 (range 43-81) NS ^ 
*Due to the retrospective nature of these data and historical classification of optimal 
resection in older cases as <2cm RD, optimal surgical success could not be resolved beyond 
<2cm within the Edinburgh cohort. ^ T-test; # Fisher's exact test early (I-II) versus late (III-IV) 






3.4.3 Impact of high EMSY expression within the MRC ICON7 cohort  
Expression data generated using HGS OC specimens from patients in the MRC ICON7 clinical 
trial were used to validate the association between EMSY expression and patient outcome. 
These data were generated separately to the Edinburgh cohort as part of the same 
subgrouping study to identify subgroups with differential sensitivity to bevacizumab [285]. 
Accordingly, these specimens were processed and characterised in the same manner as the 
Edinburgh cohort, allowing direct application of the EMSY expression cutoff generated within 
the Edinburgh dataset. Across the whole MRC ICON7 cohort (367 HGS OCs), multivariable 
analysis accounting for RD following surgical debulking, FIGO stage at diagnosis, trial arm 
(bevacizumab-treated vs control arm) and age at diagnosis revealed significantly superior OS 
for high-EMSY patients [multiHR=0.39 (0.19-0.80), P=0.010] (Figure 3.3C, Table 3.5). 
However, they did not demonstrate a significant PFS advantage [multi HR=0.84 (0.54-1.31), 
P=0.44].  
 
Table 3.2 Univariable and multivariable analyses of clinical outcome in high-EMSY HGS OCs 









HR 95% CI P HR 95% CI P 
Edinburgh OS 37 228 0.63 0.43-0.93 0.020 0.59 0.39-0.9 0.013 
 PFS   0.67 0.45-1 0.052 0.60 0.38-0.93 0.022 
MRC ICON7 
cohort 
OS 24 343 0.68 0.35-1.32 0.255 0.39 0.19-0.8 0.010 
PFS   1.27 0.82-1.97 0.280 0.84 0.54-1.31 0.440 
Pils  
cohort 
OS 24 146 0.31 0.1-1.02 0.053 0.27 0.08-0.87 0.028 
PFS   0.70 0.41-1.22 0.210 0.52 0.29-0.92 0.026 
Mateescu 
cohort 
OS 11 64 0.4 0.17-0.94 0.035 0.43 0.18-0.99 0.048 
PFS   0.51 0.24-1.09 0.084 0.59 0.27-1.25 0.168 
Tothill 
cohort 
OS 35 210 0.50 0.27-0.93 0.029 0.60 0.32-1.13 0.112 
PFS   0.70 0.44-1.09 0.114 0.63 0.39-1.04 0.072 
TCGA cohort OS 77 472 0.95 0.68-1.34 0.789 1.18 0.83-1.66 0.358 






Table 3.3 Multivariable analysis for OS by EMSY expression within the Edinburgh cohort 









high-EMSY 0.59 0.39 0.90 0.013 
low-EMSY ref ref ref ref 
Debulking status 
  
<2cm 0.68 0.49 0.94 0.021 
≥2cm ref ref ref ref 




I 0.55 0.29 1.05 0.069 
II 0.29 0.15 0.58 0.000 
III ref ref ref ref 
IV 1.45 0.99 2.12 0.056 
Age at diagnosis years 1.01 1.00 1.03 0.142 
Ref, reference population 
 
 
Figure 3.3 Impact of EMSY expression on clinical outcome in HGS OC. (A) OS in the Edinburgh 
cohort; (B) PFS in the Edinburgh cohort; (C) OS in the MRC ICON7 clinical trial cohort; (D) OS 
in the MRC ICON7 cohort stratified by treatment arm. #, multivariable P value accounting for 
debulking status, stage at diagnosis and patient age. ^, multivariable P value, high-EMSY vs 
low-EMSY in placebo arm; +, multivariable P value, bevacizumab-treated versus placebo arm 





Table 3.4 Multivariable analysis for PFS by EMSY expression within the Edinburgh cohort. 









high-EMSY 0.60 0.38 0.93 0.022 
low-EMSY ref ref ref ref 
Debulking status <2cm 0.63 0.45 0.89 0.009 
≥2cm ref ref ref ref 




I 0.42 0.21 0.86 0.017 
II 0.27 0.14 0.53 <0.001 
III ref ref ref ref 
IV 1.42 0.93 2.18 0.107 
Age at diagnosis years 1.01 1.00 1.03 0.123 
Ref, reference population 
 
Table 3.5 Multivariable analysis for OS by EMSY expression within the MRC ICON7 cohort. 









high-EMSY 0.39 0.19 0.80 0.010 
low-EMSY ref ref ref ref 
Debulking status 
  
<1cm 0.53 0.39 0.73 <0.001 
>1cm ref ref ref ref 




I 0.48 0.22 1.04 0.064 
II 0.19 0.08 0.46 <0.001 
III ref ref ref ref 
IV 1.51 0.95 2.39 0.078 
Trial arm 
  
bevacizumab 1.32 0.98 1.78 0.069 
placebo ref ref ref ref 
Age at diagnosis years 1.03 1.01 1.04 0.001 
Ref, reference population 
 
Intriguingly, analysis of the high-EMSY population specifically revealed inferior OS in the 
bevacizumab-treated arm compared to the control arm [multiHR=11.78 (1.31-106.32), 
P=0.028] (Figure 3.3D, Table 3.6), despite limited power in these two arms (n=14 and n=10, 
respectively). Accordingly, the impact of EMSY expression was re-evaluated in the MRC 
ICON7 cohort limiting analysis to the control arm (n=182), revealing striking OS benefit in the 





Table 3.6 Multivariable analysis for OS by trial arm within the high-EMSY MRC ICON7 patients. 









bevacizumab 11.78 1.31 106.32 0.028 
placebo ref ref ref ref 
Debulking status 
  
optimal 0.70 0.16 3.18 0.646 
suboptimal ref ref ref ref 
Stage at Diagnosis 
  
  
II 0.00 0.00 Inf 0.999 
III ref ref ref ref 
IV 0.21 0.03 1.42 0.109 
Age at diagnosis years 1.04 0.98 1.11 0.208 
Ref, reference population 
 
Table 3.7 Multivariable analysis for OS by EMSY expression within the MRC ICON7 control 
arm. 









high-EMSY 0.10 0.01 0.73 0.023 
low-EMSY ref ref ref ref 
Debulking status 
  
optimal 0.46 0.29 0.73 0.001 
suboptimal ref ref ref ref 




I 0.52 0.16 1.7 0.280 
II 0.20 0.05 0.81 0.025 
III ref ref ref ref 
IV 1.93 0.99 3.75 0.053 
Age at diagnosis years 1.03 1.00 1.05 0.025 
Ref, reference population 
 
 
3.4.4 Validation of superior outcome in HGS OCs with high EMSY 
expression  
Publicly available transcriptomic datasets of HGS OC were used to further validate the 
association between EMSY expression and outcome. Gene expression data were accessed 
via the curatedOvarianData package [487]. Heterogeneity of transcriptomic characterisation 
methodology prevented direct application of the EMSY expression threshold generated 
within the Edinburgh cohort. We therefore sought to use a percentile-based cutoff threshold 





the Edinburgh cohort (Figure 3.2). To test the fidelity of this approach, a cut-off at the top 
14th percentile of expression within the MRC ICON7 dataset, in which the high-EMSY survival 
benefit had already been reproduced (see section 3.4.3). Again, this identified superior OS in 
the high-EMSY group treated with chemotherapy alone [multi HR=0.21 (0.07-0.68), P=0.009] 
(Figure 3.4, Table 3.8), indicating the validity of this approach. 
 
Figure 3.4 OS in the top 14% of EMSY expressing HGS OCs within the MRC ICON7 control arm. 
#, multivariable P value accounting for RD following debulking, stage at diagnosis and age. 
 
Table 3.8 Multivariable analysis for OS by EMSY expression within the MRC ICON7 control 
arm after defining high-EMSY expression using a percentile cutoff. 
MRC ICON7 control 
cohort 14% high EMSY 





EMSY status high-EMSY 0.21 0.07 0.68 0.009 
low-EMSY ref ref ref ref 
Debulking status optimal 0.45 0.28 0.73 0.001 
suboptimal ref ref ref ref 
Stage at Diagnosis I 0.5 0.15 1.65 0.256 
II 0.2 0.05 0.82 0.025 
III ref ref ref ref 
IV 1.77 0.91 3.45 0.091 





Expression data were retrieved for the publicly available HGS OC cohorts from studies by 
TCGA [210] (TCGA cohort), Tothill et al. [211] (Tothill cohort), Mateescu et al [486] (Mateescu 
cohort) and Pils et al [485] (Pils cohort). In multivariable analyses accounting for FIGO stage 
at diagnosis, RD following debulking and patient age, high-EMSY patients in the Pils cohort 
demonstrated superior OS [multiHR=0.27 (0.08-0.87), P=0.028] (Figure 3.5A, Table 3.9) and 
PFS [multiHR=0.52 (0.29-0.93), P=0.026] (Figure 3.5B, Table 3.10). 
Within the Mateescu cohort, high-EMSY patients displayed significantly superior OS at the 
multivariable level [multiHR=0.43 (0.19-0.99), P=0.048] (Figure 3.5C, Table 3.11), alongside a 
non-significant trend for superior univariable PFS [uniHR=0.51 (0.24-1.09). P=0.084] (Figure 
3.5D). PFS was not significantly longer in the high-EMSY group upon multivariable analysis 
[multiHR=0.59 (0.27-1.25), P=0.168] (Table 3.12), however data regarding RD following 
debulking and patient age were not available for the Mateescu cohort, preventing the ability 






Figure 3.5 Clinical outcome of high-EMSY HGS OCs expression across multiple datasets. OS 
and PFS within the Pils et al cohort (A and B); OS and PFS within the Mateescu cohort (C and 
D); OS and PFS within the Tothill cohort (E and F); OS within the TCGA cohort and PFS within 
advanced stage TCGA patients (G and H). #, multivariable P value accounting for debulking 
status, stage at diagnosis; ^, univariable P value (debulking status and patient age not 





Table 3.9 Multivariable analysis for OS by EMSY expression within the Pils cohort. 




95% CI P-value 
EMSY status 
  
high-EMSY 0.27 0.08 0.87 0.028 
low-EMSY ref ref ref ref 
Debulking status 
  
optimal 0.64 0.35 1.19 0.163 
suboptimal ref ref ref ref 





1.81 0.43 7.71 0.421 
II 
III 
ref ref ref ref 
IV 
Age at diagnosis years 1.04 1.01 1.07 0.004 
Ref, reference population 
 
 
Table 3.10 Multivariable analysis for PFS by EMSY expression within the Pils cohort. 




95% CI P-value 
EMSY status 
  
high-EMSY 0.52 0.29 0.92 0.026 
low-EMSY ref ref ref ref 
Debulking status 
  
optimal 0.50 0.32 0.76 0.001 
suboptimal ref ref ref ref 





0.62 0.15 2.57 0.511 
II 
III 
ref ref ref ref 
IV 
Age at diagnosis years 1.02 1.00 1.04 0.053 
Ref, reference population 
 
 
Table 3.11 Multivariable analysis for OS by EMSY expression within the Mateescu cohort. 




95% CI P-value 
EMSY status 
  
high-EMSY 0.43 0.18 0.99 0.048 
low-EMSY ref ref ref ref 





0.49 0.23 1.05 0.066 
II 
III 
ref ref ref ref 
IV 





Table 3.12 Multivariable analysis for PFS by EMSY expression within the Mateescu cohort. 




95% CI P-value 
EMSY status 
  
high-EMSY 0.59 0.27 1.25 0.168 
low-EMSY ref ref ref ref 





0.45 0.22 0.93 0.032 
II 
III 
ref ref ref ref 
IV 
Ref, reference population 
 
Within the Tothill cohort, high-EMSY patients demonstrated significant OS benefit at the 
univariable level [uniHR=0.50 (0.27-0.93), P=0.029] (Figure 3.5E), however the trend was not 
significant after accounting for FIGO stage at diagnosis, RD following debulking and patient 
age [multi HR=0.60 (0.32-1.13), P=0.112] (Table 3.13). The high-EMSY group displayed a 
similar non-significant trend for superior PFS which approached statistical significance in a 
multivariable model accounting for these variables [multi HR=0.63 (0.39-1.04), P=0.072] 
(Figure 3.5F, Table 3.14).  
Within the TCGA cohort, high-EMSY patients demonstrated a weak trend for longer 
univariable PFS which was not statistically significant [uniHR=0.74 (0.50-1.09), P=0.122], 
however this passed the threshold of significance when investigating advanced stage disease 
specifically [uniHR=0.62 (0.41-0.94), P=0.023] (Figure 3.5H). Multivariable analyses for RD 
following debulking, patient age and FIGO stage at diagnosis identified the same trend, 
however this did not pass the threshold for statistical significance [multi HR=0.69 (0.45-1.05), 
P=0.081] (Table 3.15). There was no apparent OS benefit for the high-EMSY group within the 






Table 3.13 Multivariable analysis for OS by EMSY expression within the Tothill cohort. 




95% CI P-value 
EMSY status 
  
high-EMSY 0.60 0.32 1.13 0.112 
low-EMSY ref ref ref ref 
Debulking status 
  
optimal 0.67 0.44 1.01 0.056 
suboptimal ref ref ref ref 





0.32 0.10 1.02 0.055 
II 
III 
ref ref ref ref 
IV 
Age at diagnosis years 1.03 1.01 1.05 0.016 
Ref, reference population 
 
 
Table 3.14 Multivariable analysis for PFS by EMSY expression within the Tothill cohort. 




95% CI P-value 
EMSY status 
  
high-EMSY 0.63 0.39 1.04 0.072 
low-EMSY ref ref ref ref 
Debulking status 
  
optimal 0.56 0.40 0.79 0.001 
suboptimal ref ref ref ref 





0.21 0.08 0.51 0.001 
II 
III 
ref ref ref ref 
IV 
Age at diagnosis years 1.02 1.00 1.03 0.054 
Ref, reference population 
 
 
Table 3.15 Multivariable analysis for PFS by EMSY expression within the advanced stage TCGA 
cohort. 







high-EMSY 0.68 0.45 1.04 0.076 
low-EMSY ref ref ref ref 
Debulking status 
  
optimal 1.09 0.81 1.47 0.576 
suboptimal ref ref ref ref 
Stage at Diagnosis 
  
III ref ref ref ref 
IV 0.87 0.58 1.3 0.501 
Age at diagnosis years 1 0.99 1.02 0.617 





3.4.5 Impact of sampling site on identification of high-EMSY subgroup 
with superior clinical outcome 
The sampling site of the transcriptomically characterised tumour specimens were available 
for the Tothill cohort. Interestingly, high-EMSY patients from which samples were taken from 
metastatic sites rather than the primary adnexal mass showed no OS or PFS benefit 
[multiHR=0.85 (0.37-1.97), P=0.710 and multiHR=0.91 (0.43-1.89), P=0.794] (Figure 3.6B and 
Figure 3.6D, Table 3.16 and Table 3.17). Conversely, those arrayed from the primary adnexal 
mass (ovary or FT) displayed markedly prolonged OS [multiHR=0.28 (0.09-0.90), P=0.032] 
(Figure 3.6A, Table 3.18) with corresponding trend for superior PFS [multiHR=0.55 (0.28-
1.10), P=0.091] (Figure 3.6C, Table 3.19).  
 
Figure 3.6 Interaction between sampling site (primary mass versus extra-adnexal) and 
prognostic impact of high EMSY expression within the Tothill cohort. (A) OS in high-EMSY HGS 
OC from adnexal specimens; (B) OS in high-EMSY HGS OC from extra-adnexal specimens; (C) 
PFS in high-EMSY HGS OC from adnexal specimens; (D) PFS in high-EMSY HGS OC from extra-





Table 3.16 Multivariable analysis for OS by EMSY expression within the Tothill cohort where 
arrayed specimen was not from the primary adnexal mass. 








EMSY status high-EMSY 0.85 0.37 1.97 0.710 
low-EMSY ref ref ref ref 
Debulking status optimal 0.72 0.36 1.42 0.339 
suboptimal ref ref ref ref 
Age at diagnosis years 1.04 1.00 1.07 0.043 
Ref, reference population 
 
 
Table 3.17 Multivariable analysis for PFS by EMSY expression within the Tothill cohort where 
arrayed specimen was not from the primary adnexal mass. 










high-EMSY  0.91 0.43 1.89 0.794 
low-EMSY  ref ref ref ref 
Debulking status 
  
optimal 0.70 0.40 1.23 0.213 
suboptimal ref Ref ref ref 
Age at diagnosis years 1.03 1.00 1.06 0.032 
Ref, reference population 
Table 3.18 Multivariable analysis for OS by EMSY expression within the Tothill cohort where 
arrayed specimen was from primary adnexal mass. 







EMSY status high-EMSY  0.28 0.09 0.90 0.032 
low-EMSY  ref ref ref ref 
Debulking status optimal 0.81 0.46 1.42 0.462 
suboptimal ref ref ref ref 
Stage at Diagnosis I 
0.36 0.11 1.17 0.089 
II 
III 
ref ref ref ref 
IV 
Age at diagnosis years 1.03 1.00 1.06 0.102 







Table 3.19 Multivariable analysis for PFS by EMSY expression within the Tothill cohort where 
arrayed specimen was from primary adnexal mass. 








EMSY status high-EMSY  0.55 0.28 1.10 0.091 
low-EMSY  ref ref ref ref 
Debulking status optimal 0.57 0.37 0.87 0.010 
suboptimal ref ref ref ref 
Stage at Diagnosis I 
0.23 0.09 0.58 0.002 
II 
III 
ref ref ref ref 
IV 
Age at diagnosis years 1.01 0.99 1.03 0.294 




3.4.6 High EMSY expression is associated with superior platinum 
sensitivity in the Edinburgh cohort 
Detailed response data for platinum-containing cytotoxic chemotherapy packages were 
collected for the Edinburgh cohort. High-EMSY patients demonstrated superior rates of 
CA125-CR at first and second exposure to platinum-containing therapy (88.0%, 22/25 vs 
55.0%, 82/149, P=0.002 and 53.3%, 8/15 vs 21.3%, 17/80, P=0.021, respectively) (Figure 
3.7A). High-EMSY patients also displayed superior rates of radioCR to platinum-containing 
therapy at second exposure, despite limited evaluable patients (44.4%, 4/9 vs 12.5%, 8/64, 
P=0.035). A corresponding but non-significant trend for radioCR was also displayed at third 
exposure, however the power of these analyses was limited (50%, 2/4 vs 5.9%, 1/17, 
P=0.080). At fourth platinum exposure, high-EMSY patients demonstrated a superior rate of 









Figure 3.7 Relative platinum sensitivity of HGS OCs with high EMSY expression within the 








Consistent with the response data, high-EMSY patients demonstrated prolonged TTP 
following third platinum exposure (median 151.5 vs 60.5 days, P=0.004) (Figure 3.8). The 
difference was significant when specifically considering only progression defined by CA125 
tumour marker (median 231 vs 50 days, P=0.003) or progression defined by radiological 
assessment (median 151.5 vs 94 days, P=0.041). A similar but non-significant trend was 




Figure 3.8 Relative time to subsequent disease progression following platinum-containing 







3.4.7 High EMSY expression is associated with superior outcome in high-
risk HGS OC  
Diagnosis of advanced stage disease with gross RD following debulking surgery usually 
confers poor prognosis in HGS OC (high-risk cases), with these patients typically experiencing 
relapsed disease within two years of diagnosis [493].  
Within the Edinburgh cohort, a larger proportion of high-risk high-EMSY patients were alive 
without disease recurrence (AWR) compared to their low-EMSY counterparts at 2 years 
(25.0%, 4/16 vs 9.2%, 10/109, P=0.081), 3 years (18.8%, 3/16 vs 3.6%, 4/110, P=0.043), 5 
years (17.6%, 3/17 vs 2.7%, 3/111, P=0.031) and 10 years (12.5%, 2/16 vs 0.9%, 1/112 
P=0.041) from diagnosis (Figure 3.9A).  
High-risk HGS OC patients within the Pils cohort demonstrated similar AWR differences at 12 
months (100%, 9/9 vs 61.5%, 24/39, P=0.041), 18 months (88.9%, 8/9 vs 17.6%, 6/34, 
P<0.001), and 2 years (50.0%, 4/8 vs 3.1%, 1/32, P=0.004) from diagnosis (Figure 3.9B). The 
same trend in the Tothill cohort of high-risk HGS OC characterised from primary site 
specimens did not approach statistical significance (100%, 5/5 vs 62.5%, 20/32, P=0.152) 
(Figure 3.10A), though small numbers clearly reduced the power of this comparison. In the 
context of advanced stage disease alone, significantly more high-EMSY patient were AWR at 
12 and 18 months from diagnosis (95%, 19/20 vs 67.8%, 78/115, P=0.014 and 70%, 14/20 vs 







Figure 3.9 Relative frequency of high-risk (advanced stage and suboptimally debulked) HGS 
OC patients alive without disease recurrence at time points from diagnosis in (A) the high-







Figure 3.10 Relative frequency of patients alive without disease recurrence at time points 







3.5 Discussion  
It is estimated that up to 50% of HGS OCs harbour genetic or epigenetic hits in the HR 
pathway. Around half of these are accounted for by germline or somatic BRCAm, the flagship 
HR pathway defects which have been the subject of intensive investigation since their 
discovery [120, 160, 164, 168, 257, 262, 263, 371, 373, 377, 379, 476]. Ultimately, the 
identification of these lesions has resulted in the production of targeted molecular therapies 
– PARP inhibitors – that have demonstrated marked efficacy in this patient group and is now 
an archetypal example of treatment stratification in cancer patient care [120, 160, 164, 168, 
377]. Accordingly, identification and characterisation of other molecular events in the HR 
pathway has been the subject of great interest, with the hope of finding further predictors 
of survival and PARP inhibitor sensitivity. In particular, the impact of mutational inactivation 
of HR players such as RAD51 family members and of BRCA1 gene silencing by promoter 
hypermethylation, have been investigated [188, 210, 265, 299, 494]. Surprisingly, the 
C11orf30/EMSY gene, encoding the BRCA2-binding protein EMSY, has received relatively 
little attention in this regard, with few studies characterising EMSY CN status or expression 
levels, or correlating these data to clinical outcome in OC [269, 282, 481].  
Collectively, the in silico analyses presented here identify a subgroup of HGS OC that is 
defined by high expression of EMSY, who appear to demonstrate an HR deficient phenotype 
comprising superior outcome and greater sensitivity to multiple lines of platinum-based 
chemotherapy. Previous studies have described the frequency of EMSY CN gain in HGS OC, 
but generally have not associated these findings with clinical outcome or chemosensitivity 
[210, 269, 282, 482]. To our knowledge, a single study has investigated the impact of 11q13 
amplification on OC survival, reporting no survival difference according to CN within serous 





EMSY transcript, and failed to distinguish HGS from LGS OC which demonstrate markedly 
different survival and molecular landscapes [128, 219, 244]. The reported strength of the 
relationship between EMSY CN and expression levels is variable  [269, 270, 282], and poor 
CN-expression correlation may underpin why the phenotype observed in HGS OC patients 
harbouring high EMSY expression has not yet been reported (and this comparison is explored 
and discussed within Chapter 4 of this work).  
This study presents the first reported association between EMSY expression and HGS OC 
patient outcome, and we have been able to replicate this association in multiple independent 
publicly available datasets. For the Edinburgh dataset, we were able to collect detailed 
response data to chemotherapy for each patient, identifying greater sensitivity to platinum-
containing therapy in the high-EMSY group. Indeed, the radioCR rate to these regimes was 
around 3.5-fold greater compared to their low-EMSY counterparts at second platinum 
exposure. Together with their prolonged survival profile, the hypersensitivity of these 
patients to platinum is consistent with the notion that high EMSY expression in these tumours 
renders them deficient in HR. Hence, this subgroup could represent patients who may derive 
greater benefit from PARP inhibition versus HR-proficient OCs.  
Of particular interest is the finding that the survival benefit conferred by high EMSY 
expression appeared to be abrogated by the addition of bevacizumab to chemotherapy in 
the MRC ICON7 cohort. While the numbers of patients in this comparison was low (n=24 total 
between both arms) – and clearly these analyses do not meet the outlined REMARK 
guidelines for biomarker identification [495] – these data add to the growing evidence 
eluding to subgroups of HGS OC that do not benefit from the addition of antiangiogenic 
agents to first-line care [285, 296]. Indeed, these data may even suggest that there may be 





HGS OCs and further investigation of anti-angiogenic therapy efficacy specifically in the 
context of known mechanisms of HR perturbation is warranted. These data will be of great 
interest given the ongoing investigations of the clinical efficacy of combining anti-angiogenics 
with PARP inhibitors [185].  
Interestingly, high EMSY expression appears to confer substantial disease-free survival 
benefit in the context of otherwise dismal prognosis: within the Edinburgh cohort, the 
proportions of high-risk HGS OC patients AWR in the high-EMSY group were over twice- and 
five-times that of the low-EMSY population at 2 and 5 years from diagnosis, respectively. Ten 
years from diagnosis, over 10% of the high-EMSY group were AWR compared to less than 1% 
of their low-EMSY counterparts and while the numbers of patients for comparison were low 
in this analysis, the association was statistically significant. These data suggest that patients 
with HGS OC that demonstrate high EMSY expression have a propensity for long-term disease 
free survival even in the context of poor prognostic factors.  
Within the Tothill dataset, the high-EMSY group whose arrayed specimen was primary site 
displayed markedly superior outcome in comparison to the low-EMSY group, while the 
comparison between patients transcriptomically characterised from metastatic sites showed 
no apparent survival difference. These data suggest that sampling away from the primary 
tumour mass may impede the ability to detect these high-EMSY patients. This phenomenon 
has multiple possible explanations: firstly, specimens from the primary tumour mass may 
have a propensity for greater ratio of cancer cells to non-malignant cell types, modulating 
bulk transcriptional profiles; secondly, differential composition of the tumour 
microenvironment and its interactions with tumour cells across anatomical sites may alter 
EMSY expression; thirdly, tumour heterogeneity between primary and metastatic disease 





for this discrepancy, differential EMSY expression between primary and distant sites has clear 
implications for the translation of research findings into routine clinical practice. Prospective 
identification and phenotypic characterisation of high-EMSY HGS OC may well be hindered 
by these differences, and the limited available data suggest that extra-adnexal sampling may 
have contributed to weaker associations between EMSY expression and outcome in some of 
the above described cohorts. In both of the local gene expression cohorts presented here 
(Edinburgh and MRC ICON7 cohorts), RNA was extracted from macrodissected FFPE 
specimens, enriching for tumour versus stromal cells: both of these cohorts demonstrated 
marked OS benefit within the high-EMSY group.  
While these data demonstrate both the power and potential of in silico analysis of pre-
existing gene expression datasets, it is not without limitations. Amplification of 11q13, in 
which EMSY is encoded, has previously been described as a common event in both OC and 
BC. This locus represents a relatively gene-rich region, with other potential genes of interest, 
including CCND1 and PAK1, in relative proximity. However, previous studies have identified 
EMSY as the likely critical gene in this amplicon [269, 282, 482], and the phenotype described 
above is more consistent with the known function of EMSY as an HR player than those of the 
PAK1 or CCND1 gene products [496, 497]. 
Furthermore, with almost all patients included in this study being diagnosed before the 
introduction of routine germline BRCA sequencing for HGS OC cases in Scotland, we were 
unable to overlay germline BRCAm data with EMSY expression. Moreover, these patients pre-
date the use of PARP inhibition in HGSOC treatment, precluding the assessment of PARP 
inhibitor efficacy within this patient group. Sequencing for BRCA, alongside other known HR 
pathway genes, is now required to investigate the mutual exclusivity of the identified high-





(and is explored within Chapter 4 of this thesis). These data will facilitate the comparison of 
clinical outcome between BRCAwt high-EMSY HGS OC with HR-proficient HGS OC to 
characterise the clinical outcome of the high-EMSY group with greater granularity. Similarly, 
comparison with other identified molecular subtypes, including those that harbour CCNE1 
CN gain, should also be performed.  
Collectively, the above described data identify a BRCAm-like subgroup of HGS OC with 
prolonged survival and greater sensitivity to multiple lines of platinum-containing 
chemotherapy. Given the previously described role of EMSY in disrupting the HR pathway, 
and the consistency of the clinical phenotype of high-EMSY HGS OC with HR-deficiency, 
further investigation of this group as a potentially novel HR-deficient population should now 






4 CHAPTER 4: INTEGRATED MOLECULAR SUBTYPING OF HIGH 
GRADE SEROUS OVARIAN CARCINOMA  
4.1 Introduction  
Over the last two decades, a wealth of molecular data has been produced characterising HGS 
OC at the DNA sequence and gene expression level [210, 211, 256, 285-287]. The output of 
these analyses has produced molecularly-defined subtypes and other markers that have 
been associated with patient outcome. However, translation of these findings into 
stratification of patient management has essentially been limited to BRCAm patients, with 
the remaining BRCAwt population considered as a single disease entity, despite extensive 
clinical and molecular heterogeneity within this group.  
Clearly, further molecular stratification has the potential to improve management of patients 
presenting with HGS OC, whether through identification of further groups that may benefit 
from existing targeted therapies or by defining groups that are best suited for inclusion in 
clinical trials of new treatment strategies. Similarly, robust identification of patient groups 
that experience distinct clinical outcome has the potential to improve patient 
prognostication.  
 
4.1.1 Genomic subtyping of HGS OCs  
While those patients displaying BRCA1m or BRCA2m have essentially comprised the extent 
of clinically actionable genomic subgroups of HGS OC, a number of other subgroups defined 
at the genomic level have been identified as potentially clinically relevant. These include HGS 
OCs harbouring CCNE1g [256, 276] and non-BRCA HRm in genes such as PALB2 or the RAD51 
family [187, 260, 265, 266]. While non-BRCA-HRm patients are anticipated to experience a 





hypersensitivity and marked PARP inhibitor sensitivity [170, 260, 266] – the rarity of these 
cases has precluded extensive characterisation of this patient group and their clinical 
behaviour [187, 210]. Furthermore, the majority of studies to date have failed to distinguish 
between the BRCA1m and BRCA2m population, instead describing these as a single entity. 
The differential impact of BRCA1m versus BRCA2m has only recently been described [352], 
and further characterisation and comparison of these tumours is required to better define 
the phenotypes of these discrete groups.  
CCNE1g has been described as an event occurring in a sub-population of HR-proficient HGS 
OC [210] and has received mixed reports with regard to its association with clinical outcome. 
While some investigators have reported inferior survival in CCNE1g HGS OCs [210, 276], 
others have described no significant difference for those expressing high Cyclin E levels [279]. 
Critically, survival in the CCNE1g population has typically been reported against the collective 
non-CCNE1g population, and these comparisons are confounded by the retention of 
favourable prognosis HR-deficient populations in the comparator arm [210, 279].  Similarly, 
there has been some suggestion that these tumours may represent those with higher levels 
of intrinsic chemoresistance [256, 278, 498], but extensive comparison of chemotherapy 
response versus HR-proficient non-CCNE1g patients has not been performed.  
Direct comparison of CCNE1g HGS OC versus their non-CCNE1g counterparts specifically in 
the context of HR-proficiency is urgently needed to characterise the outcome of these 
patients with sufficient granularity and confidence to facilitate translation of this group into 






4.1.2 Tumour-infiltrating lymphocytes in HGS OC 
It has become clear that the presence of TILs is prognostic in OC [71, 82] and more recent 
data have demonstrated that the burden and prognostic implication of TILs varies between 
histological subtypes [79, 499]. Specifically, higher CD3+ and CD8+ cell burden – reflective of 
whole T-cell and cytotoxic T-cell populations, respectively – have been associated with 
prolonged OS and PFS in HGS OC, among other histotypes [79, 499]. These data are 
concordant with the wealth of research now demonstrating that effective tumour 
engagement by the immune system confers improved prognosis in a range of malignancies 
[82, 500-502]. Indeed, pharmacological manipulation of the immune system-tumour 
interface in the hope of promoting recognition and effective engagement of cancer cells has 
demonstrated marked efficacy in a number of disease settings and is an area of intensive 
investigation [91, 503-505].  
 
4.1.3 Transcriptomic subgroups associated with clinical outcome and 
bevacizumab sensitivity  
As outlined in section 1.9.3, unsupervised transcriptomic analysis from Edinburgh has 
previously identified three molecular subtypes of HGS OC: Angio, Immune and AngioImmune 
[285]. Compared to the Angio and AngioImmune subtypes, the Immune group was 
associated with superior OS (HR=0.66, 95% CI 0.46-0.94 and HR=0.63, 95% CI 0.42-0.95, 
respectively).  As the subgroup without upregulation of angiogenesis-related genes, it was 
demonstrated that the Immune subgroup may derived least benefit from the anti-angiogenic 
agent bevacizumab; indeed, the patients from the MRC ICON7 clinical trial classified into the 
Immune group were reported to experience inferior outcome with the addition of 






4.1.4 High-EMSY HGS OC 
The results described here in Chapter 3 identify a novel subtype of HGS OC, defined by high 
levels of EMSY expression, which appear to display and HR-deficiency phenotype. However, 
the relationship between this phenomenon and EMSY CN has not been explored, nor has the 
mutual exclusivity of this group with the genomically-defined subtypes. In particular, the 
overlap of these patients with patients that display genomic abnormalities affecting the HR 
pathway remains to be determined. Critically, analysis of the behaviour of high-EMSY 
patients who do not display other identifiable HR pathway defects is critical with regard to 
determining whether this group represents a true novel BRCAm-like subgroup of HGS OC.  
 
4.1.5 Efforts at integrated genomic and transcriptomic analysis to date  
There has been some suggestion that BRCAm patients may be enriched in some 
transcriptomic groups of HGS OC and that the CCNE1g population is under-represented in 
favourable transcriptomic subtypes [256, 286]. However, the clinical implications of the 
overlap between transcriptomic and genomic subgrouping has not been explored. Critically, 
these data have not been overlaid with TIL burden in HGS OCs, which is known to impact 
substantially upon patient outcome [82], although some studies have suggested that the 
BRCAm population may harbour a greater TIL burden [506, 507]. Furthermore, while the 
differential clinical implications of BRCA1m versus BRCA2m have become increasingly clear 
[352], BRCAm HGS OC have continued to be considered as a single entity in the limited data 






4.1.6 Key areas of unmet need in molecular subtyping of HSG OC  
While there has been some limited effort to overlay genomic features with transcriptionally-
defined molecular subtypes of HGS OC, these studies have suffered from both limited 
numbers and grouping of distinct molecularly-defined genomic events that have historically 
been considered equivalent, namely BRCA1m and BRCA2m. Furthermore, direct integration 
of these layers of molecular profiling with data regarding TIL burden is yet to be performed, 
and previous work has not described the consequences of interplay between molecular 
subtyping layers. Crucially, it remains to be demonstrated whether multi-layer molecular 
characterisation of these tumours provides additional pertinent information with regard to 
clinical outcome.  
While many studies have sought to identify molecular subtypes of HGS OC and correlate 
these findings to clinical outcome, most have not compared these data to chemotherapy 
response and have instead limited analyses to OS and PFS. Moreover, most comparisons have 
been performed in a two-class manner, comparing the group of interest versus the collective 
marker-negative population. These analyses have the potential to draw false conclusions 
when failing to account for previously identified subgroups with known differential 
prognosis, most notably those rendered HR-deficient by BRCAm.  
Collectively, multi-layer characterisation of large HGS OC cohorts – for which detailed clinico-
pathological, survival and chemotherapy response data are available – has the potential to 
identify subtypes of HGS OC patients that experience distinct disease journeys with high 
granularity, paving the way for improved care stratification and better prognostication. In 
particular, these analyses have the potential to identify those patients who benefit least from 
available treatment options and may therefore be good candidates for inclusion in clinical 





1.1 Study aims 
This study aims to use a large retrospective dataset – for which rich clinical annotation is 
available – to investigate the overlay and interplay of HGS OC subtypes defined by gene 
expression, DNA sequence and TIL burden.  
Specifically, this study aims to:  
1. Collect a large retrospective cohort of OCs and perform contemporary pathology 
review to identify those of HGS histology 
2. Extract DNA from FFPE tissue, macrodissected to enrich for tumour cell content, for 
panel-based NGS and CN determination for EMSY and CCNE1 
3. Perform per-patient classification of HGS OCs into HR-centric subtypes: BRCA1m, 
BRCA2m, high-EMSY, CCNE1g and other non-CCNE1g-HR-proficient (oHRP) 
4. Compare the clinicopathological characteristics, clinical outcome and 
chemosensitivity of the HR-centric subtypes with the oHRP reference group  
5. Determine the overlap of the HR-centric subgroups outlined above with previously 
described transcriptomically-defined subtypes of HGS OC 
6. Construct a tissue microarray (TMA) from the HGS OC cohort  
7. Determine the levels of CD3+ and CD8+ TILs using the HGS OC TMA  
8. Determine whether the subgroups defined above demonstrate differential levels of 
TILs 
9. Perform integrated molecular subtyping of HGS OCs to identify interactions between 






4.2 Methods  
4.2.1 Cohort collection and pathology review  
Cohort identification is summarised in Figure 4.1. 447 OCs, treated at the Edinburgh Cancer 
Centre between 1984 and 2006, were reviewed to identify HGS OCs for molecular analysis. 
Ethical approval for use tumour material was obtained from South East Scotland Human 
Annotated Bioresource (Lothian NRS Bioresource Ethics Reference 15/ES/0094-SR705 and 
SR752). These included the HGS OC cases identified as part of the EMSY study described in 
Chapter 3 of this work, and a further 182 cases for which contemporary pathology review 
had not yet been performed. Pathology review was performed by Professor C. Simon 
Herrington using H&E stained images on all cases for which tissue was received; IHC staining 
for WT1 and P53 was performed to aid histological subtyping where appropriate, as 
described in section 2.3.3. 
 
4.2.2 Clinical data collection  
Ethical approval for clinical data collection and correlation to molecular analyses was 
obtained from NHS Lothian Research and Development (reference ID 2007/W/ON/29). 
Access to clinical data was covered by a letter of clinical research access granted in 
association with the same reference ID. Clinical data were collected retrospectively using the 
Edinburgh Ovarian Cancer Database and available paper and electronic health records. 
CA125 tumour marker responses were reported according to GCIG guidelines [451]. 
Radiological responses were reported as per WHO or RECIST criteria, with many patients 














4.2.3 Tissue macrodissection and nucleic acid extraction and QC 
Macrodissection of 10µm FFPE sections was guided by corresponding H&Es marked to 
identify tumour areas appropriate for nucleic acid extraction. Up to ten 10µm FFPE sections 
were macrodissected per case for use in DNA extraction based upon total tumour area, 
density and cellularity. DNA was extracted from macrodissected material using the QIAamp 
DNA FFPE Tissue Kit and Deparaffinization Solution (Qiagen, Venlo, Netherlands) according 
to the manufacturer’s instructions.  
 
4.2.4 DNA QC and quantification 
Extracted DNA was quantified using the Qubit Fluorometer High Sensitivity dsDNA assay 
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s 
instructions. Further DNA QC was performed using the Nanodrop ND-1000 
Spectrophotometer to assess 260/230nm and 260/280nm wavelength absorption ratio.  
 
4.2.5 Characterisation of CCNE1 and EMSY copy number  
CN variants in EMSY and CCNE1 were characterised by TaqMan Genotyping qPCR Copy 
Number Assays using the StepOne Plus Real-Time PCR System (Applied Biosystems, Thermo 
Fisher Scientific, Waltham, MA, USA) and StepOne Software Version 2.3 (Life Technologies, 
Thermo Fisher Scientific, Waltham, MA, USA). VIC dye–labelled TaqMan Copy Number 
Reference Assay was used as a reference assay, alongside FAM dye-labelled Hs06316346_cn 
targeting EMSY or FAM dye-labelled Hs07158517_cn targeting CCNE1. Amplicons were 





Amplification efficiency was assessed using serial dilutions of NA12878 genome in a bottle 
DNA in triplicate [508] (Figure 4.2). Efficiency was calculated using the gradient of the line of 
best fit for Ct value against the logarithm (base 10) of ng DNA input (efficiency = -1 + 10-1/slope 
of Ct versus log10 of input DNA) [509], yielding assay efficiencies of 103.4%, 97.0% and 103.3% for 
CCNE1, EMSY and RNaseP, respectively (Table 4.2). These data indicate excellent 
amplification efficiency in all assays. 
 
Table 4.1. Details of TaqMan qPCR probes and targets. 






Hs07158517 CCNE1 Chr19:30,310,716 91 Within intron 6 
Hs06316346 EMSY Chr11:76,217,424 86 Within intron 9 
RNaseP Copy Number 
Reference Assay 
RNaseP 











Table 4.2 Amplification efficiency of TaqMan qPCR assays. 
Assay r r2 Slope Efficiency 
CCNE1 -0.998 0.996 -3.243 103.4% 
RNaseP -0.998 0.996 -3.245 103.3% 
EMSY -1.000 0.999 -3.396 97.0% 
 
 
CN assays for FFPE-derived DNA were performed alongside control assays using NA12878 
DNA, OVCAR3 cell line DNA and FUOV1 cell line DNA, representing DNA with normal CN, 
EMSY CN gain and CCNE1g, respectively [508, 510]. NA12878 DNA was included within each 
assay run. CN variants were called using CopyCaller v2.0 (Life Technologies, Applied 
Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) using NA12878 as calibrator 
sample (CN=2). TaqMan probe details are summarised in Table 4.1. EMSY amplification was 
defined as CN ≥6; CCNE1 gain was defined as CN ≥4.  
 
4.2.6 Panel-based NGS of DNA and classification of variants  
NGS was performed using a custom Integrated DNA Technologies (IDT) custom gene capture 
panel with unique molecular indices (UMIs). Whole genome libraries were generated using 
200ng input DNA. A single sample failed library preparation. 100ng of generated library were 
pooled in groups of 16 for target gene capture and sequenced using an Illumina NextSeq by 
the Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh, UK. 
Following alignment and consensus read generation using UMIs (see section 4.2.7 below), 








4.2.7 NGS data analysis and variant classification 
Sequence reads were processed using the bcbio v1.0.6 pipeline by Dr Alison Meynert, MRC 
Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. Reads 
were aligned to the human genome reference assembly hg38 with bwa v0.7.17, then sorted 
and duplicates marked with bamsormadup (biobambam v2.0.79). UMIs were added as tags 
by umis v0.9.0b0, and files were converted to BAM format and indexed using samtools v1.6. 
Reads were grouped by UMI, and consensus reads were called and filtered with fgbio v0.4.0. 
Consensus reads were extracted with bamtofastq (biobambam) and re-aligned, sorted and 
indexed as above. The aligned consensus reads underwent base quality score recalibration 
with the Genome Analysis Toolkit (GATK) v3.8.  
Variant calling was performed using a multi-caller approach: variants were called with 
Freebayes v1.1.0.46, VarDict Java v1.5.1, and GATK Mutect2, then decomposed and 
normalized with vt v2015.11.10. Freebayes variants were annotated with GATK 
VariantAnnotator; VarDict variants with vcfanno and bcftools v1.6. VCF manipulation was 
performed with Picard v2.15.0 and vcflib 1.0.0_rc1. A two of three majority vote system was 
used to curate high confidence calls, with filter-passed variants identified by at least two 
callers qualifying variants for inclusion in the final callset. The DKFZ bias filter was applied to 
identify likely false positive variants caused by strand bias or FFPE-induced DNA damage. 
 
4.2.8 Variant classification 
Called variants were annotated using the Ensembl VEP v90.9 against Ensembl release 90. 
Variants documented as pathogenic were retained as mutations, and those documented as 
benign were discarded. Within the remaining callset, nonsense mutations, frameshifting 





synonymous variants, missense variants of undocumented significance, and non-coding 
variants were discarded as VUS.  
TP53 mutations were identified separately with additional reference to the UMD TP53 
variation database [511]. Owing to the known almost ubiquitous presence of TP53 mutation 
within HGS OC, manual review of aligned sequence read for the 39 supposed TP53wt HGS 
OCs was performed. 24 of 39 (61.5%) supposed TP53wt samples harboured TP53 mutations 
upon manual review, the vast majority (83.3%, 20/24) of which affected splice sites (1 large 
deletion, 3 indels, 16 SNVs). This apparent poorer sensitivity to splice site events was 
attributed to the proximity of these variants to read ends, compounded by the relatively 
reduced coverage at exon-intron boundaries owing to the capture design being targeted 
toward coding regions.  Indeed, splice site mutations were highly significantly enriched in the 
manual review versus background variant calling within TP53 (83.3%, 20/39 versus 1.5%, 
5/332, Fisher’s exact P<0.001).  
 
4.2.9 Identification of likely non-HGS OC from genomic data 
Of the 15 remaining TP53wt samples, 8 (53.3%) harboured gene mutations associated with 
non-HGS OC histotypes (ARID1A, CTNNB1, KRAS, PIK3CA). These were excluded from 
subsequent analysis as likely non-HGS OC, while the remaining 7 TP53wt OC were retained 






4.2.10 Assessment of CD3+ and CD8+ cell infiltration 
A HGS OC TMA was constructed using H&E-stained slides, marked to identify tumour area, 
as a guide for coring FFPE tissue blocks. 0.8mm cores were taken in triplicate for each HGS 
OC case, alongside cores from a series of control tissues, forming 6 TMA blocks (two TMA 
blocks in triplicate). TMA processing was performed by the Lothian NRS Bioresource in 
accordance with ethical agreements for TMA construction (ES/15/0094-SR927).  
IHC for CD3 and CD8 was performed using 5µm FFPE sections cut onto to charged glass slides. 
IHC was performed on the Leica Bond III Autostainer (Leica Biosystems, Illinois, US) by the 
Division of Pathology Laboratories, University of Edinburgh, Western General Hospital, 
Edinburgh, UK. CD8 and CD3 staining was performed using Bond ready-to-use CD8-4B11 and 
CD3-LN10 antibodies with Bond epitope retrieval solution 2 for 20 minutes in IHC protocol F. 
Sections of human tonsil were used as a positive control, with a corresponding section used 
as negative control without primary antibody. IHC-stained slides were digitized using the 
Hamamatsu Nanozoomer (Hamamatsu Photonics, Hamamatsu, Japan) at 40X magnification.  
Tumour-infiltrating CD3+ and CD8+ cells were quantified using QuPath digital pathology 
image analysis software [512]. For each core (Figure 4.3A), tumour area was annotated as a 
region of interest (Figure 4.3B), and positive cells were quantified using the positive cell 
detection analysis protocol (mean whole-cell chromogen optical density) to identify 
lymphocytes that were specifically infiltrating the tumour area (Figure 4.3C). CD3+ and CD8+ 
cell densities were quantified as the percentage of positive cells within the identified tumour 
area.  
Validation of automated TIL detection was performed by manual positive cell counting in a 





representing a validation set of >20% of tumour-containing patient cores. Two observers 
scored the validation cores. Comparison of the tumour-infiltrating positive cell counts was 
performed using spearman’s correlation test after demonstration of non-normality for cell 
count distribution (Shapiro-Wilk test P<0.0001 for both CD3 and CD8) and Lin’s concordance 
correlation coefficient [513]. These statistical comparisons are summarised in Table 4.3 and 
Table 4.4, and indicate excellent agreement between the automated scoring and manual 
validation scoring.  
 
Figure 4.3 Analysis of tumour-infiltrating lymphocytes using QuPath. (A) tumour-containing 






Table 4.3 Comparison of manual versus automated CD3 scoring by Spearman’s correlation 
test. 
Spearman’s Rho P Value 
QuPath autoscore Observer 1 Observer 2 
CD3 QuPath autoscore  P<0.0001 P<0.0001 
Observer 1 Rho=0.98  P<0.0001 
Observer 2 Rho=0.97 Rho=0.97  
CD8 QuPath autoscore  P<0.0001 P<0.0001 
Observer 1 Rho=0.98  P<0.0001 
Observer 2 Rho=0.96 Rho=0.95  
 
Table 4.4 Comparison of manual versus automated CD3 scoring by Lin’s concordance 
correlation. 
Concordance correlation  
coefficient 
95% confidence interval for coefficient 
QuPath autoscore Observer 1 Observer 2 
CD3 
 
QuPath autoscore  CI, 0.88-0.92 CI, 0.68-0.73 
Observer 1 CC=0.90  CI, 0.84-0.88 
Observer 2 CC=0.71 CC=0.86  
CD8 QuPath autoscore  CI, 0.95-0.97 CI, 0.72-0.79 
Observer 1 CC=0.96  CI, 0.83-0.87 
Observer 2 CC=0.76 CC=0.85  
CC, concordance correlation coefficient; CI, 95% confidence interval for coefficient 
 
4.2.11 Transcriptional subtyping of HGS OCs 
Transcriptional HGS OC subtyping data were available from a previous study identifying 
molecular subgroups of HGS OC with differential outcome and sensitivity to bevacizumab 
[285]. For the 265 HGS OC from the EMSY study, one of the three identified molecular 
subtypes was assigned to each patient (Angio, Immune or AngioImmune) according to the 
unsupervised hierarchical clustering performed during the de novo subgroup identification. 
For the remainder of the cohort, subtyping was performed using a signature developed to 
prospectively identify the Immune subgroup, and classification was therefore limited to 





where subtype specific (Angio vs AngioImmune) resolution is required, the patients classified 
only as ProAngio were excluded from analysis where appropriate. 
Transcriptional subtyping into high-EMSY and low-EMSY patients was available from data 
presented here in Chapter 3. Classification was not available for the patients which were not 
in this study: for statistical analysis relating to the HR-centric subgroup described in section 
4.3.3, patients in this group without BRCAm, non-BRCA-HRm or CCNE1g were included in the 
oHRP reference population.  
 
4.2.12 Statistical analyses 
Statistical analyses were performed using R version 3.3.3. Frequency of clinicopathological 
features, rates of chemotherapy response and other comparisons of frequency were 
performed using the Chi-squared test and Fisher’s exact test, as appropriate. Comparisons of 
TTP were conducted using the Mann Whitney-U test after demonstration of non-normality 
by the Shapiro-Wilk test. Comparisons of OS and PFS were performed using Cox proportional 
hazards regression models for univariable and multivariable analyses within the Survival R 
package [490]. Survival comparisons are presented as uniHRs and multiHRs alongside their 
corresponding 95% CIs. Multivariable models accounted for RD following surgical debulking, 
patient age and disease stage at diagnosis, unless otherwise specified. Correlation analysis 
was conducted using Pearson’s product moment correlation for normally distributed data 







4.3.1 Frequency of pertinent molecular events in HGS OC 
Mutation frequency of genes sequenced by IDT gene capture panel-based NGS are 
summarised in Figure 4.4 and Table 4.5. Of the 362 HGS OCs, 355 (98.1%) harboured TP53 
mutation, consistent with previous reports of the near-ubiquitous mutational inactivation of 
this pathway in this tumour type. BRCA1 and BRCA2 were the subsequently most commonly 
mutated genes, with pathogenic mutations detected in 46 (12.7%) and 24 (6.6%) cases, 
respectively. BRCA1m and BRCA2m occurred mutually exclusively (co-occurrence in 0.0% of 
cases). Non-BRCA HRm was detected in 8 (2.2%) of cases (3 BRIP1, 2 CHEK2, 1 RAD51C, 1 
BAP1 & NBN, 1 PALB2). Non-BRCA HRm co-occurred with BRCA1m in 2 cases (1 PALB2, 1 
CHEK2).   
Mutational inactivation of RB1 and NF1 was detected in a minority of cases (11/362, 3.0% 
and 10/362, 2.8%, respectively). Interestingly, mutational inactivation of NF2 was detected 
in a similar number of HGS OCs (8/362, 2.2%). NF2 mutation was mutually exclusive with NF1, 
RB1, BRCA1, BRCA2, non-BRCA HRm and CCNE1g. 
CCNE1g was detected in 54 (14.9%) of cases, concurrent with previous reports [210]. CCNE1g 
was mutually exclusive with BRCA1m, also consistent with previous studies [280], with a 
single co-occurrence of CCNE1g with BRCA2m. EMSY amplification was detected in 24 (6.6%) 






Figure 4.4 Integrated molecular landscape of HGS OC. CN gain, CN ≥4; CN amplification, CN ≥6. Mutations identified in the Non-BRCA HRD group 





Table 4.5 Gene mutation frequency in 362 HGS OCs. 
Gene HGS OC cases with mutation %cases mutant 
TP53 355 98.1 
BRCA1 46 12.7 
BRCA2 24 6.6 
RB1 11 3.0 
NF1 10 2.8 
NF2, PIK3CA 8 2.2 
CDK12 5 1.4 
ARID1A 4 1.1 
FANCA, KRAS, SLFN11, PER3, 
BRIP1 
3 0.8 
MSH6, CTNNB1, SLX4, CHEK2, 
PRKDC 
2 0.6 
CHD4, AC004223.3, PTEN, EMSY, 
FANCF, BRAF, PARP2, PAXIP1, 
ATM, CCNE1, RAD51C, BAP1, NBN, 
PALB2, FANCM, TP53BP1, GNAS, 
FANCC, RNASEH2B, PPP2R1A, 
MSH2, SLC25A40, ERCC4 
1 0.3 
ABCB1, ATR, ATRX, BARD1, 
BCL2L1, BLM, C11orf65, CHEK1, 
EGFR, ERBB2, EZH2, FANCB, 
FANCD2, FANCE, FANCG, FANCI, 
FANCL, KIT, MAD2L2, MDM2, 
MLH1, MRE11, MUS81, MUTYH, 
NDUFB2, NRAS, PARP1, PDGFRA, 
PMS2, PPP2R2A, RAD50, RAD51, 
RAD51B, RAD54L, RNASEH2A, 
RNASEH2C, RPA1, RUNDC3B, 









4.3.2 EMSY amplification is a poor marker of the high-EMSY group  
EMSY CN demonstrated weak but significant correlation with EMSY expression as calculated 
in Chapter 3 (Spearman’s rho=0.20, P=0.002). Only a minority of EMSY-amplified patients 
were in the high-EMSY group (31.6%, 6/19 evaluable cases), despite statistically significant 
enrichment of high-EMSY patients within the EMSY-amplified group versus the non-amplified 
group (31.6%, 6/19 versus 13.2%, 30/228, respectively, P=0.010).  While the high-EMSY group 
demonstrated hallmarks of an HR-deficient phenotype (see results described in Chapter 3 
and section 4.3.5 below), those displaying EMSY amplification demonstrated no significant 
difference in survival [multiHR for OS=1.38 (0.86-2.21), P=0.180 and multiHR for PFS=1.33 
(0.81-2.18), P=0.265] (Table 4.6) or sensitivity to multiple lines of platinum-based 
chemotherapy (platinum 2 radioCR rate 25.0%, 2/8 vs 18.1%, 17/94, P=0.640; platinum 2 
CA125-CR rate 44.4%, 4/9 vs 23.8%, 30/126, P=0.229). 
 
4.3.3 HR-centric subgrouping of HGS OCs 
HGS OCs were classified using an HR-centric taxonomy accounting for BRCAm, non-BRCA-
HRm status, CCNE1g status and EMSY expression status, as outlined in Figure 4.5.   
 
Table 4.6 Clinical outcome in HGS OCs showing amplification of EMSY. 
 
OS: EMSY amp. vs no amp. PFS: EMSY amp. vs no amp. 
HR 95% CI P-value HR 95% CI P-value 
univariable 1.35 0.88-2.08 0.174 1.30 0.81-2.06 0.276 
multivariable 1.38 0.86-2.21 0.180 1.33 0.81-2.18 0.265 







Figure 4.5 HR-centric subgrouping of HGS OCs. 
 
4.3.4 Clinicopathological features of HR-centric HGS OC subgroups  
4.3.4.1 Age at diagnosis   
The clinicopathological features of these subgroups is outlined in Table 4.7. BRCA1m and 
BRCA2m patients were significantly younger at diagnosis compared to the oHRP reference 
group (P<0.001 and P=0.019). BRCA1m and BRCA2m patients were also significantly younger 
at diagnosis versus the high-EMSY group (P=0.001 and P=0.030) and CCNE1g group (P<0.001 
and P=0.002). The median age in the CCNE1g group was significantly older than all other 
groups combined (median 68 versus 61 years, P=0.008), consistent with previous reports 
[256]. However, the CCNE1g group was not significantly older at diagnosis compared to the 





  Table 4.7 Clinicopathological features of HR-centric HGS OC subgroups.  
   oHRP CCNE1g BRCA1m BRCA2m Non-BRCA-HRm High-EMSY  
Cases 





























n 207 57.2 53 14.6  46 12.7  24 6.6  6 1.7  26 7.2   
Age  median 62 33-86 68 42-85 0.095 54 35-78 < 0.001 53 41-74 0.019 65 55-76 > 0.2 61 43-81 > 0.2 @ 
Stage at 
diagnosis 
I 9 4.4 2 3.9 > 0.2 3 6.8 > 0.2 1 4.6 > 0.2 0 0.0 > 0.2 0 0.0 > 0.2 ^ 
II 14 6.9 7 13.7  3 6.8  2 9.1  1 25.0  4 15.4   
III 135 66.2 38 74.5  32 72.7  15 68.2  2 50.0  15 57.7   
IV 46 22.6 4 7.8  6 13.6  4 18.2  1 25.0  7 26.9   




<2cm 70 38.9 20 40.0 > 0.2 20 54.1 0.128 11 55.0 > 0.2 2 40.0 > 0.2 11 44.0 > 0.2 # 
≥2cm 110 61.1 30 60.0  17 46.0  9 45.0  3 60.0  14 56.0   




CR 23 32.4 8 36.4 > 0.2 8 53.3 0.147 3 60.0 > 0.2 1 50.0 > 0.2 6 66.7 0.065 & 
PR 31 43.7 8 36.4 > 0.2 6 40.0 0.177 2 40.0 > 0.2 1 50.0 > 0.2 2 22.2 > 0.2 $ 
NC 7 9.9 4 18.2  1 6.7  0 0.0  0 0.0  0 0.0   
PD 10 14.1 2 9.1  0 0.0  0 0.0  0 0.0  1 11.1   




CR 68 48.2 17 51.5 > 0.2 19 70.4 0.038 17 94.4 < 0.001 2 66.7 > 0.2 13 81.3 0.016 & 
PR 58 41.1 11 33.3 > 0.2 7 25.9 > 0.2 1 5.6 > 0.2 1 33.3 > 0.2 3 18.8 > 0.2 $ 
NC 11 7.8 5 15.2  1 3.7  0 0.0  0 0.0  0 0.0   
PD 4 2.8 0 0.0  0 0.0  0 0.0  0 0.0  0 0.0   
 NE 66  20   19   6   3   10    
TTP 
First 197 0-4475 141 0-3232 > 0.2 295 31-1712 0.009 391 105-2610 0.002 455 190-1148 0.105 204 0-627 > 0.2 + 
Radio 258 2-4207 221 12-3232 > 0.2 310 58-1758 0.109 552 156-2625 0.002 455 199-1148 > 0.2 210 0-700 > 0.2 + 
CA125 195 0-4475 130 0-2738 > 0.2 258 31-1606 0.079 315 105-2610 0.011 203 190-1154 > 0.2 204 0-627 > 0.2 + 
@ - t test; ^ Chi-squared test, stage I/II vs stage III/IV; # Chi-squared test, <2cm RD versus 2cm RD; & Fisher’s exact test, CR versus PR/SD/PD; $ Fisher’s exact test, 





4.3.4.2 Stage at diagnosis and RD following debulking  
The CCNE1g group comprised significantly fewer stage IV patients compared to the oHRP 
group (7.8%, 4/51 versus 22.5%, 46/204, P=0.018) and high-EMSY group (7.8%, 4/51 versus 
26.9%, 7/26, P=0.037). 
There was no significant difference in RD following surgical debulking between specific HR-
centric subgroups. However, collectively the BRCAm patient population had a borderline-
significant higher proportion of patients with <2cm RD compared to the oHRP group (54.4%, 
31/57 versus 38.9%, 70/180, P=0.056).  
 
4.3.5 Chemosensitivity and clinical outcome in HR-centric HGS OC 
subgroups  
4.3.5.1 Intrinsic chemosensitivity and time to first progression  
The high-EMSY group displayed a strong trend for higher rate of radioCR versus the oHRP 
group (6/9, 66.7% versus 32.4%, 23/71, P=0.065) (Figure 4.6A). Collectively, the BRCAm 
population demonstrated a similar frequency of radioCR to the high-EMSY group, but the 
difference versus the oHRP group did not approach significance (55.0%, 11/20 vs 32.4%, 
23/71, P=0.113). These analyses were in part hindered by the limited numbers of patients 
evaluable for radiological response to first-line chemotherapy.  
The BRCA1m, BRCA2m and high-EMSY groups all demonstrated significantly higher rates of 
CA125-CR compared to the oHRP group (70.4%, 19/26, 94.4%, 17/18 and 81.3%, 13/16 vs 
48.2%, 68/141; P=0.038, P<0.001 and P=0.016, respectively) (Figure 4.6B). CCNE1g patients 
demonstrated inferior rates of CA125-CR than those in the BRCA2m group (51.5%, 17/33 vs 
94.4%, 17/18, P=0.002), with the same comparison versus the high-EMSY group approaching 






Figure 4.6 Chemosensitivity of HR-centric HGS OC subgroups. RadioCR rate at first (A) and 
second (B) chemotherapy; CA125-CR rate at first (C) and second (D) chemotherapy; TTP 





Time to first progression was significantly longer in the BRCA2m population (median 391 
days) compared to the oHRP group (median 197 days, P=0.002) (Figure 4.6E) and CCNE1g 
group (median 141 days, P=0.003), which was significant when considering only radiological 
(P=0.002 and P=0.010) and CA125 (P=0.011 and P=0.018) progression, specifically. BRCA1m 
patients also demonstrated longer TTP (median 295 days) versus the oHRP (P=0.009) and 
CCNE1g (P=0.008) groups.  
There was no difference in rates of CR or OR (CR plus PR) to first-line therapy or TTP between 
the CCNE1g group and the oHRP group. 
 
4.3.5.2 Chemosensitivity at relapse  
In comparison to the oHRP group, BRCA2m patients demonstrated superior rates of radioCR 
(57.1%, 4/7 vs 13.0%, 9/69, P=0.014), radioOR (100.0%, 7/7 vs 37.7%, 26/69, P=0.002), 
CA125-CR (58.3%, 7/12 vs 14.3%, 13/91, P=0.002) and CA125-OR (100.0%, 12/12 vs 56.0%, 
51/91, P=0.003) at second chemotherapy (Figure 4.6C and Figure 4.6D). TTP from second 
chemotherapy was significantly longer in BRCA2m patients versus the oHRP group, whether 
considering radiological progression (median 278 versus 90 days, P=0.001) or CA125 
progression (median 205 versus 98.5 days, P=0.007). 
There was no difference in rates of radiological or CA125 response between BRCA1m patients 
and oHRP patients to second-line chemotherapy, nor was there a significant difference in TTP 
from second chemotherapy between the BRCA1m and oHRP groups.  
The high-EMSY group demonstrated superior rates of CA125-CR at second chemotherapy 
compared to the oHRP group (50.0%, 5/10 versus 14.3%, 13/91, P=0.015). TTP by CA125 





(median 322 versus 98.5 days, P=0.025). The CCNE1g group demonstrated a trend for higher 
rates of CA125-CR and CA125-OR versus the oHRP group which approached the threshold for 
statistical significance (31.6%, 6/19 vs 14.3%, 13/91, P=0.094 and 78.9%, 15/19 vs 56.0%, 
51/91, P=0.075). However, more CCNE1g patients received non-platinum regimes for 
second-line therapy versus the oHRP cohort (58.8%, 20/34 vs 109/137, 79.6%, P=0.024).  
At third-line chemotherapy, BRCA2m and high-EMSY groups demonstrated high rates of 
CA125-CR that approached significance when compared to the oHRP group (36.4%, 4/11 
P=0.059 and 42.9%, 3/7 P=0.061, respectively). Corresponding trends for prolonged 
subsequent time to radiological and CA125 progression were observed in the high-EMSY and 
BRCA2m groups, respectively (median 230 vs 67 days, P=0.022 and median 183 vs 67 days, 
P=0.079, respectively). 
 
4.3.5.3 Clinical outcome  
The OS and PFS of the HR-centric subgroups is depicted in Figure 4.7 and summarised in Table 
4.8 and Table 4.9.  
The CCNE1g group demonstrated inferior OS compared to the oHRP group upon 
multivariable analysis [multiHR=1.57 (1.12-2.20), P=0.009]. While there was no significant 
univariable PFS difference between the oHRP and CCNE1g groups, multivariable analysis 
revealed a trend for poorer PFS in this patient group that approached statistical significance 
[multiHR=1.39 (0.96-2.00), P=0.079].  
The BRCA2m group demonstrated markedly superior OS compared to the oHRP group 
[multiHR=0.42 (0.25-0.71), P=0.001] with corresponding trend for superior PFS at the 





group demonstrated similarly prolonged OS and PFS versus the oHRP group [multiHR for 
OS=0.48 (0.29-0.79), P=0.004 and multiHR for PFS=0.47 (0.28-0.81), P=0.006] and CCNE1g 
group [multiHR for OS=0.30 (0.17-0.54), P<0.001 and multiHR for PFS=0.34 (0.19-0.62), 
P<0.001]. 
While BRCA1m patients appeared to demonstrate better clinical outcome upon univariable 
analysis versus the oHRP group [uniHR for PFS=0.71 (0.49-1.01), P=0.059 and uniHR for OS= 
0.80 (0.57-1.12), P=0.199], there was no significant difference upon multivariable analysis 
[multiHR for PFS=0.81 (0.53-1.24), and multiHR for OS=0.98 (0.66-1.46)]. BRCA1m 
experienced significantly prolonged PFS and borderline-significant prolonged OS versus the 
CCNE1g group [multiHR for PFS= 0.59 (0.35-0.98), P=0.042 and multiHR for OS=0.62 (0.39-
1.01), P=0.053]. 
Severely limited numbers in the non-BRCA-HRm group precluded statistically meaningful 
comparison of outcome in this patient group, however HR estimates generally lay between 










Table 4.8 Comparison of OS between HR-centric subgroups of HGS OC. 
OS vs oHRP group vs CCNE1g group  
Type HR 95% CI P HR 95% CI P 
CCNE1g uni 1.31 0.96-1.78 0.083 - - - 
multi 1.57 1.12-2.20 0.009 - - - 
BRCA1m uni 0.80 0.57-1.12 0.199 0.61 0.41-0.92 0.018 
multi 0.98 0.66-1.46 >0.2 0.62 0.39-1.01 0.053 
BRCA2m uni 0.44 0.28-0.70 0.001 0.34 0.20-0.56 <0.001 
multi 0.42 0.25-0.71 0.001 0.27 0.15-0.48 <0.001 
high-
EMSY 
uni 0.52 0.32-0.84 0.008 0.40 0.23-0.68 0.001 
multi 0.48 0.29-0.79 0.004 0.30 0.17-0.54 <0.001 
nBRCA-
HRm 
uni 0.65 0.27-1.59 >0.2 0.50 0.20-1.24 0.135 
multi 0.65 0.21-2.04 >0.2 0.41 0.13-1.33 0.138 
Uni, univariable; multi, multivariable 
 
Table 4.9 Comparison of PFS between HR-centric subgroups of HGS OC. 
PFS vs oHRP group vs CCNE1g group  
Type HR 95% CI P HR 95% CI P 
CCNE1g uni 1.22 0.87-1.71 >0.2 - - - 
multi 1.39 0.96-2.00 0.079 - - - 
BRCA1m uni 0.71 0.49-1.01 0.059 0.58 0.37-0.90 0.016 
multi 0.81 0.53-1.24 >0.2 0.59 0.35-0.98 0.042 
BRCA2m uni 0.55 0.34-0.87 0.011 0.45 0.26-0.76 0.003 
multi 0.59 0.35-1.01 0.056 0.43 0.23-0.79 0.006 
high-
EMSY 
uni 0.50 0.30-0.84 0.008 0.41 0.23-0.73 0.002 
multi 0.47 0.28-0.81 0.006 0.34 0.19-0.62 <0.001 
nBRCA-
HRm 
uni 0.56 0.23-1.37 >0.2 0.46 0.18-1.16 0.101 
multi 0.44 0.14-1.39 0.162 0.32 0.10-1.03 0.057 
Uni, univariable; multi, multivariable 
 
4.3.6 Impact of immune infiltration on outcome  
Tumour infiltrating CD3+ and CD8+ cell densities were quantified as the percentage of cells 
in the tumour area displaying marker positivity. CD3+ and CD8+ density was highly variable 
across the HGS OC cohort (Figure 4.8), with 7.8% (26/333) and 9.0% (30/333) of samples 





between density of CD3+ and CD8+ cells (Spearman’s rho=0.92, P<0.0001) (Figure 4.9), with 
a significantly higher density of CD3+ cells than CD8+ cells (paired Mann Whitney-U test 
P<0.0001).  
Patients in which the CD8+ cell density was ≥1% demonstrated significantly prolonged OS 
and a trend for prolonged PFS in the context of <2cm RD following debulking [multiHR=0.51 
(0.34-0.78), P=0.002 and 0.69 (0.46-1.05), P=0.083, respectively] (Table 4.10, Figure 4.10A 
and Figure 4.10B), but not in the context of ≥2cm RD [multi HR=0.93 (0.76-1.52), P=0.672 and 
0.82 (0.84-1.77), P=0.303, respectively] (Table 4.11, Figure 4.10C and Figure 4.10D). Similarly, 
those with CD3+ density ≥1% demonstrated a trend for improved OS that approached 
significance in the context of <2cm RD [multiHR=0.69 (0.46-1.03), P=0.073] (Figure 4.11A), 











Figure 4.9 Correlation of CD3+ and CD8+ cell density. 
 
A survival model accounting for both CD3+ and CD8+ cell density revealed a significant 
independent OS benefit for CD8+ infiltration [multiHR=0.42 (0.23-0.76), P=0.004], but not 
CD3+ infiltration [multiHR=1.30 (0.73-2.30)], in the context of <2cm RD (Table 4.12). 
Intriguingly, while higher CD8+ cell density conferred improved PFS in this model 
[multiHR=0.38 (0.20-0.70), P=0.002], higher CD3+ density appeared to confer inferior PFS 







Figure 4.10 Impact of CD8+ cell density in the context of <2cm RD following debulking (A and 
B) and ≥2cm RD (C and D) on OS (A and C) and PFS (B and D). 
 
 
Table 4.10 Impact of CD3+ and CD8+ cell density on OS and PFS in the context of <2cm RD 
following debulking surgery. 
<2cm RD OS PFS 
HR 95% CI 
P-
value 
HR 95% CI 
P-
value 
CD3+ univariable 0.73 0.49-1.08 0.114 0.94 0.63-1.41 0.768 
multivariable 0.69 0.46-1.03 0.073 1.00 0.66-1.51 0.992 
CD8+ univariable 0.62 0.41-0.92 0.017 0.74 0.49-1.11 0.149 







Table 4.11 Impact of CD3+ and CD8+ cell density on OS and PFS in the context of ≥2cm RD 
following debulking surgery. 
≥2cm RD OS PFS 
HR 95% CI P HR 95% CI P 
CD3+ univariable 1.00 0.73-1.39 0.979 1.13 0.80-1.59 0.495 
multivariable 0.90 0.65-1.26 0.537 1.07 0.75-1.52 0.701 
CD8+ univariable 1.12 0.80-1.58 0.517 1.20 0.84-1.72 0.327 





Figure 4.11 Impact of CD3+ cell density in the context of <2cm RD following debulking (A and 







Table 4.12 Multivariable analysis accounting for both CD3+ and CD8+ cell density in patients 
with <2cm RD. 
joint multivariable 
CD3/CD8 model: <2cm RD 
OS PFS 
HR 95% CI P-value HR 95% CI P-value 
CD3+ 1.30 0.73-2.30 0.371 2.16 1.16-4.03 0.015 
CD8+ 0.42 0.23-0.76 0.004 0.38 0.20-0.70 0.002 
 
 
4.3.7 Overlay of HR-centric subgrouping with transcriptional subtyping 
and TIL burden  
4.3.7.1 TIL density between HR-centric and transcriptional subtypes of HGS OC 
Comparison of CD3+ and CD8+ cell density between HR-centric subgroups and transcriptional 
HGS OC subtypes was performed (Figure 4.12). BRCA2m patients displayed significantly 
greater CD3+ cell density versus the CCNE1g and oHRP group (Mann Whitney-U test P=0.021 
and P=0.044, respectively). The BRCA1m group also demonstrated a trend for greater levels 
of CD3+ cells versus the CCNE1g group which approached significance (P=0.066).    
Of the transcriptional subtypes, the Immune subgroup demonstrated the highest CD3+ cell 
burden, with significantly greater CD3+ density versus the Angio and AngioImmune subtypes 
(P<0.0001 and P=0.047, respectively) (Figure 4.12B). Accordingly, the Immune patients also 
demonstrated significantly greater levels of CD3+ cells compared to those tumours classified 
only as ProAngio (P<0.001).  
Similarly, the Immune group showed greater levels of CD8+ cells versus the Angio group 
(P<0.0001) (Figure 4.12D). There was no statistically significant difference in CD8+ density 
between the Immune and AngioImmune groups (P=0.104). The BRCA1m group 
demonstrated higher CD8+ cell density at the borderline of statistical significance versus the 
CCNE1g group (P=0.053) (Figure 4.12C). The other HR-centric subgroups did not demonstrate 






Figure 4.12 Comparison of CD3+ (A and B) and CD8+ (C and D) cell density between HR-centric 






4.3.7.2 Overlay of HR-centric subgroups between transcriptional subtypes of 
HGS OC 
Overlap between the HR-centric subgroups and previously described transcriptional 
subtypes is summarised in Table 4.13 and Figure 4.13. The Immune group comprised a 
greater proportion of BRCAm tumours versus the Angio group (28.9%, 35/121 vs 6.3%, 4/64, 
P=0.001), which was significant when considering specifically BRCA1m (17.4%, 21/121 vs 
4.7%, 3/64, P=0.020) and BRCA2m (11.6%, 14/121 vs 1.6%, 1/64, P=0.021). 
The Angio group comprised the greatest proportion of high-EMSY cases, showing a trend 
toward a higher proportion versus the AngioImmune subtype (14.1%, 9/64 vs 5.9%, 6/101, 
P=0.097). Collectively, the non-Immune subtypes comprised a greater proportion of CCNE1g 
cases versus the Immune subtype (9.1%, 11/121 vs 17.4%, 42/242, P=0.050).  
 






Table 4.13 Overlap between HR-centric and transcriptionally-defined subgroups of HGS OC. 
total 





n % n % n % n % n % n % 
Immune 121 11 9.1 61 50.4 21 17.4 14 11.6 3 2.5 11 9.1 
Angio 64 11 17.2 39 60.9 3 4.7 1 1.6 1 1.6 9 14.1 
Angio-
Immune 101 13 12.9 64 63.4 11 10.9 6 5.9 1 1.0 6 5.9 




241 42 17.4 146 60.6 25 10.4 10 4.1 3 1.2 15 6.2 
 
4.3.7.3 Integrated molecular subtyping of HGS OCs 
An integrated molecular subtyping approach was proposed, comprising both 
transcriptomically-defined and HR-centric subgrouping approaches. CCNE1g and oHRP 
groups were considered poor prognosis groups with regard to HR-centric subtyping, while 
the non-Immune subtypes were considered poor prognosis with regard to transcriptomic 
subtyping. The interaction between these data were used to categorise patients into three 
integrated molecular subtyping groups: those with both favourable transcriptomic and HR-
centric subgrouping (consensus-favourable), those with both unfavourable transcriptomic 
and HR-centric subgrouping (consensus-unfavourable), and the remaining patients (no-
consensus).   
These three groups each displayed distinct OS profiles (Figure 4.14). The consensus-
favourable group displayed prolonged OS versus the consensus-unfavourable [multiHR=0.49 
[0.33-0.74], P<0.001] and no-consensus [multiHR=0.64 (0.42-0.98), P=0.038] groups, while 
the consensus-unfavourable showed reduced OS versus the no-consensus group 






Figure 4.14 OS (A) and PFS (B) of integrated molecular subtypes of HGS OC. 
 
Table 4.14 Clinical outcome of integrated molecular HGS OC subtypes versus the no-
consensus group. 
Versus no-consensus group OS PFS 
HR 95% CI P HR 95% CI P 
consensus-
favourable 
uni 0.69 0.48-0.99 0.046 0.60 0.41-0.88 0.009 
multi 0.64 0.42-0.98 0.038 0.56 0.36-0.86 0.008 
consensus-
unfavourable 
uni 1.38 1.09-1.76 0.008 1.18 0.92-1.53 0.191 
multi 1.31 1.00-1.70 0.047 1.05 0.80-1.40 0.713 
Uni, univariable analysis; multi, multivariable analysis 
 





HR 95% CI P HR 95% CI P 
consensus-
favourable 
uni 0.50 0.35-0.71 <0.001 0.51 0.35-0.73 <0.001 
multi 0.49 0.34-0.74 <0.001 0.53 0.35-0.81 0.003 







The consensus-unfavourable group was significantly older at diagnosis versus the consensus-
favourable and no-consensus groups (median 64 years versus 59 and 59 years, P<0.001 and 
P=0.002, respectively). There was no significant difference in stage at diagnosis or RD 
following primary debulking between the integrated molecular subtypes (Table 4.16). The 
consensus-favourable group demonstrated greater intrinsic chemosensitivity compared to 
the no-consensus and consensus-unfavourable groups (Table 4.16).  
At second chemotherapy, the consensus-favourable group demonstrated higher rates of 
radioCR versus the no-consensus and consensus-unfavourable group (53.9%, 7/13 vs 13.6%, 
6/44 and 10.2%, 6/58; P=0.006 and P=0.001, respectively). TTP after second chemotherapy 
was longer in the consensus-favourable group versus the consensus-unfavourable group 
(median 159 versus 99 days, P=0.032). The no-consensus group displayed a trend for longer 
TTP versus the consensus-unfavourable group, but this did not meet statistical significance 
(median 129 versus 99 days, P=0.097).  
The consensus-favourable group showed greater CD3+ and CD8+ cell density versus the 
consensus-unfavourable group (P<0.0001 for both comparisons) (Figure 4.15). Compared to 
the consensus-unfavourable group, the no-consensus group also showed significantly 
greater CD3+ and CD8+ cell density (P<0.0001 and P=0.004, respectively). For both CD3+ and 
CD8+ cells, the consensus-favourable group demonstrated a non-significant trend for greater 























  N Range/% N Range/% N Range/% P-value P-value P-value  
Cases n 188 . 125 . 49 . . . .  
Age years 64 33-86 59 35-82 59 38-81 <0.001 0.635 0.002 ~ 
FIGO stage 
at Dx 
I 6 3.3 8 6.5 1 2.2 0.226 0.811 0.608 # 
II 14 7.7 12 9.8 5 11.1 . . . 
III 127 69.4 77 62.6 33 73.3 . . . 
IV 36 19.7 26 21.1 6 13.3 . . . 





<2cm 67 40.4 46 41.8 21 51.2 0.908 0.395 0.279 + 
2cm 99 59.6 64 58.2 20 48.8 . . . 
NA 




CR 29 40.3 12 30.0 8 66.7 0.312 0.040 0.119 ^ 
PR 25 34.7 21 52.5 4 33.3 0.479 0.181 0.061 $ 
NC 9 12.5 3 7.5 0 0.0 . . . 
PD 9 12.5 4 10.0 0 0.0 . . . 




CR 65 51.6 45 55.6 26 83.9 0.669 0.008 0.001 ^ 
PR 47 37.3 30 37.0 4 12.9 0.473 0.671 0.306 $ 
NC 10 7.9 6 7.4 1 3.2 . . . 
PD 4 3.2 0 0.0 0 0.0 . . . 
NE 62 . 44 . 18 . . . . 
TTP.1 days earliest 193 0-4207 203 0-4475 406.5 100-2610 0.299 0.003 <0.001 ± 
radio 264.5 2-4207 259 0-3232 547 97-2625 0.898 0.008 0.005 ± 
CA125 158 0-2856 200.5 0-4475 319 74-2610 0.452 0.002 0.001 ± 
~ T-test; # Fisher's exact test, early vs late stage; + Chi-squared test <2cm RD vs 2cm RD, ^ Fisher's exact test, CR vs PR/SD/PD; $ Fisher's exact test, ORR (CR/PR) vs SD/PD; 






Figure 4.15 Comparison of CD3+ (A) and CD8+ (B) cell density between integrated molecular 
subtypes of HGS OC. 
 
 
4.3.8 Independent prognostic impact of multi-level molecular 
characterisation in HGS OC: exploratory analysis 
HR-centric subgroup-specific implications of transcriptional subtype and CD8+ cell burden 
were investigated. Contrary to the findings when considering the entire cohort (see section 
4.3.6), there was no significant association between CD8+ cell burden and OS in the CCNE1g 
group [uniHR for OS=1.17 (0.60-2.29), P=0.651]. 
Intriguingly, in the context of the oHRP group, AngioImmune patients demonstrated a 
prolonged OS versus the Angio subtype [multiHR=0.58 (0.37-0.89), P=0.014), while the same 
comparison in the CCNE1g group demonstrated longer OS in the Angio subtype [multiHR for 
OS=0.32 (0.12-0.86), P=0.024]. Within the high-EMSY group, Angio patients experienced a 
trend for inferior OS compared to the Immune and AngioImmune subtypes at the univariable 





There was an apparent transcriptional subtype-specific prognostic effect of CCNE1g: within 
the Immune group, CCNE1g patients experienced markedly inferior outcome versus the 
oHRP group [multiHR for OS=3.76(1.67-8.44), P=0.001 and multiHR for PFS=3.32 (1.49-7.41), 
P=0.003] (Table 4.17). Conversely, in the context of the Angio subtype, the CCNE1g group 
experienced significantly prolonged PFS [multiHR=0.26 (0.10-0.68), P=0.006], with a 
corresponding trend for prolonged OS that did not reach statistical significance [uniHR=0.54 
(0.27-1.08), P=0.083].  
 
 
4.3.9 Exploratory analysis of further genomic subgroups of HGS OC  
4.3.9.1 HR context-specific TP53 mutation spectra and impact on clinical 
outcome  
While TP53 mutation is almost ubiquitous in HGS OC (98.1% of cases in this cohort), different 
mutation types produce distinct aberrant protein expression patterns [514]. The two 
predominant aberrant patterns are the so-called P53-positive and P53-null patterns (see 
section 2.3.3). Frameshifting indels, nonsense mutations and splice site mutations produce 
the P53-null pattern (TP53-null mutation), while missense variants and in-frame changes 
produce the P53-positive pattern (TP53-positive mutation), with rare exceptions [514].  
HR-deficient HGS OCs (BRCA1m, BRCA2m, non-BRCA HRm plus high-EMSY) demonstrated a 
significantly higher rate of nonsense TP53 mutations versus the HR-proficient population 
(19.0%, 19/100 vs 10.2%, 26/255; P=0.039) (Figure 4.16 and Table 4.18). The majority of 







Table 4.17 Transcriptional subtype-specific impact of CCNE1g on outcome. 
 
OS: CCNE1g versus oHRP PFS: CCNE1g versus oHRP 
HR 95% CI P-value HR 95% CI P-value 
Immune subtype uni 1.44 0.75-2.76 0.270 1.53 0.79-2.96 0.202 
multi 3.76 1.67-8.44 0.001 3.32 1.49-7.41 0.003 
Angio subtype uni 0.54 0.27-1.08 0.083 0.59 0.28-1.23 0.160 
multi 0.52 0.23-1.16 0.111 0.26 0.10-0.68 0.006 




Table 4.18 TP53 mutation type by HR status. 
TP53m 
HGS OC 
TP53-positive mutations TP53-null mutations 
total 
in frame missense frameshift splice nonsense 
n % n % n % n % n % 
HR-
proficient 
9 3.5 153 60.0 50 19.6 17 6.7 26 10.2 255 
HR-
deficient 
3 3.0 51 51.0 19 19.0 8 8.0 19 19.0 100 
 
 







In the context of HR-deficiency, TP53-positive mutations were associated with prolonged PFS 
versus TP53-null mutations upon multivariable analysis [multiHR=0.43 (0.25-0.74), P=0.002] 
with no corresponding difference seen in the HR-proficient cohort [multiHR=0.90 (0.67-1.22), 
P=0.490] (Figure 4.17, Table 4.19). Intriguingly, the greater effect size observed upon 
multivariable analysis suggest an interaction with clinicopathological factors: indeed, analysis 
restricted to patients with late stage disease (stage III/IV) at diagnosis revealed significant OS 
benefit and markedly prolonged PFS in this subset (Figure 4.17E and F).  
In the HR-deficient group, there was no significant difference in response to first-line 
chemotherapy between the TP53-null and TP53-positive groups (radioCR: 56.3%, 9/17 vs 
64.3%, 9/14, P=0.722; radioOR: 87.5%, 14/17 vs 100.0%, 14/14, P=0.485; CA125-CR: 83.3%, 
25/30 vs 75.8%, 25/33, P=0.542; CA125-PR: 100.0%, 30/30 vs 97.0%, 32/33, P=1.00). 
 
Table 4.19 Clinical outcome in TP53-positive versus TP53-null HGS OC. 
 
OS: TP53 positive vs TP53 null PFS: TP53 positive vs TP53 null 
HR 95% CI P HR 95% CI P 
HR-proficient uni 0.87 0.67-1.13 0.295 0.83 0.63-1.10 0.187 
multi 0.90 0.57-1.20 0.460 0.90 0.67-1.22 0.490 
HR-deficient uni 0.82 0.53-1.26 0.363 0.69 0.44-1.08 0.105 
multi 0.63 0.37-1.05 0.075 0.43 0.25-0.74 0.002 
late stage 
HR-deficient 
uni 0.64 0.38-1.06 0.085 0.45 0.26-0.78 0.004 
multi 0.42 0.22-0.77 0.006 0.22 0.10-0.45 <0.001 












4.3.9.2 FANC family mutations do not appear to confer an HR-deficient 
phenotype  
Mutations in FANC family genes were detected in 6 HGS OC cases (3 FANCA, 1 FANCC, 1 
FANCF, 1 FANCM). The single case of FANCF mutation co-occurred with BRCA2m. The 
remaining cases did not demonstrate high rates of primary platinum sensitivity (CA125-CR 
rate 25.0%, 1/4 evaluable cases). Indeed, the CA125-CR rate was significantly lower in the 
FANC-mutant group versus the HR-deficient group (CA125-CR 25.0%, 1/4 vs 79.7%, 51/64, 






4.4 Discussion  
Clearly, substantial advances in our understanding of the biology underlying HGS OC have 
been made to date. However, limited reproduction and under-investigation of molecular 
subtypes beyond BRCAm have limited molecular stratification of clinical care to germline 
BRCA sequencing in the majority of centres. Here we describe subtypes of HGS OC at the 
genomic and transcriptomic level, alongside TIL burden, with high granularity. We then 
investigate the association between these subtypes and clinical outcome and response to 
multiple lines of chemotherapy. Finally, we perform exploratory analysis to interrogate the 
interplay and overlay of molecular subtyping layers, describing novel interactions between 
genomic events, transcriptomic subtypes and TIL burden.  
 
4.4.1 Composition and behaviour of the HR-deficient HGS OC umbrella 
group  
It has long been known that, collectively, BRCAm patients experience superior sensitivity to 
platinum-based chemotherapy and prolonged survival [262, 264, 380]. The data reported 
here add to the growing body of evidence describing the differential impact of BRCA1m 
versus BRCA2m [352]: while patients whose tumours harbour BRCA2m experience markedly 
favourable clinical outcome, the BRCA1m group experience a more subtle phenotype. The 
BRCA1m group appeared to demonstrate better outcome at the univariable level, however 
multivariable analysis revealed no significant survival benefit in this population.  
Interestingly, while the BRCA1m group displayed favourable intrinsic chemosensitivity 
(CA125-CR rate around 70% versus <50% in the oHRP group) with a TTP following initial 
chemotherapy of around 1.5 times that of the oHRP group, this chemosensitivity benefit 
appears to be lost upon relapse: the BRCA1m group demonstrated no significantly greater 





chemosensitive (radioOR and CA125-OR rate 100% at second chemotherapy in the BRCA2m 
group). Collectively, these data support the notion that not all tumours with HR pathway 
defects should be considered equal, and that patients harbouring BRCA1m appear to 
experience a less marked HR-deficient phenotype in comparison to their BRCA2m 
counterparts. 
The work described here within Chapter 3 identifies a novel subtype of HGS OCs, defined by 
high EMSY expression, which display an HR-deficient phenotype. While this group did not 
demonstrate complete mutual exclusivity with genomic subtypes of HGS OC (Figure 4.4), 
high-EMSY patients not attributed to other HR-centric subtypes (high-EMSY, BRCAwt, non-
BRCA HR gene wild-type and non-CCNE1g) demonstrate marked OS benefit and 
chemosensitivity, reminiscent of that demonstrated by the BRCA2m group. While somewhat 
anecdotal, the phenotypic similarity between HGS OCs demonstrating high EMSY expression 
and BRCA2m is consistent with the proposed mechanism by which EMSY-overexpressing 
tumours are rendered HR-deficient: namely, EMSY-mediated inhibition of BRCA2 function 
[269].  
The high-EMSY group showed only limited overlay with the HGS OCs demonstrating EMSY 
amplification, with EMSY CN demonstrating weak correlation with transcript expression. 
These data suggest that CN changes are neither necessary nor sufficient to confer high EMSY 
expression. This may well explain why EMSY CN has not previously been associated with 
differential outcome or chemosensitivity in HGS OC, and suggest CN-independent 
mechanisms of EMSY expression regulation yet to be elucidated. Future studies should seek 
to investigate epigenetic mechanisms of EMSY expression regulation, including the potential 
role of EMSY promoter methylation. High-EMSY patients who otherwise demonstrate no 





population, supporting the notion that EMSY overexpression confers HR-deficiency by 
inhibition of BRCA2 function, and the possibility of prospectively identifying these patients 
should now be carefully considered. A key factor for the investment in routine upfront 
detection of this group will be the potential for high-EMSY HGS OCs to display marked PARP 
inhibitor sensitivity, and the ability to detect these patients prospectively by techniques 
compatible with clinical practice, such as IHC for EMSY protein. 
The frequency of non-BRCA HRm was low in this cohort (around 2%), underscoring the 
challenges in defining the clinical behaviour of this small HGS OC population. While limited 
numbers hindered most statistical comparisons of these patients versus their HR-proficient 
counterparts, this group generally displayed an HR-deficient-like survival profile and 
demonstrated median TTP over three-fold that of the oHRP group following second 
chemotherapy (median >300 days versus <100 days).  
Furthermore, while mutations in genes encoding FANC family members are detected in a 
minority of cases, these do not appear to occur with mutual exclusivity to bona fide HR 
pathway events, and these cases do not demonstrate marked platinum sensitivity. However, 
over-interpretation of these data should be avoided given the severely limited number of 
FANC-mutant cases. 
Future work should focus on further dissection of the oHRP group within this cohort in order 
to discriminate true HR-proficient patients from those with genomic signatures of HR-
deficiency, including those demonstrating genomic scarring, BRCAm-like SNV signatures or 
CN signatures. Such analysis will allow for better characterization of the clinical behavior of 





may well uncover further candidate interactions between molecular subgrouping layers, and 
will facilitate more accurate depiction of the behavior of true HR-proficient HGSOCs.  
  
4.4.2 Elucidating the behaviour of CCNE1g HGS OC  
Consistent with previous reports, we identified CCNE1g in around 15% of HGS OCs [210], and 
this molecular event occurred in an almost completely mutually exclusive manner to other 
pertinent genomic events (Figure 4.4) [280]. While the CCNE1g group were older at diagnosis 
versus the collective non-CCNE1g cohort (median 68 versus 61 years), the difference 
specifically compared to the oHRP group did not pass the threshold for statistical significance. 
The clinical behaviour of this subtype has remained controversial [279], with some authors 
reporting CCNE1g as a marker of poor outcome and chemoresistance [256, 276]. Perhaps 
most notably, the TCGA analysis reported these patients as a group of poor prognosis 
compared to all non-CCNE1g HGS OC, but not when compared to the BRCAwt group [210]. 
Critically, in this study the CCNE1g group is specifically compared against their non-CCNE1g 
HR-proficient counterparts to avoid confounding of the comparison by dilution of the non-
CCNE1g population with HR-deficient tumours that display favourable outcome. CCNE1g 
patients were demonstrated to experienced inferior outcome that was only discernible upon 
multivariable analysis. This phenomenon is likely underpinned by the relative depletion of 
HGS OC patients diagnosed with stage IV disease in the CCNE1g group (fewer than 10% of 
patients) versus the oHRP comparator group (greater than 20% of patients), underscoring 







Contrary to the reports of inherent chemoresistance in CCNE1g HGS OC [256, 276], these 
patients did not display significant differences in primary chemotherapy response (Table 4.7). 
Indeed, at second-line therapy there was a trend for higher rates of CA125 response in the 
CCNE1g population versus the oHRP group which approached statistical significance 
(approximately 80% versus around 60%, P=0.075). However, a significantly greater 
proportion of the CCNE1g group were treated with non-platinum regimes at relapse (less 
than 60% received platinum versus around 80% in the oHRP group). The median TTP in the 
CCNE1g group was 141 days versus 197 days in oHRP patients: these data suggest that over 
half of CCNE1g patient would have been considered platinum resistant at relapse (and thus 
challenged with non-platinum regimes), while over half of oHRP patients would have been 
considered at least partially platinum sensitive (and therefore likely to be re-challenged with 
platinum combinations), potentially explaining this difference in distribution of treatment 
choice at relapse. Together these data suggest that the CCNE1g group do not demonstrate 
significantly different upfront chemotherapy response rates, but are more likely to 
experience more rapid disease recurrence associated with poor prognosis, which is therein 
considered platinum-resistant.  
Given that the CCNE1g group appear to comprise those with poor prognosis, despite a 
propensity not to present with distant metastatic disease, these patients likely represent the 
group with most to gain from trials of alternative therapeutic strategies, including novel 
targeted agents. Given the known role of the CCNE1 gene product in the cell cycle, the 
numerous cell-cycle-targeted novel therapeutics currently in the development pathway may 
be best directed toward the CCNE1g population. These include inhibitors of the cell cycle 
regulators WEE1 kinase [181, 182] and cycle cell checkpoint kinases 1 and 2 [183, 184]. 





diagnosis, these patients may represent cases where ultra-radical debulking surgery may be 
both achievable and confer significant substantial benefit [515]. 
 
4.4.3 Surgical outcome-dependent implication of TIL burden in HGS OCs 
Concordant with previous reports, we identify a significant association between tumour-
infiltrating CD8+ and CD3+ cell burden and prolonged survival in HGS OC [79, 82]. However, 
while the landmark study describing this phenomenon in OC reported this association in the 
context of both optimal and suboptimal primary debulking [82], the data presented here 
suggest a distinct interaction between extend of RD and implications of TIL burden. The 
explanation between this discrepancy may lie in the differential definition of optimal surgical 
resection between these two studies: Zhang et al describe benefit for greater TIL burden in 
the context of 1cm RD [82], while we describe no benefit in the context of 2cm RD. 
Collectively, these data may be explained by the interpretation that the benefit of greater 
immune cell engagement is abrogated in the context of gross macroscopic RD, but not in the 
context of nominal macroscopic RD.  
While univariable analysis of CD3+ cells indicated an association with prolonged survival, 
CD3+ and CD8+ burden were highly correlated. Multivariable analysis accounting for both 
CD3+ and CD8+ cell burden revealed significant independent association of CD8+ cells, but 
not CD3+ cells, with better outcome. This suggests that CD8+ cytotoxic T cells play an active 
role in immune engagement and destruction of cancer cells, prolonging patient survival, 
while other T cell subclasses may play a less significant role. Indeed, after accounting for 
CD8+ cell burden, higher CD3+ cell density was actually associated with inferior PFS (HR=2.16, 
95% CI 1.16-4.03), suggesting that some populations of CD8-/CD3+ cells have a detrimental 





immunoregulatory role of some T cell populations [71, 83], and indeed the ratio of regulatory 
T cells to cytotoxic T cells has been associated with markedly differential survival in OC [71]. 
Further investigation of T cell subclasses and their independent impact upon patient 
outcome is now warranted, particularly of known FOXP3-positive regulatory T cell 
populations, to more comprehensively define the immune environment of these tumours. 
Critically, these analyses will need to account for density of immune cell populations known 
to confer better prognosis (namely CD8+ cells) and modulatory impact of clinical factors such 
as RD following debulking in order to determine the independent impact of other cell classes.  
 
4.4.4 Insights from multi-level molecular characterisation of HGS OCs 
Overlay of TIL burden with genomic and transcriptomic characterisation revealed that the 
BRCAm population demonstrated the greatest TIL burden, consistent with previously 
reported analysis [506]. The association between BRCAm status and TIL engagement raises 
the question of whether the mutational processes underpinning HR-deficient HGS OCs 
contribute toward the ready engagement of the host immune system. The greater 
mutational burden of these tumours may well underpin the generation of a wider tumour-
specific neoepitope library which the immune system can utilize to identify, engage and 
destroy malignant cells [516].  
Interestingly, TIL analysis revealed that one of the identified transcriptional subtypes – the 
Angio subtype – represents a subtype almost ubiquitously devoid of CD8+ cells. Hence, the 
reported poorer outcome within this patient group may be underpinned by complete 
ignorance of the immune system to the tumour. If this phenomenon is underpinned by poor 
immune recognition of tumour antigens, these tumours may represent those who could 





system [91, 517]. Moreover, these patients may experience differential response to 
immunomodulatory therapies targeting immunosuppressive molecules [503-505].  
No significant difference in CD8+ burden was observed between the AngioImmune and 
Immune disease subtypes, suggesting that the survival difference reported between these 
groups is not underpinned by differential engagementment of cytotoxic T cells. However, the 
CD3+ burden was significantly greater in this the AngioImmune group. Together with the 
association of inferior PFS and greater CD3+ burden after account for CD8+ cell infiltration, 
these data could suggest that tumours of the AngioImmune subtype may more readily recruit 
CD3+/CD8- immunoregulatory cells that abrogate the benefit of CD8+ infiltration. 
Characterisation of immunoregulatory cell populations and the expression of 
immunoregulatory molecules in tumours of the AngioImmune subtype is now warranted, 
and may indicate potential efficacy of specific immunomodulatory therapies in these cases 
[503-505].  
Other subtypes associated with differential clinical outcome – namely the high-EMSY and 
CCNE1g groups – were not characterised by differential TIL burden compared to the oHRP 
group.  
Generally, there was limited overlap of genomic and transcriptomic subtypes: while there 
was significant enrichment of the CCNE1g within the non-Immune subtypes, the magnitude 
of this effect was discrete (17% versus 9%). The difference in the proportion of BRCAm 
patients in Immune versus Angio patients was more pronounced (29% versus 6%), with the 
AngioImmune group showing an intermediate BRCAm frequency (around 17%). Given the 
higher frequency of BRCAm patients in the Immune subtype and the described lack of benefit 





BRCAm population may represent those who benefit least from anti-angiogenic agents. 
Conversely, the CCNE1g patient group, over-represented in non-Immune subtypes, may 
resemble those in which agents such as bevacizumab may be most effective. Together with 
the data presented in Chapter 3 suggesting inferior outcome of high-EMSY patients receiving 
bevacizumab as part of first-line therapy, the notion that BRCAm patients may also benefit 
less from anti-angiogenics suggests the need for analysis of anti-angiogenic efficacy stratified 
by HR-proficiency status. Indeed, this notion has the potential to impact profoundly upon the 
interpretation of results from ongoing trials combining anti-angiogenic agents with PARP 
inhibitors [185].  
The concordance of differential TIL burden and bevacizumab sensitivity between the Angio 
and Immune subtypes of HGS OC may elude to interaction between anti-angiogenic 
therapies and modulation of the efficacy of the anti-tumoural immune response. 
Investigation of the impact of anti-angiogenic therapies on the tumour microenvironment in 
HGS OC is warranted to investigate whether agents such as bevacizumab alter the host-
tumour interface, and whether this interaction has consequences with regard to the survival 
benefit otherwise conferred by immune engagement of the tumour [82]. Moreover, low TIL 
burden may therefore indirectly provide a marker of anti-angiogenic sensitivity in HGS OC. 
However, while reduced TIL access to the tumour from decreased vasculature is an attractive 
model for reduced anti-cancer TIL efficacy, there have been reports of immunomodulatory 
benefit from pro-angiogenic microenvironments, supported by reported synergy between 
anti-angiogenic and immunomodulatory strategies in other malignancies [518]. Thus, the 
concurrent association of derived bevacizumab benefit and TIL burden between subtypes 





An integrated genomic-transcriptomic molecular subtyping approach classified patients into 
three groups: consensus-favourable, no-consensus and consensus-unfavourable, each with 
distinct OS profiles from one another, suggesting added benefit for resolving clinical outcome 
of HGS OC patients with multi-level molecular characterisation. The relative OS probability 
for these groups three years from diagnosis was 30-40%, 50-60% and around 70%, 
respectively, with the consensus-favourable group characterised by marked 
chemosensitivity and the highest TIL burden. Conversely, the consensus-unfavourable group 
demonstrated dismal outcome, and represents a group in which novel therapeutic strategies 
are urgently required to improve survival. Notably, this group are HR-proficient, and are 
therefore less likely to demonstrated marked sensitivity to PARP inhibition.  
Multi-level characterisation of this large well clinically annotated cohort presents the rare 
opportunity for analysis of subgroup context-specific implications of molecular events in HGS 
OC. While it should be stressed that these analyses are hypothesis-generating by nature, they 
reveal striking contextual dependencies with regard to the clinical impact of certain 
molecular events within this cohort. Most notably, the impact of CCNE1g may be modulated 
by transcriptional subtype: in the context of the Immune subtype, CCNE1g conferred 
markedly poor survival (multiHR for OS=3.76, 95% CI 1.67-8.44), while CCNE1g may be 
associated with prolonged progression-free survival in the context of the Angio subtype 
(multiHR for PFS=0.26, 95% CI 0.10-0.68). These data may well explain discrepancies in the 
reported association of CCNE1g with clinical outcome in HSG OC [210, 276, 279]. There was 
also a suggestion for context-specific implication of CD8+ burden: greater CD8+ cell burden 
was associated with prolonged survival across the wider HGS OC cohort, but not in the 





specific implications of molecular events and provide a compelling argument for multi-level 
characterisation to elucidate the true implications of HGS OC subgroups.  
The candidate interactions described here pave the way for a more granular, refined 
molecular subgrouping approach: by way of example, a patient assigned to the Immune 
transcriptional subgroup may be expected to experience relatively favourable disease 
course. However, concurrent identification of CCNE1g allows refinement of this classification, 
with the clinical benefit of the Immune group abrogated by CCNE1 CN gain.  
Clearly, independent validation of the specific associations described here are needed, and 
these analyses may well uncover additional interactions between molecular subtyping layers 
in HGS OC.  
 
4.4.5 Novel association of TP53 mutation type with outcome in HR-
deficient HGS OC  
Finally, this work uncovers a potentially novel association between TP53 mutation type and 
outcome specifically in HR-deficient HGS OC, and a greater rate of nonsense TP53 mutation 
in these tumours. TP53-positive mutations appeared to confer better prognosis when 
compared to the TP53-null group, where mutation is predicted to completely oblate cellular 
P53 levels (multiHR for OS=0.42, 95% CI 0.22-0.77 and multiHR for PFS=0.22, 95% CI 0.10-
0.45 in the late stage disease setting). One hypothesis to explain this phenomenon is a 
possible role of residual TP53-positive mutant P53 activity in conferring the platinum 
hypersensitivity that is a hallmark of HR-deficient HGS OC. However, contrary to this notion, 
TP53-null HR-deficient HGS OCs did not display significant differences in chemotherapy 





Validation of this phenotype in molecularly characterised HGS OC cohorts with well curated 
clinical annotation is now required to determine whether these TP53-null HR-deficient 
patients do indeed experience a less favourable disease course versus their TP53-positive 
counterparts. Such validation may prove non-trivial given the predominant association of 
with PFS in our dataset and the variability of strictness in criteria for calling progression in 
available datasets: notably, in our cohort progression was only called in the context of 
adherence to established criteria [451]. Nevertheless, the outcome of these analyses will be 
of particular interest given that stratification for the most common mechanism of HR-
deficiency is already in place clinically, and that IHC capable of distinguishing TP53 mutation 
types is already routinely used [236, 514].  
TP53-positive mutant gene products are known to demonstrate residual activity [519] and 
have been shown to enhance the classic pro-survival and mitogenic signalling pathways EGFR 
[520], TGF-β [521] and MET [522]. Associations between TP53 mutation types in models of 
other disease settings have associated TP53-positive tumours with more aggressive, invasive 
and metastatic phenotypes [523] and it is therefore unclear why, in the setting of HR-
deficient HGS OC, TP53-positive mutants may experience more favourable outcome. 
Following the recent efforts to identify bona fide HGS OC cell lines from those previously 
misidentified [510, 524], in vitro manipulation may well represent a convenient model 
system for interrogating the implication of TP53 mutation type on cellular signaling and 
survival explicitly in the context of HR-deficiency. Specifically, genome editing of BRCAm HGS 
OC cells harbouring TP53-positive mutations to produce matched TP53-null lines may prove 
an invaluable resource for investigating potential differential chemosensitivity or cell survival 





candidate mechanisms underpinning altered survival profiles of patients harbouring TP53-
positive versus TP53-null tumours that are HR-deficient.  
 
4.4.6 Future research directions for molecular subtyping with potential 
clinical utility 
While these analyses represent an extensive research effort to understand the overlay and 
interplay between molecular subtyping layers in HGS OC, and focus on the clinical 
implications of this in-depth characterisation, further study is urgently needed if the output 
of these analyses is to be utilized clinically. In particular, the identified candidate interactions 
– most notably between CCNE1g and transcriptional subtype and between TP53 mutation 
type and HR status – require replication in independent cohorts before consideration of their 
potential clinical utility can be made. Similarly, development of techniques to prospectively 
identify high-EMSY patients will prove critical in determining the potential of these patients 
to be identified and differentially managed.  
Despite the large number of cases characterised in this study, limited numbers of rare HGS 
OC subtypes continue to preclude comprehensive analysis of the clinical phenotype 
demonstrated by these patient groups. The flagship example of this is the non-BRCA HRm 
group, representing only around 2% of the patients described here. While these HGS OCs 
appear to behave in a similar manner to their BRCAm counterparts with regard to survival 
and chemosensitivity, robust analysis of these patients was not possible in light of these small 
numbers.  
Similarly, we identify a small group of HGS OCs demonstrating NF2 mutation, which appeared 





subpopulation of cases (around 2%), precluding meaningful analysis of the clinical behaviour 
of this group. In light of the recent identification of NF1 loss in a high proportion of HGS OCs 
[256], the identification of NF2 mutations in this cohort is of marked interest given the 
phenotypic similarity of germline NF1 and NF2 inactivation – namely neurofibromatosis. 
Furthermore – as with NF1 – the NF2 gene product, Merlin, has been identified as having a 
role in negative regulation of Ras signaling [525, 526], suggesting potential biological 
similarity between NF1- and NF2-mutant HGS OC. Given the established mechanism by which 
NF1 inactivation can activate the MAPK pathway (see section 1.12.2), and the suggestion that 
NF2 mutation may confer similar biology, these NF1/NF2-mutant  HGS OC may represent 
good candidates for targeted intervention with MEK inhibitors [527]. Indeed, MEK inhibition 
is already used for treating MAPK-activated malignancy [528] and it has been suggested that 
MEK inhibition may be efficacious in NF1-associated tumours [529-531]. 
It is clear that extensive characterization of both the non-BRCA-HRm and NF2-mutant HGS 
OC groups – alongside other subtypes that represent only a minority of cases – is non-trivial. 
Vast cohorts of HGS OC will be required to properly elucidate the behaviour of such rare 
subtypes, and multi-centre international collaborative efforts will likely be required in order 
to achieve sufficient power for meaningful interpretation of these analyses. 
While we have performed comprehensive characterisation of multiple molecular events, we 
were not able to characterise this cohort for recently reported GBEs in RB1 and NF1 in the 
absence of WGS data for this archival cohort [256]. Development of techniques to identify 
HGS OCs harbouring these events that are lower in cost and do not require high quality frozen 
tumour material will be critical for determining the long-term clinical outcome of these 
patient groups, and for investigating the mutual exclusivity of these events with other HGS 





Moreover, while the genomic and transcriptomic subgroups described here contribute 
toward more precise deconvolution of clinical heterogeneity demonstrated by patients with 
HGS OC, further molecular analyses offer the opportunity for even greater resolution. 
Analysis of DNA methylation patterns, proteomic characterisation and investigation of the 
microRNA profile of these tumours may well uncover further clinically meaningful biological 







5 CHAPTER 5: DICUSSION AND CONCLUSION 
OC remains a leading cause of female cancer death, displaying extensive clinical and 
molecular heterogeneity even when considering only the HGS histological subtype of 
disease. Relapsed HGS OC represents the area of greatest unmet need, with accrual of 
therapy resistance ultimately leading to treatment failure and patient death.  
It is clear that the substantial biological diversity of HGS OCs contributes to the clinical 
heterogeneity of patients presenting with HGS OC. Molecular characterisation and subtyping 
of these tumours presents the opportunity to deconvolute this clinical heterogeneity, leading 
to advances in both our understanding of HGS OC and improvement of patient management.  
Stratification based on these analyses offers the potential to tailor therapy, directing patients 
toward the treatment avenues in which they are likely to derive the most benefit, with the 
potential to exploit specific identified biology using targeted interventions. Indeed, targeted 
therapeutic intervention in OC has become an exemplar of successful molecular stratification 
with the advent of PARP inhibitor therapy [120, 160, 169-171].  
Management of HGS OC finds itself in a pivotal era: the first implementation of stratified 
management using targeted molecular therapy is now routinely used across many centres, 
with other biologically-targeted agents also licensed for use in the recurrent disease setting 
[60, 176]. In tandem with this paradigm shift toward the perception of these tumours by their 
biology rather than their histological appearance, high-throughput technologies identifying 
molecular events at the genomic and transcriptomic level facilitates the identification of 
further biological subtypes of disease. Indeed, this shift is evident across a multitude of 
disease sites. The identification of similar actionable biology underpinning multiple tumour 
types facilitates testing of molecularly-directed agents in multiple settings, with PARP 





With the arrival of molecular OC care stratification – essentially by BRCAm status thus far – 
three key research avenues have flourished, each to which the work described here 
contributes: (i) further characterisation of BRCAm HGS OC; (ii) identification of cases 
demonstrating a similar phenotype to BRCAm patients which may be good candidates for 
similar stratification options; and (iii) further molecular subtyping of HGS OC, most urgently 
in the HR-proficient setting, in the hope of identifying patients with differential clinical 
outcome, therapy sensitivity and potentially actionable biology.  
Extension of the phenotype demonstrated by the BRCAm flagship patient subgroup has been 
an area of keen research interest. Upon the backbone of identifying the BRCAm population 
as part of routine care, these analyses present the opportunity to rapidly translate findings 
into clinical practice. The work described here in Chapter 2 builds upon the established 
phenotype of these patients – who are known to demonstrate prolonged survival, greater 
platinum sensitivity and marked PARP inhibitor sensitivity – identifying that those harbouring 
damaging BRCA sequence events are also more sensitive to the non-platinum DNA damaging 
agent PLD. Intriguingly, a higher response rate to PLD was uncovered in patients 
demonstrating the BRCA1 SNP rs1799950, considered by many conventions as a “common” 
genetic variant (present in around 5% of the European population). These analyses suggest 
the need for closer investigation of common genetic variation, particularly those variants at 
the threshold for definition as common variation, with regard to treatment efficacy in the 
context of cancer care.  
The described data provide a rationale for further stratification of care within the BRCAm 
population, and PLD should readily be considered for the treatment of these tumours upon 
development of platinum resistance in BRCAm HGS OCs. Similarly, the corresponding low 





sequencing without demonstrating pertinent sequence events should instead be directed 
toward alternative regimes such as weekly paclitaxel.  
While this model of care stratification is appealing, it is not without limitations. These include 
the now common treatment of platinum-sensitive relapsed OC with carboplatin-PLD 
combination therapy following the publication of the CALYPSO trial, indicating greater 
efficacy of this regime over carboplatin-paclitaxel chemotherapy [154]. Given that the vast 
majority of BRCAm OC is platinum sensitive at first relapse, many BRCAm patients are now 
indirectly funnelled toward PLD as an effective therapeutic option in light of these data. 
Indeed, the greater efficacy of platinum-PLD combination in this setting may well be 
underpinned by the enhanced response rate of BRCAm to PLD described here. However, 
since publication of the CALYPSO data, uptake of platinum-PLD combination therapy as the 
preferred treatment for platinum sensitive relapse has been variable, with many centres 
opting for conventional platinum-taxane combination chemotherapy. The data presented 
here bolster the rationale for platinum-PLD combination in this setting, given that the BRCAm 
appear to derive marked benefit from PLD and that the platinum-sensitive relapse population 
is enriched for these patients.  
Future work should investigate the optimal chronology for introduction of different 
chemotherapy classes upon relapse. Specifically, they should seek to identify whether PLD 
should be reserved for use as a single agent in BRCAm patients who have developed platinum 
resistance, or whether combination therapy with PLD at platinum-sensitive BRCAm relapse 






The identification and characterisation of HGS OC subtypes that demonstrate a similar 
phenotype to the BRCAm population is extremely appealing. These patients represent those 
with the potential to benefit from the same stratification mechanisms as BRCAm patients – 
most notably PARP inhibition – and offers the promise of rapid integration of further 
identified subgroups into clinical practice, making use of the current BRCAm paradigm as a 
model.  
The data presented in Chapter 3 of this work identify one potential such group, who express 
high levels of EMSY transcript. With EMSY reported to bind and functionally inactivate 
BRCA2, these patients are predicted to be rendered HR-deficient and phenotypically mimic 
their BRCA2m counterparts [269]. The clinical characteristics of the high-EMSY group are 
demonstrated to indeed be reminiscent of BRCA2m patients, displaying prolonged survival 
and marked platinum sensitivity – hallmarks of the so-called BRCAness phenotype. While the 
work described here in Chapter 3 is limited to in silico analyses, the survival benefit of the 
high-EMSY group is recapitulated in multiple independent datasets of transcriptomically-
characterised HGS OCs, bolstering confidence that these patients comprise a true clinically 
relevant subgroup.  
Clearly, characterisation of the PARP inhibitor sensitivity of this group will be of marked 
value, and the potential for this biological group to ultimately influence patient management 
will likely rely on demonstration of such an association, as well as the ability to prospectively 
identify these patients with high fidelity. Future work should seek to investigate the impact 
of EMSY expression on PARP inhibitor sensitivity in those patients not rendered HR deficient 
by virtue of BRCAm. The development and implementation of methodology to detect these 





While the BRCAm (and indeed the wider HR-deficient) HGS OC population has been the focus 
of an intense research effort over the last decade, the reality is that the majority of HGS OC 
cases do not display BRCAm. These BRCAwt cases arguably represent a disease entity with 
an even greater unmet need, given that they are generally not good candidates for use of 
PARP inhibitors. These patients more rapidly accrue platinum resistance and quickly succumb 
to disease following relapse. The characterisation of biology driving these tumours is 
therefore of great interest, and molecular studies must look beyond BRCAm in the hope of 
identifying clinically meaningful subtypes of BRCAwt HGS OC with potentially targetable 
biology.  
The work outlined here in Chapter 4 performs multi-layer molecular characterisation of 
tumour specimens, identifying groups of patients defined within the HR-deficient and HR-
proficient umbrella classes of HGS OC. Rich clinical annotation was available for this cohort, 
allowing us to correlate subtypes of disease with chemotherapy response as well as OS and 
PFS in the context of clinicopathological features. While the HR-proficient umbrella group 
represent a group of overall greater chemoresistance and unfavourable outcome, this group 
remain relatively clinically heterogeneous, representing a continuum of platinum sensitivity 
gradation.  Specifically within the HR-proficient population, we identify the CCNE1g 
population as a group with poor prognosis when accounting for clinical factors, most notably 
stage at diagnosis, as these patients are shown to demonstrate a propensity for diagnosis 
without distant metastatic disease. Contrary to reported suggestions of intrinsic 
chemoresistance in this group [256, 276], we identify no evidence of differential 
chemotherapy response in the first-line setting versus their HR-proficient counterparts. 
Given their poor survival, CCNE1g patients may be those that have most to gain from clinical 





cycle also proffers the rationale for the use of cell-cycle directed therapies in these patients, 
in the hope of improving outcome. 
Further to characterising the clinical impact of the CCNE1g group, we characterise the overlap 
of subgroups defined at the genomic and transcriptomic levels, and of those defined by high 
TIL burden indicating active immune engagement. We demonstrate relative enrichment and 
depletion of BRCAm and CCNE1g patients in the Immune and non-Immune subtypes, 
respectively, and demonstrate that one of the poor transcriptional subtypes – the Angio 
group – is essentially a subtype of immune ignorance. Whether tumours of the Angio subtype 
represent those that are simply non-immunogenic – or whether there is active dampening 
of the immune response – remains to be established, but has clear implication with regard 
to the potential utility of immunomodulatory therapies or anti-cancer vaccines in this setting 
[91, 503-505, 532]. Our analyses also contribute to the growing evidence dissecting the 
phenotype of BRCA2m patients from their BRCA1m counterparts, demonstrating that 
BRCA2m cases display an exaggerated survival and platinum hypersensitivity profile. 
Integrated genomic and transcriptomic subgroup analysis is performed, producing a more 
granular picture of HGS OC based on the consensus of favourable versus unfavourable 
genomic and transcriptomic groupings. Critically, these ‘integrated’ molecular groups each 
display distinct survival from one another, evolving beyond a simple two-tiered “favourable” 
versus “poor” outcome subgrouping approach, which is the typical product of many 
molecular subgrouping studies. This higher-resolution approach to tumour sub-classification 
is a vital step toward more comprehensive deconvolution of the clinical heterogeneity 
exhibited by HGS OC patients. Moreover, we demonstrate potential contextual 
dependencies of the clinical impact of certain molecular events, demonstrating both the 





While clinical implication of multi-level molecular characterisation may seem distant, the 
data presented here identify a number of key patient groups: firstly, those of both poor 
transcriptomic and poor genomic subtypes, who experience dismal prognosis and represent 
those patients served least well by currently available therapeutic strategies. These patients 
resemble those with most to gain from novel strategies, and arguably should be directed 
toward ongoing trials of differential patient management. Secondly, they highlight potential 
novel patient groups and molecular event interactions that warrant further investigation as 
populations who experience differential clinical outcome and therapy sensitivity. 
Furthermore, these data provide detailed descriptions of the clinical implications of 
molecular subtypes, highlighting the need for consideration of molecular biology 
underpinning disease when analysing the efficacy of novel treatment strategies – particularly 
of targeted molecular therapies.  
In conclusion, the work described here builds upon the substantial research effort to date 
defining the underlying biology of HGS OC and the clinical implications of identified biological 
subtypes. Critically, such analyses rely upon the availability of tumour material with which to 
perform molecular analyses, and the quality and depth of the clinical annotation associated 
with these samples. Given the importance of identifying such associations, as well as the 
rarity of some of these subgroups of interest, extensive international effort must be made to 
incorporate research access into the routine clinical management pipeline. Detailed 
prospective clinical data collection and tumour sampling should be performed where 
possible throughout the patient journey to aid research efforts into characterising the 
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